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SPLICING SYSTEMS FOR STUDYING SIGNALING TO THE SPLICEOSOME 
 
Hercules S. Apostolatos 
 
ABSTRACT 
 
Alternative splicing is a major contributing factor to protein diversity. The human 
genome project validated that there are about 25,000 genes, but over 100,000 proteins. 
Genes contain numerous exons that are specifically regulated; thus, elucidating 
alternative splicing mechanisms of pre-mRNAs is an immense undertaking. Two basic 
tools are used to study this mammoth task. For in vitro studies, usually in vitro 
transcription followed by splicing assays is used. For in vivo studies, the main technique 
is the construction of minigenes. These techniques enable one to study the 
mechanisms/conditions that explain an exon‟s inclusion or exclusion in the mature 
mRNA. 
In this project, studies were focused in the protein kinase C (PKC) family, and 
specifically in certain exons of PKCβ and PKC  genes. The PKCβ gene codes two 
proteins: PKCβI and PKCβII. The pre-mRNA of PKCβ contains 18 exons. If exon-17 
(exon-βII) is included in the spliced transcript, protein PKCβII is expressed. If exon-βII is 
skipped (excluded), protein PKCβI is expressed. Previous and current results indicate that 
insulin treatment not only favors exon-βII inclusion, but also regulates 3‟-UTR size in 
mature mRNA. We identified up to five different PKCβII mRNAs that differ only in the 
3‟-UTR size (all five mature transcripts express the same PKCβII protein). 
PKCβII is required for glucose uptake in skeletal muscle and adipocytes. 
Additional studies revealed that inclusion of exon-βII involves SRp40 in its 
xvi 
phosphorylated form. Small interfering RNA (siRNA) knockdown of Akt2 and Clk1 
further revealed that SRp40 was phosphorylated by Akt2/Clk1, and that Akt2 
phosphorylates Clk1. The knockdown of Clk1 or SRp40 down-regulated glucose uptake.     
The PKC  gene contains 18 exons. The standard size of exon-10 is 97-bases, and 
when included in the mature transcript, PKC I is expressed. Exon-10 has an additional 
5‟-splice site that extends the exon size to 190-bases. When this extended size is included 
in the mature transcript, PKC VIII is expressed which has a profound effect in the fate of 
the cell by blocking apoptosis. Our results reveal that all-trans retinoic acid regulates the 
inclusion of exon-10 extended size. Moreover, the inclusion involves SC35 (SRp30b). 
Finally, we elucidated the position of the SC35 cis-element. 
 1 
INTRODUCTION 
Project Overview 
Protein diversity depends on several aspects, but alternative splicing is by far the 
main factor [1, 2]. Protein diversity is very obvious, but how it is implemented is not. 
Using the protein diversity observed in cells as a yardstick, when the human genome 
project was completed, most people were surprised on the low number of total genes 
found [3]. Since alternative splicing is the main cause of protein diversity, one needs to 
build tools to find out how alternative splicing is regulated. Since a gene is comprised of 
numerous exons and introns [4], one is forced to focus on how a single exon is included 
or excluded in the mature transcript.  
It is at his junction that in vitro studies and minigenes [5] enter as methods to 
tackle this endeavor. In vitro transcription followed by splicing assays provides the first 
springboard towards this undertaking. Similarly, a splicing vector provides the platform 
for an exon of interest (and optionally its flanking intronic sequences) to be studied. The 
typical splicing vector comes with a pair of exons and a functionally excisable intron 
between them. This platform enables one to insert an exon of interest and study the 
conditions under which the inserted exon is included or excluded in the final mature 
vector transcript [5]. Because the mature vector transcript usually represents fractional 
sequences of two or more genes, this is why the constructs built are called minigenes, or 
heterologous minigenes.  
 2 
The exons and their related intronic sequences studied in this project are 
alternatively spliced variants from the PKC family of proteins. Specifically, we studied 
exons and their related intronic sequences from PKC  and PKC . PKC‟s are 
serine/threonine kinases which phosphorylate either serine or threonine residues.   
 
Best friend of protein diversity 
The flow of biological information is from DNA to RNA to protein. In higher 
organisms, before and/or after DNA transcription stops there are additional processes 
being implemented before splicing begins. Three of these processes are capping of the 5‟ 
terminus, cleavage near the poly(A) signal, and synthesis of the poly(A) tail (up to 200 
bases). The resulting transcript is referred to as pre-mRNA. Through alternative splicing, 
different mRNA isoforms are pieced together by joining exons in various permutations. 
Figure 1. 38,016 Shades of DSCAM 
The DSCAM gene produces splicing isoforms of about 7.8 kb comprised of 24 exons 
(middle drawing). Exons 4, 6, 9, and 17 are encoded as arrays of mutually exclusive 
alternative exons. Each mRNA will contain one of 12 possible alternatives for exon 4 (in 
red), one of 48 for exon 6 (blue), one of 33 for exon 9 (green) and one of 2 for exon 17 
(yellow). In the final protein product (bottom), the colors depict the regions exons 4, 6, 9, 
and 17 can alter. If all possible combinations of single exons 4, 6, 9, and 17 are used, the 
DSCAM gene can produce 38,016 different mRNAs and proteins [4]. 
 3 
The main factor in protein diversity is alternative splicing, which allows a 
relatively small number of genes to produce several fold number of isoforms that lead to 
different proteins as figure 1 indicates in the Drosophila DSCAM protein [6]. Recent 
estimates indicate that the percent of human genes employing alternative splicing is as 
high as 76% [7]. Alternative splicing is a major regulatory process, and more often than 
not it is tissue specific, cell cycle specific, and cell differentiation specific. Alternative 
splicing is so complex and difficult to study that many aspects are not yet understood.    
 
Brief Introduction to SR proteins  
The role of serine-arginine rich (SR) proteins is to regulate the selection of splice 
sites in eukaryotic pre-mRNA transcripts [8]. The term SR indicates that these proteins 
contain long serine/arginine repeats. SR proteins not only regulate splice site utilization 
during alternative splicing, but they are also needed for constitutive splicing where the 
same splice sites are selected all the time [9]. 
As figure 2 demonstrates, exons and introns provide binding sites (cis-elements) 
for SR proteins. However, these binding sites may be blocked by other proteins whose 
function is to repress spliceosome assembly [10]. Sometimes these repressors are 
themselves SR proteins. As a result, the binding of an SR protein near a splice site does 
not always enhance the selection of that splice site for utilization. Thus, the final selection 
is the result of a tug of war between SR proteins and repressors near and far away from a 
prospective splice site. An exonic cis-element that enhances splicing is referred to as ESE 
(exon splicing enhancer), and an ISE is an intronic splicing enhancer [11]. Similarly, if a 
binding site represses or silences the utilization of a splice site, the cis-elements are 
 4 
referred to as ESS and ISS. Some studies indicate that the result of this tag of war is 
closely related to the ratio between the competing proteins bound to the ESE, ESS, ISE, 
and ISS elements. 
 
The SR proteins, besides having an Arginine/serine (RS) domain in order to 
interact with other proteins, also have  an RNA-recognition motif (RRM) in order to bind 
to RNA [9]. Phosphorylation of the RS domain at serine residues activates interaction 
Figure 2. Spliceosome Assembly on Regulated and Unregulated Splice Sites 
A pre-mRNA (top) is spliced according to where the spliceosome assembles and defines its introns 
and exons. The U1 snRNP binds to 5‟ splice sites. The U2 snRNP and auxiliary proteins, including 
U2AF and SF1, bind to the branch point and the 3‟ splice site. The binding of these initial 
components and the assembly of the early spliceosome complexes is thought to define the intron to 
be excised. In later steps, the full spliceosome forms and catalyzes the cleavage and ligation 
reactions at the earlier defined splice sites. The spliceosome can assemble between exon 1 and 
exon 3 to excise a single large intron and form mRNA-1. Alternatively, two spliceosomes can 
excise two smaller introns, thus including a new exon in the mRNA (mRNA-2). These outcomes 
can be determined by negative regulatory proteins (red) that either prevent U1 or U2 binding at 
particular sites (as shown), or block spliceosome assembly after U1 or U2 binding. Regulatory 
proteins can also act positively (blue) to enhance spliceosome assembly at sites that are otherwise 
recognized poorly. Most systems of alternative splicing seem to be controlled by multiple 
regulatory proteins that may exert both positive and negative control. Splicing patterns can also be 
affected by other factors, including RNA secondary structure and transcription rate [4]. 
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with other proteins (which also includes other SR proteins). Each SR protein loosely 
adheres to a consensus sequence for its RRM domain making difficult to predict cis-
elements.  
 
Splicing sites, branch point, pyrimidine tract  
There are certain terms in splicing that may not be intuitively associated with the 
proper regions involved. The boundary between an exon and an intron is referred to as a 
splice site. A 5‟ splice site refers to the 5‟ end of the intron (which is also the 3‟ end of 
the exon). A 3‟ splice site refers to the 3‟ end of the intron (which is also the 5‟ end of the 
exon). Figure 3 depicts the various regions involved, the consensus sequence of each 
region, and the frequency of occurrence of each consensus base. 
 
  
The four regions of primary importance are the poly-pyrimidine tract (also known 
as pyrimidine rich region), the branch point, the 5‟ splice site, and the 3‟ splice site [13]. 
Figure 3. Intron Exon boundaries and consensus sequences 
The consensus sequence of the 5‟ splice site is {AC}AGGU{AG}AGU where the bases 
shown in brackets means either or. The frequency of occurrence of each base or group of 
bases is shown below the bases. Notice that the bases GU at the 5‟ end of the intron have 
close to 100% frequency. The 3‟splice site consensus sequence is CAGG where again the 
last 2 bases at the 3‟ end of the intron have close to 100% frequency. The branch point is 
about 20 to 50 bases upstream of the 3‟ end of the intron, and the poly-pyrimidine tract is 
downstream of the branch point [12]. 
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Regions of secondary importance are binding sites for SR proteins, binding sites for 
repressor proteins, and sequences that result in secondary structures.    
The poly-pyrimidine tract is in close proximity to the 3‟ splice site, and it is about 
15 bases long. Further upstream from the poly-pyrimidine tract is the branch point, and it 
is about 20 to 50 bases upstream from the 3‟ splice site [14]. An intron may contain more 
than one branch point, and the branch point utilized may be as far as 400 to 500 bases 
upstream from the 3‟ splice site. The 3‟ splice site consensus sequence is only four bases 
(CAGG), and the last two intronic bases are invariably AG. The 5‟ splice site consensus 
sequence is nine bases (A/C A G G T A/G A G T), and the first two intronic bases are 
invariably GT. Thus, most introns start with GT and end with AG. Interestingly, most 
exons start with a G and end with a G, and most exon-exon ligation sites have the 
consensus sequence A/C A G G.  
  
The path to intron excision (Pandora’s Box Odyssey) 
The path to translatable RNA is different in prokaryotic cells compared to 
eukaryotic cells. In the former, ribosomes can process mRNA for translation even while 
the transcript is still being transcribed. On the other hand, mRNA in eukaryotes is first 
transcribed in the nucleus, and after additional processing, is transported to the cytoplasm 
for translation. The initial transcript referred to as pre-mRNA undergoes several 
modifications in the nucleus before it is exported to the cytoplasm. The four main 
processes are capping of the 5‟ end, cleavage of the 3‟ end near a poly(A) signal, addition 
to the 3‟ end up to 200 adenines, and removal of the introns. 
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Capping of the 5’ end 
Capping involves the addition of a 7-methylguanosine at the 5′ end of pre-
mRNA. The process starts by first adding a GTP to the 5‟ end, but the orientation of this 
GTP is reversed compared to all the other GTP‟s in the pre-mRNA [15]. This action 
increases the size of the transcript by one base at 5‟ end. After the reverse oriented GTP 
is attached, a methyl group is added to the reversed guanosine and also to the neighboring 
one or two nucleotides [16]. When eventually the processed mRNA is transported to the 
cytosol, the 5‟ capping helps the mRNA align properly with the ribosome for translation.  
 
 
Figure 4. Capping of the 5’ end 
The right side shows the standard 5‟ to 3‟ linkage between nucleotides. The left side 
shows the 5‟ to 5‟ linkage and the site of methylation on the guanine base. The asterisks 
indicate the positions in the two neighboring nucleotides that additional methylations 
may be observed [17]. 
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Polyadenylation of the 3’ end 
Almost all eukaryotic cells produce polyadenylated mRNA. Sometimes 
transcription continues far downstream of the point of adenylation. During or at the end 
of transcription, sequences that are recognized as polyadenylation signals are processed 
for cleavage [18]. The most common conserved sequence found near a polyadenylation 
site in mammalian cells is AAUAAA which may occur more than once at different points 
of the transcript. 
 
  
Other sequences near the poly(A) signal serve as binding sites for proteins that 
act as enhancers or repressors and decide if the transcript is cleaved or not near that 
Figure 5. Polyadenylation 
The poly(A) signal consensus sequence 5′-AAUAAA-3′ is usually about 10 and 30 
nucleotides upstream of the site where polyadenylation takes place. Downstream of this 
site the dinucleotide 5′-CA-3′ may be present along with 10–20 nucleotides identified as 
a GU-rich region. All these regions serve as binding sites to the proteins that mediate 
cleavage and synthesis of the poly(A) tail [17]. 
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poly(A) signal. In mammalian cells the transcript is cleaved about 10 to 30 bases 
downstream of the poly(A) signal. Some of the proteins involved in the recognition of the 
poly(A) signal and the subsequent cleavage may be associated to the RNA polymerase II 
(RNAPII).  Cleavage is implemented by an RNA endonuclease, and the polyadenylation 
function is performed by a poly-A-polymerase that may add downstream of the cleavage 
site up to 200 adenines. The addition of the poly(A) tail defines the 3‟ end of the 
transcript.  
 
Multiple poly(A) signals 
As it was indicated earlier, more than one poly(A) signal may be present in the 
pre-mRNA transcript. Let‟s explore the consequences of that. Let‟s take the case where 
two poly(A) signals exist downstream of the last exon. Since the region downstream of 
the stop codon is referred to as 3‟ UTR (untranslated region), the two poly(A) signals 
would produce two different lengths of 3‟ UTR. Since the 3‟ UTR has been associated 
with micro-RNA binding that can influence the rate of translation, by regulating the size 
of the 3‟ UTR, the cell can regulate the availability of micro-RNA binding sites by 
deciding how long the 3‟ UTR is going to be. 
Now, let‟s explore the case where the additional poly(A) signal may be before 
the last exon. In this scenario, if cleavage occurs at this poly(A) site, or at both poly(A) 
sites, then the pre-mRNA transcript will be divided into two or three pieces. In this 
scenario the transcript upstream of the first cleavage will be polyadenylated and the other 
one or two pieces downstream of the first cleavage will be degraded. This process, 
indirectly, regulates the exclusion of one or more exons from the final transcript. In a 
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second scenario, cleavage occurs at both poly(A) signals, but adenylation occurs only in 
the cleavage of the second poly(A) signal. This scenario provides the possibility for trans-
splicing which involves the joining of exons from different transcripts. The cleavage of 
the transcript between exons in the pre-mRNA results in two independent transcripts and 
affords the assembly of two spliceosomes at the same time. This shifts the tug of war 
among the competing splicing factors including enhancers and repressors and could result 
in the inclusion or exclusion of an exon from the final transcript where the outcome 
would have been different if a single transcript is involved. The scenarios described 
above more often than not occur all at the same time resulting in several spliced variants, 
and it is usually the ratio between the spliced variants that regulates the fate or final 
translation rate of each isoform.  
In addition to regulating the rate of translation, the 3‟ UTR and the poly(A) tail 
are also involved in RNA stability [19]. The 3‟ UTR also provides binding sites for 
proteins that direct the transcript for degradation, and both the 3‟ UTR and the poly(A) 
tail are subject to tagging that leads to degradation. The length of the poly(A) tail also 
plays a role in the rate or initiation of translation, and it is more frequent during early 
development. In one instance, in cells that serve as eggs, mRNAs with short poly(A) tails 
(about 30 to 50 bases) are not been translated and not degraded either. If the egg is 
fertilized, this triggers the lengthening of the poly(A) tails which results in translation 
[20]. In this scenario the egg has processed the transcript fully except for the proper 
length of the poly(A) tail. This enables the egg to reduce the enormous transcription and 
splicing load that is needed right after fertilization. 
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Splicing in simple terms 
So far we have covered capping, cleavage near a poly(A) signal, and 
polyadenylation. By far, the most complex and highly regulated process is the excision of 
introns and the joining of exons in what is called splicing which is further defined as 
constitutive and alternative splicing.  
 
 
Figure 6. Overview of transcription and splicing 
The promoter provides a binding site for the RNA polymerase to synthesize a primary 
transcript. After further processing, the pre-mRNA undergoes splicing where the introns 
are excised and the exons are joined [21]. 
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The importance of splicing and some aspects were described previously in brief. 
Here we will cover in detail the various aspects of the mechanism of splicing. In 
simplistic terms, a gene is comprised of exons and introns, and after transcription, the 
introns are excised and the exons are joined together. Introns were discovered in 1977, 
and ever since the mechanism of splicing is becoming more and more complex.  
Let‟s continue exploring Pandora‟s Box. In the early studies, pre-mRNA 
splicing was studied through in vitro systems where pre-mRNA transcripts were 
synthesized in a tube reaction. The pre-mRNA was isolated and then treated with 
mammalian nuclear extracts. The splicing assays yielded spliced products that were 
identified mainly through NPA‟s (Nuclease Protection Assays) and more recently 
through RT-PCR. The in vitro systems allow the investigator to focus on a specific Exon-
Intron-Exon sequence and investigate the conditions, the proteins, and the steps that 
result in spliced products. During the infancy of splicing studies, to achieve the same 
results through transfection of vectors in mammalian cells would have been very difficult 
if not unattainable. 
  
The two main steps of splicing 
The first studies established that splicing can be divided into two steps. In the 
first step the transcript is cleaved at the 5‟ splice site and then the free intron end is 
covalently attached to an adenine within the intron resulting in a loop. The adenine in 
question is the main consensus base in the sequence described earlier as the branch point. 
Unlike the bonds formed between nucleotides in the transcript, the bond formed between 
the 5‟ end nucleotide of the cleaved intron and the adenine of the branch point is at the 2‟ 
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hydroxyl group of the adenine (the 3‟ carbon of the adenine is attached to a neighboring 
nucleotide). The other step involves cleavage of the transcript at the 3‟ splice site 
followed by the covalent joining of the two exons in the standard 5‟ to 3‟ ligation. The 
second cleavage releases the intron completely. The looped intron with a free end is 
called a lariat which is eventually linearized and then degraded. The remaining transcript 
keeps going through the same two steps until all the introns have been excised. 
 
snRNAs and snRNPs 
Through these initial studies, the consensus sequences of the 5′ splice site, the 3′ 
splice site, the branch point, and the poly-pyrimidine tract were elucidated. A picture 
emerged where the introns in the pre-mRNA have distinct elements that direct their 
excision. At this point the question was if there is a single enzyme like the RNA 
polymerase in transcription that in a processive manner drives the excision of the introns. 
Well, the results revealed otherwise. Splicing involves several single proteins, a group of 
proteins, and RNA‟s that eventually form a large complex identified as the spliceosome. 
So far five RNA molecules have been identified as been part of the spliceosome where 
their sizes very from 50 to 200 bases. They are designated as small nuclear RNAs 
(snRNAs) and are given the names U1, U2, U4, U5, and U6. Before becoming part of the 
spliceosome, the snRNAs associate with several proteins forming an identifiable complex 
referred to as snRNP (small nuclear ribonucleoprotein particle). Here is where the 
terminology gets a bit complicated. Each of the U1, U2, and U5 snRNAs forms a distinct 
complex with proteins that bears the same name. In other words, there is a U1, U2, and 
U5 snRNA, and also a U1, U2, and U5 snRNP. The U4 and U6 snRNAs also form 
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individual snRNPs, but quickly associate with each other and form a single snRNP 
complex identified as U4/U6. 
  
Splicing Mechanism 
To summarize, there are five snRNAs that form five snRNPs. There is no U3 
snRNA or snRNP. The U4 and U6 snRNPs can associate and build a single snRNP. Now 
let‟s see how these are involved in the splicing process. The U1 snRNP recognizes the 5‟ 
splice site and binds to it. The binding involves hybridization of the pre-mRNA 5‟ splice 
site consensus sequence with the U1 snRNA that is part of the U1 snRNP. In a similar 
manner the U2 snRNP binds to the branch point. Here the U2 snRNA attempts to base 
pair with the branch point consensus sequence. As the U2 binds to the branch point, the 
U1 snRNP that is already bound to the 5‟ splice site brings the 5‟ splice site close to the 
3‟ splice site. Then the U5 snRNP binds to the 3‟ splice site and the poly-pyrimidine 
tract. In all three instances, a degree of wobbling is tolerated that allows degenerate base 
pairing. At this point we have accounted for three of the four snRNPs. The last snRNP 
identified as U4/U6 binds to the other three snRNPs already bound to the pre-mRNA, and 
this completes the assembly of the spliceosome.  
As it was indicated earlier, splicing involves two main steps. To mediate the first 
step that includes the cleavage of the transcript at the 5‟ splice site, the U4/U6 snRNP 
now splits into two snRNPs. The U6 snRNP binds to U1 snRNP and dislodges it from the 
5‟ splice site. Then the U6 snRNP moves in the 5‟splice site area. This is referred to as 
rearrangement of the RNA-RNA base pairing of the snRNAs with the pre-mRNA 
transcript. The rearrangement allows proteins associated with the spliceosome and 
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through the use of ATP to facilitate the first transesterification reaction that involves 
cleavage at the 5‟ splice site and ligation to the adenine at the branch point.  
 
 
This reaction frees the 5‟ exon, and the U5 and U6 snRNPs bring the 5‟ exon 
even closer to the 3‟ exon, while the other three snRNPs are pushing the partly cleaved 
Figure 7. Splicing mechanism 
In brief, snRNP U1 binds to the 5‟ splice site and U2 to the branch point. U4 binds to U6. 
U5 binds at the 3‟ splice site and the pyrimidine tract after associating with U4/U6 
completing the spliceosome. Rearrangement follows where U4/U6 splits, U1 gets 
displaced, and U6 replaces U1. Cleavage at the 5‟ splice site and ligation to the branch 
point completes transesterification #1. Cleavage at the 3‟ splice site and ligation of the 2 
exons completes transesterification #2. Finally, the spliceosome disassociates, the 
snRNPs are recycled, and the lariat is linearized and then degraded [12]. 
 16 
intron away. Then again, proteins associated with the spliceosome and through the use of 
ATP facilitate the second transesterification reaction that involves cleavage of the intron 
at the 3‟ splice site and ligation of the 5‟ exon to the 3‟ exon. This completes the excision 
of the intron, and now the spliceosome starts to dissociate into the individual snRNPs U1, 
U2, U4, U5, and U6. The snRNPs are recycled for the next assembly of the spliceosome 
and the U4 and U6 snRNPs associate again to form a single snRNP (U4/U6). The excised 
intron that now has the shape of a lariat is first cleaved at the adenine base to make it a 
linear molecule which is further processed for degradation. 
 
Multiple isoforms of mature mRNA 
There are five basic ways that a gene can produce different isoforms and/or 
spliced variants. It should be noted here that the term „isoform‟ refers to both a mature 
mRNA and the resulting protein. However, there are instances where two or more mature 
mRNAs can result in the same protein. In this scenario, I refer to the mature mRNAs as 
spliced variants and the resultant protein as isoform. This is the case of the PKC  gene 
where there can be seven different mature mRNAs (spliced variants), but six of the seven 
are translated to the same protein PKC II (isoform), and the seventh mature mRNA is 
translated to the PKC I protein (isoform). The first method that yields different 
isoforms/spliced variants is by manipulating the start and/or the end of transcription. The 
other four are dependent on the size of intron excision and are identified as 2) Exon 
Skipping, 3) Mutually Exclusive Exons, 4) Splice / Don't Splice, and 5) Competing 5' or 
3' Splice Sites [22]. 
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Multiple starts/stops of transcription 
This method of generating different mature mRNAs depends on two aspects. In 
the first aspect, a gene may have more than one transcription start that alters the 5‟ end of 
the transcript. Transcriptions that start further upstream usually introduce a new start 
codon that alters the start of translation and also the protein‟s N-terminus. In the second 
aspect, a gene may include more than one poly-A signal. In this scenario, additional 
binding sequences near the poly(A) signal determine the utilization fate of a given 
poly(A) signal. For example, different tissues, by regulating the expression of the protein 
factors that bind near a poly(A) signal, can determine which poly(A) signal is utilized. 
The case of multiple poly(A) signals was covered in more detail previously.  
 
Exon Skipping 
Let‟s use an example of a gene with 10 exons. Exon skipping is when let‟s say 
exon seven is sometimes included in the spliced product and sometimes is skipped (not 
included in the spliced product.) In this alternative splicing mechanism, the skipped exon 
is excised with the neighboring introns. That is, the intron upstream of the skipped exon, 
the skipped exon, and the intron downstream of the skipped exon, all together, behave as 
a single intron.  Exon skipping can occur not only at non-successive exons, but also at 
consecutive exons in what would be called multiple exon skipping. In the example above, 
if exon one and ten are always in the spliced product and the other exons can be skipped; 
then, the following possibilities exist. One product with all exons, eight products with a 
single exon skipped (2 through 9). If two consecutive exons are skipped, that could be 2-
3, 3-4, 4-5, 5-6, 6-7, 7-8, and 8-9 which is 7 combinations. If 3 consecutive exons are 
skipped, that could be 2-3-4, 3-4-5, 4-5-6, 5-6-7, 6-7-8, and 7-8-9 which is 6 
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combinations. One can see the pattern that for 8 skippable consecutive exons, the 
combinations are 1 for all exons included, and 8+7+6+5+4+3+2+1 which is 1 and 36 or 
37 total combinations. Thus, for X skippable exons, the formula is one plus the 
summation of (X+1-n) in the range of n=1 to X. Because of its high potential, exon 
skipping can function as an on/off switch to regulate different aspects of cellular 
processes.  
 
Mutually Exclusive Exons 
In this alternative splicing mechanism, two specific exons cannot both be 
present in the mature mRNA.  In broad terms, for any two exons A and B that fit this 
pattern of splicing, either A is included and B is skipped, or A is skipped and B is 
included. Because only one of the two exons will be in the spliced product, this pattern 
actually reduces the number of possible permutations. Let‟s use as an example a gene 
with 5 exons where exon-1 and exon-5 are always part of the mature mRNA. If exon-2 
and exon-3 are mutually exclusive and exon-4 is skippable, then only four permutations 
are possible: 1-2-4-5, 1-2-5, 1-3-4-5, and 1-3-5. On the other hand, if exons 2, 3, 4 were 
all skippable, then seven permutations are possible: 1-2-3-4-5, 1-3-4-5, 1-2-4-5, 1-2-3-5, 
1-4-5, 1-2-5, and 1-5. The „mutually exclusive‟ pattern, in an analogy, is like a car having 
manual transmission or automatic transmission. You can‟t have both, but you need at 
least one to drive the car. Just as a race driver will not have any success using an 
automatic transmission, the mutually exclusive pattern confers the right domain to a 
protein to be successful in a certain environment. 
 
 
 19 
Splice Don’t Splice 
In constitutive splicing, introns are excised and are not part of the mature 
mRNA. In this pattern of alternative splicing, an intron plays two roles. In the first role, 
the intron behaves as an excisable intron. In the second role, the intron is retained in the 
mature mRNA. In the second scenario there are four possibilities. The first possibility is 
that the upstream exon contains a stop codon, and as a result, the intron will not be part of 
the translation. In the second possibility the upstream exon does not contain a stop codon, 
and as a result, the intron becomes part of the coding region. If the intronic sequence 
includes a stop codon, then translation will end at that spot. If the intronic sequence does 
not include a stop codon, then two more scenarios are possible. The entire intronic 
sequence will be translated and the translation will continue in the downstream exon(s) 
without a frame shift. The last possibility is that the downstream exon(s) will be 
translated with a frame shift. If a gene has three introns of dual roles, then one would 
expect three additional spliced products. Thus, this alternative splicing pattern adds one 
spliced product for each retained intron. However, if more than one intron is retained in 
the spliced product, and if no stop codons exist in the retained introns or introduced due 
to frameshift on downstream exon(s)/retained-intron(s) then the number of total spliced 
products can increase by more than the number of retainable introns.  
 
Competing 5' or 3' Splice Sites 
This pattern of alternative splicing is akin to a certain sequence having dual 
roles. In a similar manner where an intron can be excised or retained, here only a portion 
of the intron is excised and a portion of the intron is retained. The nomenclature can be 
confusing in this situation. The boundary between an exon and an intron is identified as a 
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splice site. The boundary at the 5‟ end of the intron is identified as the 5‟ splice site and 
the boundary at the 3‟ end of the intron as the 3‟ splice site. In most situations the 
boundaries are unique and intractable. Some introns however, may include one or more 
additional 5‟ splice sites downstream of the first 5‟ splice site. For example, let‟s say an 
intron is 200 bases, and that 51 bases downstream from the 5‟ end another 5‟ splice is 
observed. In this case, if the first 5‟ splice site is utilized, then the 51 bases become part 
of the excised intron. If the second 5‟ splice is utilized, then the 51 intronic bases are 
retained. The second splice site may be labeled as a distal splice site, a cryptic splice site, 
a latent splice site, or simply an additional splice site. In the PKC  gene, the intron 
between exon- II and exon- I has four additional 5‟ splice sites while in the PKC  gene, 
the intron between exon-10 and exon-11 has one additional splice site. One could view 
the excision of a lesser intronic sequence at the 5‟ end of the intron as the extension of the 
upstream exon. 
In a similar manner of competing 5‟ splice sites, at the 3‟ end of the intron, let‟s 
say that 51 bases upstream of the standard 3‟ splice site, another 3‟ splice site is observed. 
Again, if the standard 3‟ splice site is utilized, then no intronic sequence is retained. If the 
upstream 3‟ splice site is utilized, then 51 bases of intronic sequence are retained and 
become part of the spliced product. Again, one could view the excision of a lesser 
intronic sequence at the 3‟ end, in this case, as the extension of the downstream exon. 
The utilization of an additional downstream 5‟ splice site results in a new 
spliced product, but may not result in a new protein. This is the case in PKC  and PKC  
where in PKC  the additional downstream 5‟ splice sites result in new spliced products; 
however, all spliced products result in the same translatable protein because the upstream 
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exon contains a stop codon. In contrast, in PKC  the additional downstream 5‟ splice site 
results not only in a new spliced product, but also in a new protein (PKC VIII).  
Even though each alternative splicing pattern has been described separately, it is 
understood that more than one splicing pattern and/or all them can be observed in a single 
gene. Thus, one can see quickly in how many ways and to what extend alternative 
splicing can increase protein diversity. One should expect that some genes, in some 
tissues/species may exhibit exotic patterns of alternative splicing that have or have not 
yet been observe. Thus, the Pandora‟s Box odyssey, most likely, has not reached Ithaca 
yet. 
 
Transport to the cytosol 
The mature mRNA has to pass a few more hurdles before it gets translated. An 
isoform may be degraded in the nucleus before it reaches the cytosol. It also needs a 
transporter protein to get passage to the cytosol. Once in the cytosol, it may be subjected 
to degradation before and after translation. 
In an average mammalian cell, while RNA is synthesized and processed in the 
nucleus [23], the percent of RNA in the nucleus compared to the entire cell is only about 
14%. Some RNAs, such as snRNAs and snoRNAs that are involved in the processing of 
the other RNA molecules are found mainly in the nucleus and represent about 2.8% of 
the cell‟s total RNA. However, some of these molecules do go to the cytoplasm to 
complex with various proteins, but then come back to the nucleus for their function. Most 
of the mRNAs at any given moment are found in the cytosol. 
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The nuclear membrane is speckled with nuclear pores that play a role in 
facilitating the trafficking of proteins and RNAs in and out of the nucleus [24]. Because 
almost all mammalian mRNAs are very long, diffusion through the nuclear pore is not 
feasible. Thus, the passage through the nuclear pore is a process that requires energy; 
usually involving conversion of GTP to GDP. Besides GTP, other important characters 
involved in the process are the proteins Ran and karyopherins. The latter are receptor 
proteins that are divided into exportins and importins. So far about 20 human 
karyopherins have been identified, where each is involved in the transport of a different 
type of RNA molecule. While some RNAs associate with karyopherins directly, it 
appears that some RNAs have binding sites not for karyopherins, but for other proteins 
which then associate with karyopherins [25, 26]. 
The transport of some mRNAs to the cytosol is regulated by the mRNA‟s 3‟UTR. 
This region provides cis-acting elements that interact with trans-acting proteins that 
facilitate transport to the cytosol and sometimes also localization in the cytosol [27]. The 
PKC II protein may be derived from up to six different spliced variants. The difference 
between those spliced variants is the size of the 3‟ UTR. We speculate that variable 
3‟UTR provides sites for micro-RNA activity and also binding sites for proteins that 
regulate transport to the cytosol. When the II exon downstream 5‟ SSII is utilized, the 
additional 3‟UTR provides may provide not only additional micro-RNA sites, but also 
transport regulation sites. The 5‟ SSII spliced variant may be transported to the cytosol 
faster than its cousin spliced variant of SSI.
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After synthesis of the poly(A) tail, another protein that plays the role of quality 
control [28], sets in motion the transport pathway. The transport mechanism utilizes 
additional proteins in the cytosol, if needed, to deliver the mRNAs in their defined region 
of the cell. As an example, the mRNAs of cytosolic proteins that are slated for 
mitochondrial functions are delivered at the surface of these organelles. 
  
 
Figure 8. Transport of Eukaryotic RNAs through the nuclear pore 
In eukaryotes, rRNAs, tRNAs and mRNAs are transported from the nucleus to the 
cytoplasm, where these molecules carry out their cellular functions. At least some of the 
snRNAs and snoRNAs are also transported to the cytoplasm, where they are coated with 
proteins before returning to the nucleus to carry out their roles in RNA processing [17]. 
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Translation in the cytosol 
The mature mRNA has now finally made it to the cytosol. As it was indicated 
earlier, once in the cytosol, it may be subjected to degradation before and after 
translation. In addition to that, during translation the rate of translation may be sped up or 
slowed down. For translation to start, the mRNA has to come in contact with ribosomes. 
Most eukaryotic mRNAs are divided into three regions. The 5′ untranslated region 
(5′ UTR), the translated region that begins with a start codon (mainly ATG) and ends 
with a stop codon, and the 3′ untranslated region (3′ UTR). The untranslated regions 
which include the 5′ cap and the 3′ poly(A) tail, provide recognition sites and binding 
sites for proteins associated with the ribosomes to facilitate the formation of the mRNA-
Ribosome complex and stabilize the translation process. 
Ribosomes provide the platform where the mRNA is decoded three nucleotides at 
a time to synthesize the prescribed polypeptide. Ribosomes are complexes assembled by 
proteins and ribosomal RNAs. They are quite large and contain two subunits. The 
eukaryotic ribosome contains a 60S subunit and a 40S subunit; where the latter is smaller 
than the former. The function of the ribosomal RNAs in the ribosome is to facilitate 
catalysis while the proteins simply hold the complex together and enhance the rate of 
catalysis. Each triplet of nucleotides is decoded by a tRNA molecule. The amino acid 
prescribed by the triplet nucleotide is recruited by a specific tRNA. The prescribed amino 
acid is first covalently attached to its corresponding tRNA, and then it is transferred to the 
growing polypeptide. 
The translation process appears to start with the 40S subunit recognizing the 
mRNA‟s 5′ cap. This is facilitated by proteins that bind to the 5‟ cap and also associate 
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with the ribosome. The 40S subunit scans the mRNA downstream of the 5‟ cap for the 
start codon (mainly AUG). However, preference is given to the AUG that is flanked by 
the following consensus sequence: GCCPuCCAUGG.  This sequence is also known as 
the Kozak sequence where the two bases flanking AUG are the most important [29]. 
After this initiation step, the downstream decoding continues where each triplet 
nucleotide prescribes the amino acid to be incorporated next. The polypeptide keeps 
growing until a stop codon is encountered at which point translation stops and the 
polypeptide is released from the ribosome. The ribosome is recycled to start another 
round of translation. 
 
Protein expression regulated by the isoform used 
There are several levels of regulation that can participate in the rate of protein 
diversity and rate of expression. Those related to the isoform used are described here. By 
regulating the transcription start, the start of translation can be regulated as well. Several 
proteins can participate in deciding where transcription starts. A gene may contain more 
than one poly(A) signal, and thus the end of the transcription may lead to an isoform that 
codes a different protein, or an isoform that has a different 3‟ UTR. The latter can play a 
role in the rate of translation through interaction with microRNAs. The 3‟ UTR can also 
affect the mRNA degradation rate by making the transcript unstable or by providing sites 
for tagging. Alternative splicing can produce different spliced isoforms that lead to 
different protein isoforms, or different spliced isoforms that lead to the same protein.   
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Overview of Kinases and PKC’s 
A kinase is an enzyme that catalyses the phosphorylation of an acceptor molecule. 
A protein kinase is a kinase that phosphorylates the hydroxyl group of a serine, threonine 
or tyrosine. Protein kinases are classified as: a) Serine/threonine protein kinases – which 
phosphorylate either serine or threonine residues, and b) Protein Tyrosine kinases (PTKs) 
– which phosphorylate tyrosine residues. Protein kinase C (PKC) is a family of 12 or 
more related isozymes that are serine/threonine kinases and are divided into three groups.  
 
Classical PKC‟s (cPKC‟s), novel PKC‟s (nPKC‟s), and atypical PKC‟s (aPKC‟s). 
The cPKC group includes cPKC , cPKC I, cPKC II, and cPKC . All PKC‟s contain a 
regulatory domain and a catalytic domain (see figure 9). The regulatory domain of 
cPKC‟s includes the N-terminus, a binding site for phosphatidylserine (PS), a binding site 
that interacts with diacylglycerol (DAG) or phorbol esters, and a binding site for Ca2+. 
The catalytic domain includes the C-terminus, an ATP binding site, and a substrate 
binding site. 
Figure 9. Protein Kinase C Isoforms 
Schematic diagram of the different categories of PKC isoforms. The isoforms in the star-
like symbols are those expressed in insulin-responsive cells [30]. 
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Most PKC‟s are found in the brain and liver (see Table 1), but each isoform 
displays different substrate specificity and cofactor activation. 
Table 1. PKC Isoform Tissue/Cell Expression 
In this project the cell lines used mostly were skeletal muscle. 
 
PKC isoform            
Cell /Tissue α βI βII γ δ ε η Ζ Θ λ/ι μ 
Brain + + + + + + ? + ? ? ? 
Central 
Nervous 
Tissue 
+ + + - + + + + + + + 
Heart  + + + - + + + + + + ? 
Small 
Intestine 
? ? ? - + ? ? ? ? + ? 
Kidney + + + - + + ? + ? ? + 
Liver + + + - + + ? + + + ? 
Airways 
Smooth 
Muscle 
+ + + - + + + + + + + 
Lung + + + - + + + + + + + 
Neutrophil + + + - + ? ? + ? ? ? 
Monocyte + + + - + + + + - - + 
Macrophage + + + - + + + + - - + 
Eosinophile + + + - + + - - - + + 
Platelet + + + - + + ? + + ? ? 
T-Lymphocyte + + + - + + + + ? ? ? 
B-Lymphocyte + + + - + + + + ? ? ? 
Vascular 
Smooth 
Muscle 
+ + + - + + + ? ? + ? 
Retina + + + - + + ? + ? ? ? 
Spleen + + + - + + + ? ? + ? 
Testis + + + - + + ? + ? + ? 
Ovary + + + - + + ? + ? + ? 
Pancreas + + + - ? + ? ? ? + ? 
Thymus + + + - ? - ? ? ? ? ? 
Fibroblast + + - + + + ? + ? ? + 
Skeletal 
muscle 
+ + + - + + + + + + + 
Adipocyte + + + + + + + + + + + 
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The protein sizes range from 67.2 to 81.6 KD‟s (see Table 2). The regulatory 
domain is connected to the catalytic domain through a region which is subject to 
proteolysis by calpain I and II and by capspase-3. Cleavage at that region results in an 
active catalytic fragment.  
Table 2. PKC Isoform Size 
 α βI βII γ δ Ε η(L) θ δ λ 
Amino 
Acids 
672 671 673 697 673 737 683 707 592 586 
Kilo 
Daltons 
76.8 76.8 76.9 78.4 77.5 83.5 78.0 81.6 67.7 67.2 
 
Background on Insulin 
Insulin is synthesized and released by the -cells of the pancreas. Glucose is the 
primary stimulant to secretion. Insulin can function as a growth factor for many cells, and 
can also initiate multiple signaling pathways that result in glucose uptake, glucose 
metabolism, and expression of liver and adipocyte enzymes. The insulin receptor is an 
RTK, and acts via a Ras-dependent/independent pathway, that mediates the signal 
through an insulin receptor substrate (IRS). Most cases have shown affected patients to 
have mutations in the insulin receptor (IR) á-subunit. Such mutations impair insulin 
signaling by decreasing IR expression on the cell surface and/or IR affinity for insulin 
(strength of insulin attachment). The lack of insulin to store glucose causes the blood 
levels to elevate. Excess glucose reacts with hemoglobin to form excessive amounts of 
glycosylated hemoglobin and reflect the long-term elevated blood glucose. Eventually 
these can crosslink and seriously impair the oxygen carrying ability of the red blood cells.   
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Protein Kinase C in Signaling 
The PKC family members affect many cellular functions including apoptosis, cell 
proliferation, cell differentiation, and transcriptional activation [31]. The cPKC‟s are 
Ca++-dependent and can be activated by diacylglycerol, and phospholipid.  Through 
alternative splicing, the PKCβ gene codes two proteins identified as PKCβI and PKCβII. 
The alternative splicing that generates these two isoforms takes place at C-terminal exon. 
The pre-mRNA of PKCβ contains 18 exons. If exon-17 (exon-βII) is included in the 
spliced transcript, protein PKCβII is expressed. If exon-βII is skipped (excluded), protein 
PKCβI is expressed. It should be pointed out that when exon-βII is included, exon-βI is 
included as well. However, exon-βII which is 216 bases long precedes exon-βI which is 
150 bases long, and within exon-βII (156 bases from its 5‟ end) a STOP codon exists that 
renders everything downstream of the stop codon as the 3‟UTR of isoform PKCβII. Thus, 
the remainder of exon-βII, the entire exon-βI, and the 3‟UTR of exon-βI, in this case, 
they all become PKCβII 3‟UTR (see Figures 11, 12). Since in exon-βII there are 156 
bases upstream of the stop codon, and since exon-βI is 150 bases, the variable C-terminus 
size of these two isoforms is 52 and 50 amino acids respectively. And, as a result, their 
overall size differs by two amino acids only [32, 33].  
Both PKCβI and PKCβII have been detected endogenously in cells growing in 
normal media of 5.5 mM glucose concentration [34]. The role of PKCβII appears to be 
more diverse than its sister isoform. Besides PKCβII being involved in glucose uptake 
[35], and cellular proliferation [36, 37], it has also been connected to attenuation of DNA 
synthesis, and through protein-protein interactions, it is involved in the regulation of the 
insulin receptor [38].  
 30 
At the mRNA phase, the PKCβII mRNA exhibits distinctive features not 
observed in PKCβI such as an instability element that renders the PKCβII mRNA 
unstable in the presence of high glucose concentrations which can down-regulate the 
PKCβII mRNA half life and indirectly reduce its protein level [39, 40]. 
 
The insulin signalin pathway regulates the PKC  alternative splicing. The insulin 
receptor is part of the tyrosine kinase family. There are two insulin receptor isoforms and 
each is composed of two α-subunits and two β-subunits where these subunits are linked 
by disulphide bonds. There are several insulin receptor subtrates (IRS) that interact with 
the insulin receptor (see figure 10); however, in glucose metabolism IRS-1 and IRS-2 are 
the most important. These substrates become phosphorylated upon binding to the insulin 
receptor and then interact with downstream elements in the insulin transduction pathway. 
Figure 10. PKC Isoforms in Insulin Responsive Tissues 
Summary of PKC isoforms with their known substrates in insulin-responsive tissues. The 
documented relations of isoform–substrate interactions for the various isoforms are: 
PKC -IRS(-1); PKC II-IR, PKB(Akt), MARCKS, GLUT4 transporter; PKC -IR, IRS-
1, PKB; PKC -PKB, GSK3; PKC -IRS-1; (PKC -glucose transporter) [30]. 
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One of these elements is the PI3-kinase which is considered the main mediator. 
Phosphoinositide-3-kinases (PI3Ks) are signal transducer proteins that phosphorylate the 
carbon-3 hydroxyl group of the inositol group of phosphatidylinositol. The regulatory 
domain of a PI3K has six subunits and the catalytic domain, also known a p110, has four 
subunits. In the model proposed in this project, the regulatory subunit p85 and/or the 
catalytic domain p110 are involved in the insulin signalin pathway that regulates the 
splicing of exon- 2 in PKC . Once activated, a PI3-K launches a complex 
phosphorylation cascade that may involve the phospholipids Phosphatidylinositol (4,5)-
biphosphate  (PIP2) and/or Phosphatidylinositol (3,4,5)-triphosphate (PIP3), PDK1 
(phosphoinositide-dependent kinase 1), PKB (protein kinase B) and Clk/Sty. PKB is also 
known as Akt. 
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Splicing of PKC  
As it was indicated earlier, the PKC  gene consists of 18 exons. The last three 
exons are identified as C4, betaII, and betaI. The intronic sequence between exon betaII 
and exon betaI is around 6,000 bases depending on the species involved. Exon betaII is 
216 bases long, and exon betaI is 150 bases long. There is a stop codon at the 3‟ end of 
exon betaI, and there is also a stop codon within exon betaII. The latter stop codon is 
located 156 bases downstream from the 5‟ end of exon betaII. Since exon betaII is 216 
bases long, and since the stop codon is after 156 bases from the exon‟s 5‟ end, it means 
Figure 11. PKC  pre-mRNA variants 
The PKC  gene consists of four constant regions and five variable regions. The constant 
region C4 and the variable region V5 are shown in more detail. Because the PKC  gene 
contains two poly(A) signals, after transcription two pre-mRNA variants are possible. 
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that the rest 60 bases are 3‟ UTR. Within the intron downstream of exon betaII there are 
additional 5‟ splice sites. Also, besides the main poly(A) signal downstream of exon-
betaI, there is an additional poly(A) signal downstream of exon-betaII. Thus, the PKC  
gene can generate two pre-mRNA transcripts (see Figure 11).  
 
If the first poly(A) signal is utilized, then the pre-mRNA generated is spliced into 
one mRNA variant which codes for PKC II. If the main (second) poly(A) signal is 
utilized, then the pre-mRNA generated can be spliced into six possible spliced variants. 
Using the alternative splicing pattern of exon skipping, when exon-betaII is skipped, then 
the spliced variant generated is translated to protein PKC I. If exon-betaII is included, 
then there are five possible spliced variants. The shortest of the five spliced variants is 
generated when the conventional 5‟ splice site is utilized, which results in the shortest 
size of 3‟ UTR. The other four spliced variants are generated from the additional 5‟ splice 
Figure 12. PKC I Isoform 
There is only one PKC I spliced variant that results in the PKC I protein. The PKC I 
spliced variant is generated when exon-betaII is skipped during splicing. The splicing 
event ligates exonC4 to exon-betaI. 
Splicing 
C4 II I 
(A)n 
I C4 
(A)
n 
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sites that are downstream from the conventional betaII exon boundary. The conventional 
5” splice site is identified as splice site I or SSI. The four additional 5‟ splice sites are 
identified as SSII, SSIII, SSIV, and SSV. 
  
 
To summarize, the PKC  gene generates two pre-mRNA variants. The first pre-
mRNA variant is generated through utilization of the first poly-A signal, and it is spliced 
into a single spliced variant. The second pre-mRNA variant is generated through the 
utilization of the second (main) poly-A signal, and it can be spliced into six different 
spliced variants. Protein PKC I arises from the translation of a single spliced variant 
which occurs when the main (second) poly(A) signal is utilized, and during splicing, 
exon-betaII is skipped. Protein PKC II may be translated from six different spliced 
variants (mRNAs). One spliced variant arises when the first poly-A signal is utilized. The 
Figure 13. PKC II Isoform Utilizing the first poly-A signal 
The PKC  gene contains two poly-A signals. When the first poly-A signal is utilized, 
there is only one possible spliced variant which is translated into the PKC II protein. The 
3‟UTR of this spliced variant does not include exon-betaI and its associated 3‟UTR. 
II C4 I 
PAS PAS 
C4 II 
(A)n 
Transcription/Adenylation 
Splicing 
II 
(A)n 
C4 
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other five spliced variants arise when the main (second) poly-A signal is utilized, and 
during splicing exon-betaII is included with a varying length of 3‟UTR for each spliced 
variant. In all, the PKC  gene can potentially generate seven different spliced variants. 
The most likely scenario is that all spliced variants are generated all the time; however 
the ratio of each spliced variant fluctuates depending on the cellular processes the cell is 
trying to carry out. 
 
 
The first PKC  pre-mRNA generates one splice variant for PKC II. The second 
PKC  pre-mRNA can generate six spliced variants; one for PKC I, and five for PKC II. 
Thus, the PKC  gene generates two pre-mRNA variants, a total of seven spliced variants, 
of which one translates to PKC I protein and all the other six translate to PKC II protein. 
As it was indicated earlier, exon-betaII contains a stop codon; thus, all the spliced 
Figure 14. PKC II Isoform Utilizing the last poly-A signal and the first 5’ SS  
The diagram depicts splicing of the second PKC  pre-mRNA variant into one of the five 
possible spliced variants. Exon-C4 ligates to exon-betaII, and exon-betaII utilizing the 
first 5‟ splice site (SSI) ligates to exon-betaI. The region downstream of the stop codon 
within exon-betaII becomes the 3‟UTR which includes exon-betaI and its own 3‟UTR. 
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variants for PKC II are translated to the same protein. The main difference in the 
PKC II spliced variants is the size of the 3‟UTR. 
 
  
The PKC II 3‟UTR can be divided into three sub-regions. The stop codon inside 
the betaII exon and the subsequent 57 downstream bases (60 bases total) make up the 
first sub-region. This sub-region is present in all six PKC II spliced variants. The second 
sub-region is the betaI exon and its downstream 3‟UTR. This sub-region is present in all 
five PKC II spliced variants that arise from the second PKC  pre-mRNA, and it is 
absent in the PKC II spliced variant that arises from the first PKC  pre-mRNA. The 
third sub-region is a section of the intronic sequence downstream of exon-betaII. The 
length of this section varies in each PKC II spliced variant. Table 3 summarizes the 
details of each 3‟UTR sub-region. 
Figure 15. PKC II Isoform Utilizing the last poly-A signal and the 5’ SSII  
The diagram depicts splicing of the second PKC  pre-mRNA variant into one of the five 
possible spliced variants. Exon-C4 ligates to exon-betaII, and exon-betaII by utilizing the 
second 5‟ splice site (SSII) ligates to exon-betaI. This spliced variant has additional 3‟ 
UTR area compared to the spliced variant utilizing SSI. 
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Table 3. Summary of PKC  spliced variants 
Isoform Pre-mRNA Poly-A Signal Spliced Variants 
PKC I II Last 1 
PKC II I First 1 
II Last 5 
PKC II Spliced 
Variant 
Pre-
mRNA 
5’ Splice 
Site 
3’ UTR Regions (estimated) 
Exon- II 5’ Intron Exon- I 
PKC II-SV-1A I N/A 60 b (450 b) NO 
PKC II-SV-2A II SSI 60 b Zero b YES 
PKC II-SV-2B II SSII 60 b  (97 b) YES 
PKC II-SV-2C II SSIII 60 b  (136 b) YES 
PKC II-SV-2D II SSIV 60 b  (368 b) YES 
PKC II-SV-2E II SSV 60 b  (707 b) YES 
 
Figure 16. The PKC II six spliced variants  
The diagram depicts the two PKC  pre-mRNA variants, and the six PKC II spliced 
variants. All six spliced variants get translated to the same PKC II protein. The main 
difference between the spliced variants is the size and content of the 3‟ UTR. 
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SRp40 effect on splicing of PKC  
At this point we have shown that the PKC  gene can generate two pre-mRNAs, 
and on the second pre-mRNA, through alternative splicing, it can generate six different 
spliced variants. One spliced variant is generated through skipping of exon-betaII that 
results in protein PKC I. The other five spliced variants are generated when exon-betaII 
is included. For three of these spliced variants, insulin initiates the switch from exon-
betaII skipping to inclusion of exon-betaII. The response occurs within 15 minutes after 
insulin treatment. Insulin affects the first three 5‟ splice sites. The length of insulin 
treatment affects the ratio of the three spliced variants (not in all cell lines). In general, 
the short time treatment favors the spliced variant with SSI, and the longer time favors 
the spliced variant with SSII. 
Insulin accomplishes the inclusion of exon-betaII via phosphorylation of SRp40. 
This involves the phosphatidylinositol 3-kinase pathway and Akt2 kinase. Insulin binds 
to the insulin receptor which activates an insulin response substrate (IRS1-4). The signal 
is then transmitted to PI3-K which further activates PDK1-2. Finally, this phosphorylates 
Akt2 which then phosphorylates SRp40. The phosphorylated form of SRp40 can now 
bind to intronic and/or exonic binding site(s) and facilitate the exon-betaII inclusion. 
SRp40 has more than one phosphorylation site.  If insulin treatment is continued, this 
may result in SRp40 having multiple sites phosphorylated. This could alter the binding 
preference of SRp40 at the intronic/exonic binding sites and the 5‟ splice site utilization. 
One can speculate that it is possible for all seven spliced variants to exist all the 
time in some kind of an equilibrium ratio among them. As conditions change, this could 
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shift the equilibrium and as a result a certain spliced variant becomes the favorite product 
while a particular spliced variant may be reduced by ten-fold, a hundred-fold, and so on.     
 
PI3-kinase pathway activated by factors other than insulin 
The PI3-kinase pathway includes three classes of Phosphoinositide 3-kinases (PI 
3Ks). The family of these proteins is involved in several cellular functions including 
differentiation, metabolism, and survival. PI3Ks are intracellular signal transducers that 
phosphorylate the carbon-3 hydroxyl group of the inositol ring of phosphatidylinositol. 
PI3Ks transmit and amplify signals from different receptors by producing phospholipid 
second messengers that in turn activate downstream targets. In insulin activation, PI3Ks 
interact with IRS-1/2 and eventually activate the PKB/Akt component of the pathway. In 
our model, Akt2 phosphorylates SRp40 directly, or it phosphorylates Clk/Sty that in turn 
phosphorylates SRp40 [41]. The phosphorylated SRp40 mediates the inclusion of exon-
II which results in PKC II. We hypothesize that PKC II is involved in the translocation 
of GLUT-4 to the cell membrane resulting in glucose uptake in skeletal muscle cells and 
adipocytes. 
As it was indicated above, PI3Ks transmit and amplify signals from different 
receptors. In other studies it has been shown that the downstream PKB/Akt component 
can transmit survival signals into cells [42-44] that protect cells from apoptosis. It has 
been reported that activation of PI3K also occurs by retinoic acid (RA). In this novel 
mechanism, RAR interacts directly with PI3K through PI3K‟s p85 regulatory subunit. It 
appears that RAR forms a stable complex with p85-PI3K that may eventually lead to 
activation of PKB/Akt component. In our study we show that the splicing of PKC  is 
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effected by RA, and that the splice variant produced mediates the survival of the cell by 
protecting the cell against apoptosis. Furthermore, we show that the splicing is facilitated 
by the SR protein SC35 (SRp30b). 
 
Background on Retinoic Acid 
Retinoic acid (RA) has 2 forms; the all-trans RA which is the active metabolite of 
Vitamin A and the cis-RA. Retinoic acid binds to two receptors: the retinoic acid receptor 
(RAR), and the retinoid X receptor (RXR) where both are subdivided into , , and . 
RAR‟s are type II nuclear receptors. An RAR heterodimerizes with RXR forming a dimer 
that binds to retinoic acid response elements (RAREs). In the absence of ligand, the 
RAR/RXR dimer also complexes with co-repressor proteins. In the presence of RA, the 
dimer changes conformation, the co-repressor dissociates, and then co-activator proteins 
bind to the dimer. This results in up-regulation of transcription of the target gene. 
In this project, our results indicate that RA regulates the inclusion of exon-10 
extended size of PKC  resulting in human PKC VIII (mouse PKC II). Furthermore, the 
inclusion is mediated by the SR protein SC-35 (SRp30b).  
 
Splicing of PKC  and PKC  involves competing 5’ splice sites. 
Protein kinase C (PKC) ßI and -ßII are alternatively spliced products of PKCß 
pre-mRNA. Insulin regulates the inclusion of PKCßII exon and promotes the switch of 
the PKCßII isoform from the -ßI isoform via alternative splicing [32]. Among other 
functions, PKCßII has a distinct physiological role in glucose uptake [35]. The insulin 
regulation of PKC II occurs within 15 min of insulin treatment. This mechanism of rapid 
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response in alternative splicing is distinct from other hormonally regulated systems that 
have been described [45-47].  
Previous work on the splicing of PKC II was mainly on endogenous products.  In 
this project, through the construction of functional heterologous minigenes, we show that 
insulin regulated the inclusion of PKCßII exon and activated additional 5'-splice sites in 
distinct cell types such as skeletal muscle, vascular smooth muscle, pre-adipocytes, 
embryonic fibroblasts, and hepatoma cells. We also demonstrate that the splicing of the 
heterologous minigenes was regulated by phosphorylation in vivo by a PI3-kinase 
pathway via Akt2 kinase. The in vitro splicing assays demonstrated that exon- II can 
utilize up to four additional 5‟ splice sites. The minigene experiments also identified the 
essential intronic sequence involved in SRp40 binding to the pre-mRNA.  
The project continued in identifying how SRp40 was phosphorylated. Previous 
studies had shown that Akt2 or PKB regulate alternative splicing [4, 48]. We produced 
biochemical and genetic evidence that Akt2 kinase phosphorylates SRp40 in vivo and in 
vitro. We showed that in mice immortalized fibroblasts lacking Akt2 [49], SRp40 
phosphorylation is not regulated by insulin, and that PKC II levels are low compared 
with cells from wild type mice. The study did not exclude phosphorylation of SRp40 by 
another kinase. The Clk kinases participate in a network of regulatory phosphorylation 
mechanisms that enable SR proteins to control RNA splicing in response to 
phosphorylation [50-53]. SR proteins, within their Arg/Ser domains, contain the highest 
number of Akt consensus motifs found in proteins [49]. Since Clk/Sty contains two Akt 
consensus motifs, Arg-Xaa-Arg-Xaa-Xaa-(Ser/Thr), we hypothesized that its activity 
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might be regulated by insulin. Our results support the proposed mechanism that Akt2 
phosphorylates Clk/Sty and that Akt2 and Clk/Sty can phosphorylate SRp40. 
Our lab had recently identified a new splice variant of human PKCδ, PKCδVIII 
(GenBank Accession No. DQ516383). Sequencing and computational analysis of the 
PKCδVIII sequence indicated that this human splice variant is generated by utilization of 
an alternative downstream 5' splice site of PKCδ pre-mRNA exon 10 [54]. Thus, at this 
point it was established that exon- I (exon-17) of PKC  and exon-10 of PKCδ have 
competing 5‟ splice sites that are utilized under certain conditions. In PKC  it is through 
insulin, and in PKC  it is through RA. We demonstrated that RA dramatically increased 
the expression of PKCδVIII via alternative splicing in NT2 cells. As in PKC , we 
constructed heterologous minigenes to identify if any SR proteins are involved. Our 
results indicate that the SR protein SC35 mediates the splicing of PKCδVIII, and we 
identified the sequence in the pre-mRNA that SC35 binds. 
In this project we have shown that the construction of heterologous minigenes and 
in vitro splicing assays can be successfully employed to elucidate the splicing mechanism 
of alternatively spliced genes. We have further used the minigenes to identify/verify 
substrates of Akt2 and Clk/Sty, and to advance the knowledge of the insulin pathway. We 
have left something for the future: the elucidation of SC35 phosphorylation pathway. One 
scenario is where RA activates PI3K as described earlier, which in turn activates 
Akt2/Clk, and which finally phosphorylates SC35. In another scenario, SC35 may be 
directly or indirectly up-regulated by RA through transcriptional up-regulation. The SC35 
promoter may include RARE‟s, or another protein(s) that regulate SC35 may include 
RARE‟s. 
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Functions of PKC  in various species 
The alternative splicing of PKCδ in humans results in PKCδI and PKCδVIII. The 
PKCδI isoform is expressed in all species. As indicated earlier, PKCs have a hinge region 
that is cleaved by caspases. PKCδI is cleaved by caspase-3 [55]. PKCδVIII in humans 
and PKCδII in mice are not cleaved by caspase-3. In this project we show that PKCδVIII 
splicing is regulated by RA. We also have preliminary data (not shown) that PKCδII in 
mice may also be regulated by RA. Most PKCs are activated by phorbol ester. However, 
in rats, PKCδIII displays weak or slow phorbol ester activation [56]. PKCδ isoforms IV, 
V, VI, and VII have unique characteristics. First, they are all expressed in mice only. 
Secondly, they are missing the first portion of the pseudosubstrate region (V1 and C2 
domains). Thirdly, they are only expressed in testis. 
PKC  has many substrates, and as a result it is involved in cellular processes with 
diverse biological activity. To name a few, PKCδ modulates the eukaryotic elongation 
factor 1-α (eEF-1α) [57]. It is involved in the regulation of the mammalian target of 
rapamycin (mTOR) [58]. It regulates quite a few transcription factors (p300, Sp1, NF-κB, 
Stat1, and Stat3) [59-62]. As it has been shown in this project and other studies it also 
plays a role in cell survival and apoptosis. While PKC VIII is a pro-survival isoform, 
other isoforms are pro-apoptotic. For example, Rad9 upon becoming phosphorylated by 
PKCδ binds to Bcl-2 thereby inhibiting it, which in turn promotes apoptosis [63]. Most 
recently, caspase-3, a key mediator of apoptosis, was shown to associate and be 
phosphorylated by PKCδ in human primary monocytes. The phosphorylation of caspase-
3 promotes its apoptotic activity in vivo and in vitro [64]. Moreover, silencing of PKCδ 
reduced etoposide-induced apoptosis and consistently overexpression of a PKCδ-cat 
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increased caspase-3-dependent apoptosis. PKCδ phosphorylates also the tumor 
suppressor p53 at Ser46, inducing cell death [65].  
 
Splicing of PKC  in humans 
The PKC  gene in humans contains 18 exons. The hinge region that is subject to 
caspase cleavage is at the junction of exon-10 and exon-11. The standard size of exon-10 
is 97-bases that results in the PKC I isoform. However, exon-10 has a competing 
downstream 5‟ splice site that extends the exon by 93 bases (31 amino acids).  
 
 
Figure 17. The two splice variants of PKC   
The schematic depicts the two PKC  mRNA variants. The PKC VIII utilizes the second 
5‟ splice site (SSII). The extra 93 bases are depicted with the region between exon-10 and 
exon-11 identified as 8. The hinge region is at the junction of exon-10 and exon-11. The 
extra 93 bases are translated into 31 amino acids that disrupt the cleavage site for 
caspace-3. The utilization of SSII is regulated by RA and mediated by SC35. 
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The competing downstream 5‟ splice site (SSII) is regulated by RA and the 
utilization of SSII is mediated by SC35. When SSII is utilized, PKC VIII is expressed 
which has a profound effect in the fate of the cell. The additional 31 amino acids disrupt 
the recognition sequence for caspase and as a result it blocks apoptosis. 
Figure 17 shows a schematic of the PKC  domains, and for clarity, the hinge 
region is shown longer. The schematic is focusing on the splicing of exons 9 to 11 and it 
depicts where exons 9 to 11 approximately lie. When SSI is utilized, the resulting mRNA 
is translated into protein PKC . When SSII is utilized, the resulting mRNA is translated 
into protein PKCδVIII. The additional 93 bases that result in PKCδVIII include the 
binding site for SC35. 
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Splicing Vectors 
Splicing vectors provide a platform for focusing on a single exon either with or without 
flanking intronic sequence(s), or even on a part of an exon. A splicing vector contains a 
basic structure of 5’-Exon-Intron-3’-Exon where in the synthesized transcript the intron 
is excised and a constitutive spliced product of the two exons is produced. The standard 
structure of a splicing vector includes a promoter upstream of the 5’-Exon-Intron-3’-
Exon structure. The 5‟ exon may be a 5‟UTR or it may be an exon from a common gene. 
Whether it is a 5‟UTR or an exon, it is identified as a splice donor (SD). The intron is a 
fully functional intron that includes a branch point, a poly-pyrimidine tract, a 5‟ splice 
site, and a 3‟ splice site. The sequences of the splice sites are most of the time identical to 
the consensus sequences. The 3‟ exon is usually an exon from a common gene. This 
second exon is identified as a splice acceptor (SA). Finally, a poly(A) signal sequence 
follows that may be preceded by an optional stop codon.  A multiple cloning site (MCS) 
is usually within the intron (generally between the 5‟ splice site and the branch point). In 
another design the MCS sequence is placed at the beginning of the SA region. Without an 
insert, the splicing vector is used as a control vector producing the so called constitutive 
spliced product (SD-SA). The insert usually contains the exon of interest and its flanking 
intronic sequences. Upstream of the exon about 50 or more bases are needed to ensure the 
intronic sequence between the exon of interest and SA will be excised. Downstream of 
the inserted exon only 6 bases are needed to maintain the splice site. The spliced products 
are detected by using unique primers that bind at the SD and SA regions. The PCR results 
can reveal if the exon is skipped during splicing or if it becomes part of a spliced product. 
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Splicing Vector pSPL3 
One of the splicing vectors used in this project is vector pSPL3 described in 
Figure 18. The Ampr gene enables selection and vector amplification in bacteria. The SD 
and SA regions behave as exons. When the vector is transfected into mammalian cells, 
transcription starts after the SV40 promoter. The SV40 Late Poly(A) Signal (LPAS) 
appends a poly(A) tail to the transcript. During splicing, the intron is excised resulting in 
a single spliced product. 
 
 
The intron between SD and SA includes a multiple cloning site so that a foreign 
sequence can be inserted. The insert is usually an exon with part of its flanking intronic 
Figure 18. Vector pSPL3, its components, and the main spliced product.  
The pSPL3 vector contains a splice donor (SD) and a splice acceptor (SA) sequences that 
operate as exons and a fully functional intron between them. Transcription starts after the 
SV40 promoter and ends at the LPAS (late poly(A) signal). The transcript results in a 
single constitutively spliced product. 
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sequences. Thus, when an exon is inserted, more than one spliced product is expected. 
The main additional spliced product is the exon inclusion as shown in Figure 19. 
 
When mammalian cells are transfected with a pSPL3 vector that includes an 
insert, the cells are harvested after 2 to 4 days and the RNA is extracted. This is followed 
by an RT (reverse transcription) reaction and then by PCR. Using unique primers that 
bind in the SD and SA regions, the PCR bands will include the spliced product with and 
without the inserted exon. The spliced product that includes the exon of interest (Exon X) 
may be enhanced or repressed by changing the components of the medium such as 
insulin, by over-expressing a splicing factor or other protein involved in splicing, or by 
knocking down through siRNA the activity of a splicing factor or other protein involved 
in splicing. 
Figure 19. Vector pSPL3 with an insert and the expected main spliced products.  
Here an exon and part of its flanking introns (shown in blue) is inserted at the MCS 
(multiple cloning site) of vector pSPL3. The construct produces a transcript that after 
splicing can produce two possible spliced products. 
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The pSPL3 vector sequence was obtained from Invitrogen. Here we describe the 
sequences that make up the SD-Intron-SA region. The Tat protein is a product of HIV-1. 
The genomic sequence of the Tat gene is two exons and one intron as shown in Figure 
20. As the diagram indicates, part of the Tat gene sequence and with some modifications 
became the backbone of the SD-Intron-SA structure of the pSPL3 vector. 
  
About 300 bases downstream in the Tat-Intron, the MCS (multiple cloning site) 
was inserted. Then, exons 1 to 3 of the rabbit beta-globin sequence were used. Exon-1 
(127 bases) and exon-2 (220 bases) are used in the SD section, and exon-3 (83 bp) is used 
in the SA section. Finally, a stop codon was inserted near the end of beta-globin exon-2, 
and at the end of beta-globin exon-3. This completes the SD-Intron-SA structure as 
shown in Figure 20. The first stop codon truncates the translation of all spliced products. 
Figure 20. The main components of the SD-Intron-SA region of vector pSPL3.  
The SD structure contains exon-1 (127 bp), exon-2 (220 bp) of the rabbit beta-globin, and 
the last 4 bases of the Tat exon-1. Then the full Tat intron with an MCS region follows. 
The SA structure contains the first 82 bases of Tat exon-2 and the rabbit beta-globin 
exon-3 (83 bp). 
215 87 
Tat Exon 1 Tat Exon 2 
Tat Intron 
2334 
4 82 
Tat Intron 
2334 
4 82 
2031 
83 
MCS 
220 127 
299 
66 3 
351 168 
SD (Splice Donor) SA (Splice Acceptor) 
Intron 
2396 
 50 
At the point of insertion of the MCS region four bases of the Tat Intron were removed, 
thus the net intronic sequence that includes the MCS region is 2396 bp. 
The tat intron not only is long, but it also contains cryptic splice sites that may 
become active under certain conditions. To test and/or avoid interference by the cryptic 
splice sites in certain conditions, two modified vectors were constructed by deleting two 
different lengths from the intronic sequence between the MCS and the SA region. From 
the original 2031 bp one modified pSPL3 vector had 776 bp removed, and the other had 
1650 bp removed. 
 
In Vitro Transcription/Splicing Strategies  
In this project, in vitro transcription was employed to synthesize RNA transcripts 
that served as pre-mRNA in splicing assays. The three common phage RNA polymerases 
used in the lab are T7, SP6, and T3. In this project T7 was used mainly, and in a few 
experiments SP6 was used. In this section, the different strategies used are described in 
constructing DNA templates for in vitro transcription. 
The first goal was to demonstrate that exon betaII splices to exon betaI in vitro. 
The second goal was to investigate if the downstream additional 5‟ splice sites would be 
utilized in in vitro splicing. In vitro transcription involves a DNA template with the 
appropriate promoter (in this case T7 or SP6), the corresponding RNA polymerase, and 
nucleotides. When the transcription reaction reaches completion, it cannot be used as is in 
a splicing assay; it must be cleaned-up and purified. However, the reaction at this point 
still contains the DNA template. At this step the DNA template poses no problem, but it 
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could interfere with subsequent downstream reactions after the splicing assays. Thus, it is 
preferable to digest the DNA template before the clean-up step. 
However, there are still other aspects to be considered. The transcription reaction 
only synthesizes RNA. A deterrent to RNA degradation, and possibly a factor in quicker 
or more efficient splicing, is the capping of the 5‟end. Thus, after transcription, a capping 
reaction is carried out to cap the 5‟ end of the synthesized pre-mRNA transcripts. 
However, a cap analog is used because it is less expensive, but just as effective. Since the 
cap analog is not used as a regular nucleotide during transcription, both reactions can be 
carried out at the same time in the same tube. Still, to give transcription a head start, the 
transcription reaction was started and incubated for 60 minutes. Then the reagents for the 
capping reaction were added and the incubation was continued for an additional 60 
minutes. After two hours of transcription (which includes up to 60 minutes capping), the 
reaction is treated with DNAse for 30 minutes to remove the DNA template. Then the 
reaction is cleaned-up and purified. 
The phage RNA polymerases are not as processive as the DNA polymerases used 
in PCR reactions such as taq. They tend to fall off the DNA template, especially if the 
transcript being synthesized exhibits strong secondary structure. Thus, the reaction may 
contain more products than the transcript of interest. To ensure accurate results, the 
transcription/digestion reaction must be run on an agarose-formaldefyde gel and the band 
of interest is then excised and then gel purified. Since most of the transcription reactions 
include one radiolabeled nucleotide, each step requires special handling and equipment 
which results in slowing down the process. Also, because the radiolabeled nucleotide is 
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the limiting nucleotide, this can result in premature termination of transcription which in 
return will affect the total yield of the desired transcript.  
Given that the DNA template must be digested after each transcription reaction, 
preparation of purified DNA template is another concern. The DNA template must have a 
double stranded promoter, and it may be a PCR fragment or a plasmid. If it is a PCR 
fragment, transcription termination occurs when the RNA polymerase reaches the 3‟ end 
of the DNA template and falls off. If the DNA template is a plasmid, then the plasmid 
may need to be linearized. The T7 RNA polymerase recognizes a sequence for 
transcription termination. Some plasmids contain this sequence and as a result 
linearization may not be needed. However, since plasmids are usually amplified in 
bacteria that produce coiled and supercoiled species, and since the reaction is carried at 
37 to 55 degrees Celsius, the promoter/terminator may not be exposed, and as a result 
transcription may never start, it may not terminate at the expected spot, and it may be 
very slow. Thus, most of the time the plasmids are digested at the point where 
transcription is expected to stop, and they are purified before they are used as templates. 
Also, the digestion site that determines where transcription will terminate is just as 
important. Because overhangs interfere with transcription efficiency, it is preferable that 
the plasmid is linearized with a blunt enzyme. If such a site is not available, then during 
or after digestion, the plasmid can be blunted by treating it with a nuclease that trims 
overhangs.    
Because of the concerns described thus far, a strategy was developed to optimize 
the process. First, over 90% of the experiments were conducted with no radiolabeled 
nucleotide, and as a result, no limiting nucleotide concentration was necessary. Second, 
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the concentration of all nucleotides was increased by 25% and the reaction time was 
increased from 60 minutes to two hours. This allowed for more product to be synthesized. 
Third, the reaction volume was scaled-up from 20ul to 50ul. Fourth, to eliminate as much 
as possible any secondary structure activity the reaction was run from 42 to 55 degrees 
Celsius depending on the transcript been synthesized. Lastly, the reaction was 
supplemented with inorganic pyrophosphatase to ensure no premature termination due to 
accumulation of phosphate. 
At the end of the reaction (transcription, capping, and Dnase digestion), a 5ul 
aliquot was prepared for gel loading. The sample was mixed with formamide loading 
dye, heated at 75 degrees Celsius for 5 minutes and then snapped-cooled on ice for 5 
minutes before loaded on the gel. The gel was a 1.4% agarose including ethidium 
bromide and 20% urea. The purpose of running only 5ul of the reaction was to ensure 
that only one transcript was synthesized. The gel was visualized on a UV trans-
illuminator and a picture was taken. Once this was ascertained, the running of the gel was 
stopped, and the remainder of the in vitro transcription reaction was purified using a spin 
column. If the visualization indicated more than one band, then the rest of the reaction 
was prepared and loaded on the same gel, was run again, and the band of interest was 
excised and gel-purified. 
Because most of the time only one transcript was visualized, purified and capped 
pre-mRNA product was prepared within four hours and was ready for a splicing assay. If 
more than one band was observed and the rest of the sample had to be run on the gel and 
then gel-purified, six hours were needed. When the same procedures were carried out 
with a radiolabeled nucleotide, it would take from two to three days, and the yield was 
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less. This strategy allowed for several experiments to be carried out quickly and at the 
same time make optimizations before repeating the experiment with a radiolabeled 
nucleotide. 
Most of the splicing assays were also carried out without a radiolabeled 
nucleotide. The splicing reactions were cleaned up and concentrated using a spin column, 
and an aliquot of about 50% to 75% of the product was prepared for loading and ran on a 
gel as described above in the in vitro transcription samples. The remaining reaction 
product was used for reverse transcription reactions either with oligo dT if applicable, or 
with specific reverse primers. This was followed by PCR and gel running to verify the 
results obtained. Some PCR products were digested with specific enzymes and/or sent for 
sequencing to further verify the results.   
 
PKC Activation 
All PKCs have a regulatory domain and a catalytic domain (see figure 9). The C2 
region in the regulatory domain in most PKCs facilitates interaction with anchoring 
proteins. The later are identified as RACKs (receptors for activated C kinase).  After 
translation, the PKCs remain in the cytosol and they are unphosphorylated. Several 
activators facilitate translocation of the PKCs to the plasma membrane (PM)  [66]. Table 
3 lists the most common activators [67-75] (activation varies in species and cell/tissue). 
Table 4. PKC Isoform Activators 
 α βI βII γ δ ε η(L) Θ δ λ 
PS + + + + + + + + + + 
Ca
2+ 
 + + + + - - - - - - 
DAG + + + + + + + + - - 
FFA + + + + + + ? + + + 
LysoPC + + + + + + ? + + + 
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It should be noted that in the absence of PS, PKC activation can be mediated by 
tyrosine phosphorylation. Hydrogen peroxide can induce tyrosine phosphorylation in 
PKCα, βI, δ, γ, and δ [76].   
 
PKC Inhibitors 
Table 5.  PKC Inhibitors 
Drug Class Admin Specificity Status 
Phorbol 12-
myristate 13-
acetate 
(PMA) 
Phorbol 
ester 
Intra-
venous 
Non-specific PKC activator: phase I 
trial in haematological 
malignancy 
Tamoxifen Non-
steroidal 
anti-
estrogen 
Oral PKCs α,β,γ non 
selective 
 
Bisindoylmal
eimide 
Indoloc
arbazole 
Oral  PKCβ Used in treatment of 
diabetic retinopathy 
LY317615 
(enzasautaurin) 
Indoloc
arbazole 
Oral PKCβ Potentiates treatment 
with gemcitabine, 5FU, 
cisplatin or 
radiotherapy 
 
PKCs are attractive targets for therapeutic intervention given their various cellular 
roles.  However, the plethora of interacting proteins and many secondary messenger 
systems coupled with cellular and tissue-specific variability for each PKC isozyme 
renders specific drug targeting difficult.  The above table (Table 5) from Twelves et al. 
represents a partial list of the PKC inhibitors in use today [77]: 
An inhibitor not listed above is Ruboxistaurin (LY333531) which is a 
macrocyclic bisindolymaleimide drug developed by Eli Lilly being tested for use as 
therapy in diabetic macular oedema and other diabetic angiopathies, including diabetic 
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retinopathy, diabetic peripheral neuropathy and diabetic nephropathy [78].  It is a 
competitive reversible inhibitor of PKCβ [79].  An analog of this inhibitor, namely   
LY379196 was used extensively in our lab in studies relating to glucose uptake. The 
following table (Table 6) represents the IC50 spectrum for LY379196 [80] which shows 
that PKCβI and PKCβII respond to the lowest M concentrations. 
Table 6. LY379196 Inhibitor IC50 Spectrum 
Enzyme IC50 (μM) 
PKCα 0.6 
PKCβI 0.05 
PKCβII 0.03 
PKCγ 0.6 
PKCδ 0.7 
PKCε 5 
PKCδ 48 
PKCμ 0.3 
Cyclic AMP Kinase >100 
Ca
2+
 -calmodulin Kinase 5 
Casein Kinase >100 
Src Tyrosine Kinase 4.4 
  
RACK mechanism 
Recent research has been focused on a model that is based upon PKC interactions 
with RACKs. The data suggest that RACKs are anchoring proteins that act akin to 
scaffolds in order to localize individual PKCs to specific membrane regions. Each PKC 
isoform responds to a distinctive RACK that may be cell specific and responsible for 
each PKC‟s subcellular localization. In this model, a RACK binds selectively to an 
activated PKC and translocates the PKC to a specific membrane compartment. The 
model suggests that each PKC isoform contains both a RACK-binding sequence and a 
sequence that mimics the PKC binding site on the respective RACK.   
 57 
EXPERIMENTAL PROCEDURES 
Materials 
Tissue culture medium was purchased from Invitrogen.  Fetal bovine serum was 
purchased from Atlanta Biologicals (Norcross, GA).  Porcine insulin was obtained from 
Sigma.  Reagents for polyacrylamide gel electrophoresis were from BioRad. SRp75 
polyclonal antibody was raised in rabbits to the synthetic peptide NH2-
(GC)KDHAEDKLQNNDSAGKAK-COOH (residues 119-136), SRp30b/SC35 antibody 
to the synthetic peptide NH2 -CRRVGDVYIPRDRYTKE-COOH (residues 38-53), and 
SRp55 antibody to the synthetic peptide NH2-CGERVIVEHARGPRRDRD-COOH 
(residues 61-78) by Bio-Synthesis, Inc. (Louisville,TX). Antibodies were characterized 
alongside unreactive preimmune antisera and were shown to recognize rat, mouse and 
human cell line proteins.  Antibody to the phospho-epitope of all SR proteins (mAb104) 
was obtained from hybridoma cells (CRL 2067; ATCC). Anti-phospho-Akt (Ser473 and 
Akt antibody) and anti-Akt substrate antibody were from Cell Signaling (Beverly, MA). 
Anti-Clk/Sty antibody was kindly provided by Dr. James Manley, Columbia University, 
NY, NY. ECL reagents were from Pierce.  Taq Platinum polymerase was from Perkin 
Elmer Life Sciences. Lipofectin ™ was from Invitrogen.  PI3K inhibitor, LY294002, and 
Src kinase inhibitor, Type-1 phosphatase (PP1), were purchased from Calbiochem. All 
other chemicals and reagents were purchased from the usual vendors.  PP1 is pre-
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incubated with cells for 30 min prior to addition of insulin. LY294002 and PP1 were pre-
incubated with cells for 30 min prior to addition of insulin. 
 
Cell Culture 
Mouse 3T3-L1 preadipocytes obtained from American Type Tissue Culture 
repository, ATCC (Manassas, VA) were maintained and passaged as preconfluent 
cultures in DMEM high glucose 4.5g/L (Invitrogen, Carlsbad, CA) with 10% newborn 
calf serum (Sigma-Aldrich, St. Louis, MO) at 37
o
C and 10% CO2.  Once confluent, cells 
were differentiated (day 0) in DMEM high glucose with 10% fetal bovine serum (Atlas 
Biological, Fort Collins, CO), 10μg/mL bovine insulin (Sigma), 1mM dexamethasone 
(Sigma), and 0.5mM isobutyl-1-methylxanthine (Sigma).  On day 2, media was replaced 
with DMEM high glucose, 10% FBS, and bovine insulin.  Day 4 and afterwards, cells 
were cultured in DMEM high glucose plus 10% FBS.  Media was changed every two 
days.  Prior to insulin treatment for glucose uptake or other assay, 4 hour serum 
starvation was accomplished by using DMEM high glucose without FBS. 
L6 rat skeletal myoblasts (obtained from Dr. Amira Klip, The Hospital for Sick 
Children, Toronto, Canada) were grown in αMEM (Invitrogen) with 10% FBS at 37oC 
and 5% CO2. When the myoblasts reached about 50% to 70% confluency, the media was 
changed to αMEM with 2% FBS. This enables the myoblasts to fuse into myotubes. 
During both phases, the media was changed every two days. To slow the confluency of 
the cells during myotube formation, sometimes αMEM with 1% FBS was used. The cells 
were used for transfection while in myotube formation and at about 70% to 80% 
confluency. Serum starvation was accomplished by using αMEM for 6 hours.   
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Rat aortic vascular smooth muscle cells (A10, ATCC CRL 1476) were grown in 
DMEM low glucose with 10% FBS at 37
o
C and 5% CO2.  Once confluency was reached, 
cell synchronization was achieved by serum deprivation (with 0.5% FBS) for 48 hours. 
HeLa cells (ATCC CCL-2) were grown in MEM (Invitrogen) with 10% FBS until 
confluent at 37
o
C and 5% CO2.  Serum starvation was achieved by incubation with MEM 
(no serum) for 6 hours. The immortalized murine fibroblasts were derived as described 
(46) and were maintained in Dulbecco‟s modified Eagle‟s medium, high glucose, 
supplemented with 15% fetal calf serum, 2 mM L-glutamine, and penicillin-streptomycin 
(1mg/ml) and kept at 37 °C in a humidified 5% CO2, 95% air atmosphere. 
The Ntera2 human teratocarcinoma cell line (NT2/D1 cells) is maintained in 
DMEM, 10% fetal bovine serum (FBS) with fresh medium every 3 days. The cells are 
supplemented with 10μM RA as indicated. 
Primary human neuronal cells were obtained from Dr. Sanchez-Ramos. (James A. 
Haley Veterans Hospital, Tampa, FL). The cells were cultured in Dr. Sanchez-Ramos‟ 
laboratory.  
 
Tissues 
Akt2-null mouse tissues were provided by Dr. Morris J. Birnbaum (Howard 
Hughes Medical Institute, Department of Medicine, University of Pennsylvania School of 
Medicine, Philadelphia, PA). Akt2-null and wild type tissues were obtained from 24 
week old male animals raised at the Chemerie Mouse Facility at University of 
Pennsylvania, an AALAC accredited facility. Akt2-null mice were impaired in the ability 
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of insulin to lower blood glucose because of defects in the action of the hormone on liver 
and skeletal muscle (25). 
 
Expression of myc-SRp40 in L6 Cells 
The cDNA construct encoding myc-SRp40 was transfected into L6 myotubes 
(100 mM dishes) as described using Lipofectin (24). Post-transfection (36 h), the cells 
were serum-starved for 24 h in 0.5 ml of ice-cold lysis buffer, centrifuged at 4 °C for 30 
min at 26,000 X g, and the myc fusion proteins were purified by protein A-agarose using 
c-myc antibody (Santa Cruz). The blot was probed with SRp40 antibody. 
 
Cloning minigenes 18, 19, 20, and 22 in pSPL3 for PKC  
L6 cells were grown in 1X alphaMEM with 10% FBS until they were about 50% 
to 60% confluent. Then they were switched to 1X alphaMEM with 2% FBS. The cells 
were grown additionally for 2 to 3 days until they reached 100% confluency at which 
point they were harvested. Using a Qiagen kit for Genomic DNA Extraction and 
following the manufacturer‟s protocol, purified rat genomic DNA was obtained and used 
as template to perform PCR‟s.  
The same forward primer with sequence CAGGAAGTCATCAGGAATAT was 
used for all the constructs. The betaII exon is 216 bases. The forward primer starts 
binding at the 70
th
 base of the betaII exon. Thus, all the PCR fragments include the 
subsequent 146 downstream bases of exon betaII (147 total). Before insertion into the 
pSPL3 vector the PCR fragments were digested with EcoRI, reducing the net size 
inserted in the vector. After ligation into the vector, only 119 bases matched the betaII 
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exon. Thus, all inserts contain a truncated betaII exon that is missing 97 bases from its 
5‟end. Figure 21 depicts the betaII exon, the partial betaII exon sequence used in the 
insert, and how it is ligated into vector PSPL3.  
 
 
Because the insert lacks flanking upstream intronic sequence of the betaII exon, 
and because at the point of insertion in the PSPL3 vector (EcoRI site at the MCS region), 
Figure 21. The pSPL3-18,19,20,22 minigene structures.  
The pSPL3 vector has an EcoRI site within the MCS region, and an NheI site 1119 bases 
upstream of the SA region. The vector was cut with EcoRI and NheI. The inserts contain 
a truncated betaII exon, and varying lengths of downstream intronic sequence. Under 
insulin treatment, the SD region, the subsequent 310 bases of intronic sequence, and the 
following 122 bases of exon betaII behave as a single exon (shown in yellow-green) and 
splice to SA. With no insulin treatment, the 122 bases of exon betaII are skipped and 
become part of the intron allowing the original SD to splice to SA. 
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there is no branch point and poly-pyrimidine tract available upstream of the truncated 
betaII exon. Thus, the exon-betaII sequence has dual roles. When there is no insulin 
treatment, because exon-betaII is subject to exon skipping, the betaII exonic sequence 
becomes part of the surrounding intronic sequence, and thus it is excised during splicing 
as part of the intron between SD and SA. Hence, the predominant spliced product 
expected is the SD-SA product. Under insulin treatment, the SD region of the PSPL3 
vector, the subsequent 310 intronic bases, and the following 119 bases of exon betaII 
make up a new SD region (SD*) that behaves as a single exon. Thus, the predominant 
spliced product expected is the SD*-SA product.  
The first 5‟ splice site of exon betaII can also be viewed as an additional 5‟ 
competing splice site with regard to the constitutive 5‟ splice site of the SD region. As it 
was indicated earlier, there is no branch point and no poly-pyrimidine tract upstream of 
the truncated betaII exon. Thus, no excision is possible between the SD region and exon 
betaII. Hence, there are only two choices during splicing. Either the constitutive 5‟ splice 
site of SD is utilized, or a competing downstream 5‟ splice site is utilized. Depending on 
the insert, there may be more than one competing 5‟ splice site.  
Construct pSPL3-18 has the longest intronic sequence downstream of the first 
exon-betaII 5‟ splice site while pSPL3-22 has the shortest intronic sequence. Table 6 
summarizes pertinent information for the deletion series of pSPL3 constructs. The 
forward primer is 20 bases long and all 20 bases bind in the betaII exon. However, in the 
PCR fragments synthesized, downstream of the primer sequence there is an EcoRI site. 
As it was indicated earlier, the pSPL3 vector is digested with EcoRI and NheI. Thus, 
when the PCR fragments are digested with EcoRI, an overhang is generated that matches 
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the vector overhang. The reverse primers have either XbaI or NheI sequences. However, 
when the PCR fragments are digested with the corresponding enzyme, the same overhang 
is generated in all the PCR fragments. The difference is that in the two PCR fragments 
that have the NheI sequence, when ligated to the vector, the NheI site is restored while in 
the others two PCR fragments the NheI site is not restored. 
Table 7. Summary of deletion series pSPL3 constructs 
Construct(s) PCR fragment size Net Insert 
Size 
Exon- II 
truncated size 
3’ Intronic 
Size 
pSPL3-18 719 683 119 564 
pSPL3-19 543 507 119 388 
pSPL3-20 524 446 119 327 
pSPL3-22 189 150 119 31 
 Forward primer  Overhang 
All 5’-CAGGAAGTCATCAGGAATAT-3’ None 
 Reverse primer  
pSPL3-18 5’-CGTCTAGACTATGAGAGGAAGTGCTTTT-3’ XbaI 
pSPL3-19 5’-TCTCTAGAAGGGCAAAGCAGCCATATACT-3’ XbaI 
pSPL3-20 5’-GCCATATAGCTAGCTCAAGCCAAGCTCCCAGCCG-3’ NheI 
pSPL3-22 5’-CACGGAGCTAGCTTGGCAATGGAAAAGGAAAA-3’ NheI 
 
Modified Ligation Protocol 
In the construction of pSPL3-18 and pSPL3-19, the PCR fragments generated 
contain an XbaI site at the 3‟ end. The PCR fragments were digested with EcoRI and 
XbaI. At completion, the reaction was cleaned-up using the “DNA Clean & Concentrate” 
kit (Zymo Research, CA). The main reason these two fragments contain an XbaI site at 
the 3‟ end instead of a NheI is because there is a NheI site 319 bases downstream of exon 
betaII. However, the overhang generated by XbaI matches the NheI overhang. The 
pSPL3 vector was digested with EcoRI and NheI. This generates two fragments of 964 
and 5067 bases long. Upon completion, the reaction was loaded on a 1.2% agarose gel to 
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isolate the fragments, and subsequently excise a gel slice for the 5067 bp band. The gel 
slice was then gel purified using the QiaQuick Gel Extraction kit (Qiagen).  
In the ligation reaction, the vector has an EcoRI and a NheI overhang while the 
PCR fragment has an EcoRI and an XbaI overhang. When the insert is ligated to the 
vector, the EcoRI site is restored, but the NheI site is not (and neither is the XbaI site). 
When two enzymes, for example XbaI and NheI, recognize different sequences, but 
generate the same overhang; the ligated products include three species. In our example, 
one species is a dimmer of two PCR fragments that restore the XbaI site. The other 
species is a dimmer of two vector fragments that restore the NheI site. The third species 
is a hybrid of the vector fragment and the PCR fragment (the desired product); however, 
this species generates a sequence that is not recognized by either enzyme. This may pose 
an advantage or disadvantage in analyzing the ligated product. 
The ligation reaction was used to transform E. Coli cells and grow them in LB 
agar plates with ampicilin. Individual clones were picked and grown in LB broth 
containing ampicilin. The culture was pelleted, the cells were lysed, and purified plasmid 
was obtained using the GeneJet Plasmid Miniprep kit (Fermentas, MD). The miniprep 
product was then analyzed by restriction digest and the reaction was loaded on a 1.0% 
agarose gel stained with ethidium bromide to visualize the bands in a trans-illuminator. 
After confirmation that the construct contained the correct insert and in the proper 
orientation, the miniprep product was sent for sequencing. The restriction digest analysis 
and the sequencing results were analyzed using the GeneTool software (Genetool, 
Canada). 
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Construction of pSPL3-PKC  minigenes 
In the PKC  minigenes, no splicing event was expected between SD and exon-
II. This is because the SD region, the subsequent 310 bases of vector intronic sequence, 
and the inserted 122 bases of exon betaII all behave as a single exon. The splicing event 
was the excision of the intron between exon- II and SA (see figure 21). In the pSPL3-
PKC  minigenes, two splicing events take place: one between SD and exon-10, and one 
between exon-10 and SA. Exon-10 was inserted with both upstream and downstream 
intronic sequences. To ensure and/or test if the length of the upstream intronic sequence 
is a factor in the splicing event between SD and exon-10, two sets of constructs were 
built. One set includes only 56 intronic bases (part of intron-9) upstream of exon-10 and 
the other set includes 117 intronic bases. The 56 bases version might be missing a 
functional branch point, while the 117 bases version might have more than one branch 
point.  
The pSPL3 vector was digested with BamHI (in the MCS region) and NheI (about 
930 bases downstream of BamHI) within the tat intronic sequence. This removes about 
930 bases which is mostly tat intronic sequence and includes one or more cryptic splice 
sites. The pSPL3 vector contains the SV40 promoter and polyadenylation signal that 
allow for enhanced expression in NT2 cells. However, the remaining intronic sequence 
between the NheI site and SA is still quite long (1119 bases) and includes consensus 5‟ 
splice site sequences that may be possible functional 5‟ splice sites (also referred to as 
cryptic 5‟ splice sites). Because these possible cryptic 5‟ splice sites might interfere with 
the minigene splicing, an additional sequence of 879 bases of the tat intronic sequence 
was deleted from the two sets. This resulted in four sets of minigenes.  
 66 
The additional sequence deleted between the NheI site and SA was as follows. As 
it was indicated earlier, the size of the tat intronic sequence between NheI and SA is 1119 
bases. After the deletion, the retained tat intronic sequence included 158 bases upstream 
of SA and 81 bases downstream of NheI. The 158 bases upstream of SA included at least 
one functional branch point, and pyrimidine tract. The primers to amplify the genomic 
PKC  from NT2 cells were designed using the Gene Tool Software (Bio Tools 
Incorporated, Canada).  
Table 8. Primer list for PKC  minigenes 
Set Forward primer  Overhang 
1a and 1b  5’-CTTTGATCATGGGAGTTCTGATAATGGTC-3’ BcLI 
2a and 2b  5’-TGGTGATCACCCCTGTTGTCTCCTCTTGG-3’ BcLI 
Set 1a Set 2a Reverse primer  
f-371 f-432 5’-cctACTAGTatcggggtctcagtctacac-3’ BcuI 
f-321 f-382 5’-GGGACTAGTTGGGGGAAGGGGCCTCAGAG-3’ BcuI 
f-274 f-335 5’-cagACTAGTtggttccttccatgtctcac-3’ BcuI 
f-234 f-295 5’-aggACTAGTagtcccctttctttggcctc-3’ BcuI 
f-217 f-278 5’-ttcACTAGTctcagggggaataaaaaccg-3’ BcuI 
Sets 1a and 1b Forward primer   
For all 10 constructs 5’-tagGGATCCgggcaagtttgtggaattgg-3’ BamHI 
 Reverse primer  
For all 10 constructs 5’-actTGATCAtacaatttctgggtcccctc-3’ BcLI 
 
The two forward primers included the BclI site that matches the overhang of 
BamHI in the vector (shown in blue color, see Table 8). The five reverse primers 
included the BcuI site that matches the overhang of the NheI site in the vector. Following 
amplification of the product, it was ligated into the digested pSPL3 vector. The 
overhangs of the selected restriction enzymes can hybridize and this enabled cloning of 
the PCR product in the proper orientation. To increase the efficiency and number of 
positive clones, the ligation reaction was digested with the above restriction enzymes 
which cleave any dimers produced by the ligation reaction. The product was verified by 
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restriction digestion and sequencing. The primers used to generate pSPL3-PKCδ 
minigene sets are listed in Table 8. The names of the minigenes were derived from the 
size of the insert. The insert size in Table 8 is depicted as f-xxx where xxx is the size. 
Thus, minigene pSPL3-PKCδ-371 contains a PCR insert of 371 bases where the first 6 
bases are the 5‟ end ligation site, the next 56 bases represent intron-9, the next 97 bases 
represent exon-10, the next 200 bases represent intron-10, and the last 6 bases are 3‟ 
ligation site. pSPL3-PKCδ-432 differs from pSPL3-PKCδ-371 only in the intronic 
sequence upstream of exon-10. In the first minigene the sequence is 117 bases while in 
the second it is 56 bases. Table 9 shows what size of each region is included in each 
minigene. 
Table 9. Content of each PKC  minigene 
Minigene Intron-9 Exon-10 Intron-10 Delta-8 
Region 
 SC35 
site 
SSII 
size 
f-371 56 97 200 93 8 9 
f-321 56 97 150 93 8 9 
f-274 56 97 103 93 8 9 
f-234 56 97 63 63 8 0 
f-217 56 97 46 46 1 0 
f-432 117 97 200 93 8 9 
f-382 117 97 150 93 8 9 
f-335 117 97 103 93 8 9 
f-295 117 97 63 63 8 0 
f-278 117 97 46 46 1 0 
 
Again, the difference between the two sets of minigenes is the size of the intronic 
sequence upstream of exon-10. In the second set the upstream intronic sequence is 
increased from 56 bases to 117 bases. In each set intron-10 is truncated progressively 
from 200 bases down to 46 bases. This affects the size of the delta-8 region, the 
availability of the SC35 binding site, and the availability of SSII. Minigenes f-234 and f-
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335 contain 103 bases of intron-10. The delta-8 region is 93 bases, thus, there are only 10 
bases downstream of the delta-8 region. SSII occupies 3 bases of the delta-8 region and 6 
bases of the remaining 10 bases of intron-10. Thus, there are only 4 bases downstream of 
SSII that are part of the insert. Minigenes f-234 and f-295 retain the SC35 binding site, 
but remove the SSII splice site. The construction of these two minigenes is to test if the 
availability of the SC35 binding site would have prompted for a downstream 5‟ cryptic 
splice site (in the vector tat intronic sequence) to be utilized.  
Minigenes f-217 and f-278 have both the SSII and the SC35 binding site removed. 
The construction of these two minigenes is to test if the treatment with RA mediates more 
than just the binding of SC35 to the predicted sequence in the transcript. SSII may be 
utilized because not only SC35 binds to the predicted sequence, but also because another 
splicing factor blocks SSI. In this scenario, the constructs that include additional 5‟ 
cryptic splice sites would have produced a spliced product that doe not include SSI. The 
constructs that have the additional 5‟ cryptic splice sites removed should result in no 
excision of the intronic sequence between exon-10 and SA. 
The minigene fragments were ligated into the digested pSPL3 vector through a 
modified ligation reaction described below. The ligated products were transformed into 
bacteria using JM109 cells (Zymo Research). All the minigenes were verified by two 
comprehensive restriction digestion patterns. All minigenes in sets 1a and 2a, and one 
minigene in sets 1b and 2b were sequenced and the results verified the expected 
constructs.  
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Overexpression/Minigene Transient Transfection 
Transient transfection was accomplished using TransIT-LT1 transfection reagent 
(Mirus Bio Corporation, Madison, WI) according to manufacturer′s protocol.  Briefly, L6 
cells were cultured in 6-well plates until 60-75% confluent. A master-mix was prepared 
with serum-free αMEM and TransIT-LT1transfection reagent. The mix was let to stand 
in the hood at room temperature for 10 min. Then individual tubes were prepared with 
master-mix and DNA so that 100μL solution contained 3.0μL TransIT-LT1transfection 
reagent per 1μg DNA.  The tubes were let to stand in the hood at room temperature for 10 
min. Before transfection, the wells were aspirated and replenished with fresh 2.5ml of 2% 
FBS aMEM. Then the transfection mixture (TransIT-LT1 Reagent – DNA complex) was 
added to cells and incubated for 48-72 hours.  
Six hours before harvesting, the media was changed as follows: For the wells that 
no serum starvation was applicable, the wells were aspirated and replenished with fresh 
2.5ml of 2% FBS aMEM. For the wells that serum starvation was applicable, the wells 
were aspirated and replenished with fresh 2.5ml of 0% FBS aMEM. At 15, 20, 30, 40, 60, 
and 90 minutes before harvesting the applicable wells were treated with an insulin 
solution freshly prepared. After harvesting, the cells were lysed, and processed for RNA 
extraction. The RNA product was quantitated, and reverse transcription was performed to 
obtain cDNA using either oligo-dT or specific reverse primers that bound to pSPL3 at the 
SA region. The cDNA was used as template to perform PCR‟s. The PCR products were 
run on 1.0% or 1.2% agarose gels stained with ethidium bromide and the bands were 
visualized and photographed in a UV trans-illuminator. Alternately, the PCR products 
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were run on 6.0% PAGE gels and then processed for silver staining. The blots were 
scanned and analyzed densitometrically. 
 
RNA Isolation 
RNA was extracted not only from lysates, but also from in vitro transcription 
reactions, and splicing assay reactions. Several methods were used to isolate RNA. The 
first method used was using an RNA isolation reagent (a phenol-guanidium based 
reagent) such as TRI Reagent (Molecular Research …), and RNA- BEE (Tel-Testt, Inc.). 
In these protocols the cells/lysate or reaction is mixed with the reagent and chloroform 
and centrifuged to separate the mixture into three phases. The aqueous upper phase that 
contains mainly RNA is separated, and the RNA is precipitated with isopropopanol. The 
yields obtained and purity achieved were rather mediocre compared to the other methods 
used. The protocols were modified several times, and some improvement was observed, 
but in the end, this method alone never reached the expected goals established. 
The next method tried was the use of kits that use filter-spin columns. Kits from 
the following six companies were used/tested: Invitrogen, Sigma, Zymo Reasearch, 
Ambion, Qiagen, and Marligen. For isolating RNA from cells, each kit came with its own 
lysis reagent (also called lysis buffer). The lysate was passed through the filter-spin 
column, washed, and then the RNA was eluted either with water or elution buffer. The 
main improvement achieved was consistency of RNA yield from one well to the next that 
was very difficult to achieve with the previous method described. The second 
improvement was purity of the RNA product. The cost per microgram of RNA isolated, 
however, increased from four to ten fold compared to the previous method. For in vitro 
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transcription reactions the Zymo research kit “RNA Clean & Concentrate” was used. 
Because no lysis buffer is needed, this clean-up kit has fewer steps (and is less 
expensive). The clean-up kit comes with a buffer that is used to dilute the transcription 
reaction and enhance the binding of RNA to the column. It also comes with a wash buffer 
to wash the column before elution. The Zymo Research kit offers a lot of flexibility. This 
allowed us to test each component and step of the protocol and make general and specific 
modifications.  The optimizations in the long run saved time and improved considerably 
the yield and the purity of the RNA isolated. 
In isolating RNA from either a lysate or an in vitro transcription reaction, the need 
arises to digest any DNA present in the sample. Most kits allow “on column” DNA 
digestion. In all the kits tried for RNA Isolation or just clean-up, the on column DNA 
digestion was tried also. The concentration and purity of the RNA product obtained was 
measured with the Thermo Scientific instrument NanoDrop 1000. The results indicated 
that all kits were relatively similar with the Ambion and Invitrogen kits resulting in a bit 
higher yields. 
The previous two methods isolate total RNA. The next method used isolates 
mRNA directly from lysates or in vitro transcription reactions. It can also be used to 
isolate mRNA from previously isolated total RNA. The kits used use either magnetic 
beads with attached oligo-dT‟s, or spin-columns with attached oligo-dT‟s. In the case of 
magnetic beads, the lysate or reaction is mixed with the magnetic beads, and this allows 
hybridization of mRNA to the oligo-dT‟s attached to the beads. After a few minutes of 
incubation, the beads are separated from the rest of the mixture through a magnet and 
washed. The beads are then re-suspended in elution buffer and heated to separate the 
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mRNA from the beads. The beads are then removed from the solution with a magnet, and 
the mRNA solution is transferred to a clean tube. 
The last method is the most expensive, but the most promising. Since usually 
mRNA is about 10% of the total RNA, the concentration of the RNA product obtained 
with this method is much lower. This method can be cost effective in 100mm plates 
because the beads can be used several times for the same sample. In 6cm wells, the cost 
increases by four to five fold. Some companies now are offering just lysis buffer for RNA 
isolation. The magnetic beads with attached oligo-dT‟s are also sold separately. One can 
anticipate that in time either the cost of the beads with attached oligo-dT‟s will come 
down, or that one can obtain the beads alone and use an inexpensive kit to attach the 
oligo-dT‟s to the beads. In this scenario, one can attach not only an oligo-dT, but any 
specific oligo and fish out from a mixture any RNA molecule of interest. 
 For in vitro transcription reactions and splicing assay reactions the Zymo 
Research kit was used mostly to obtain purified RNA. For RNA isolation from cells, in 
about 5% of all the experiments the Tri-Reagent was used, and in about 35% of all the 
experiments the RNA-BEE was used. A filter-spin column kit was used for about 50% of 
all the experiments, and magnetic beads were used for about 3% of all the experiments. 
In the rest 7% of the experiments, a combination of methods was used. For example, the 
cells were lysed with RNA-BEE, but then the Zymo Reasearch RNA clean-up kit was 
used to extract the RNA. RNA quantitation was performed using the Thermo Scientific 
instrument NanoDrop 1000, or the Eppendorf instrument Biophotometer. 
The most protocol modifications were implemented in the first method described 
above with RNA-BEE. One of the problems encountered was the foggy separation of the 
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middle layer and the upper acqueous phase after mixing the lysate with RNA-BEE and 
centrifuging. Another problem was contamination of the RNA product with phenol. And 
a third problem was a low value of A260/A280 indicating high DNA presence. This was 
resolved to some extend by modifying the protocol as follows. In the original protocol, 
for a well of a 6-well plate, 500ul of RNA-BEE and 100ul of chloroform were used. After 
centrifugation the upper aqueous layer was transferred to a fresh tube. Then the RNA was 
precipitated with isopropanol. 
In the modified protocol, before centrifugation 200ul of 2M NaAc were added 
additionally. After centrifugation, only 80% of the upper phase was transferred to a fresh 
tube. To the left over three phases, 200ul of 2M NaAc were added, the tube was mixed 
and centrifuged again. Then 80% of the upper aqueous phase was transferred to the same 
tube with the previous upper aqueous phase. This modification made the separation 
between the middle layer and the upper phase sharper, and minimized the contamination 
of the transferred phase with phenol and DNA. Before the precipitation step, besides 
isopropanol, 50ul of a solution that contained NaCl and Glycerol was added. The solution 
was prepared with 950ul 2M NaCl and 50ul glycerol. This modification helped the 
precipitate to form faster, it increased the final yield of RNA slightly, and it kept most of 
any remaining phenol and DNA in the solution. 
 
Reverse Transcription reactions 
After RNA isolation from cells, reverse transcription was performed to synthesize 
first strand cDNA. Most of the reactions were performed using oligo-dT. However, in 
some occasions specific reverse primers were used. The need to use specific primers was 
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because the target mRNA molecule sought was in very low concentration. The specific 
RT reaction synthesizes cDNA only for the transcript of interest. In a regular RT reaction, 
each transcript used for cDNA is digested after the synthesis. In the specific RT reaction, 
probably over 99% of the transcripts are not processed. To ensure that the unprocessed 
transcripts do not interfere with the next reaction, after completion, the specific RT 
reaction was treated with Rnase. 
In RNA isolated from in vitro transcription reactions and splicing assay reactions, 
most of the RT reactions were performed with a specific primer. The reason here is 
because there was only one transcript involved in each reaction, and because most of the 
transcripts synthesized did not have a poly(A) tails. The first strand cDNA synthesized 
was used in PCR reactions primarily to synthesize DNA for sequencing purposes. And 
secondarily to verify the products observed in RNA gels. Three different RT kits were 
used in this project from the following manufacturers: Qiagen, Epicentre, and Invitrogen.  
 
PCR 
PCR‟s were performed with a standard protocol where all cycles are performed 
with the same conditions. In all PCR reactions the Biometra T3 thermocycler was used. 
In instances where the concentration of the template of interest was in a very low 
concentration, then the PCR thermocycler program was divided into two stages. In the 
first stage about one third to one fourth of the total cycles would be performed in 
stringent conditions by raising the annealing temperature close to the melting temperature 
(Tm) of the primers. This was done to ensure that only the template of interest was 
amplified. Then in the second stage, the conditions were relaxed since by then enough 
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product had been synthesized to compete effectively with any other templates that would 
cause the primers to miss-bind. 
If a PCR reaction showed bands that were not expected, and the two-stage PCR 
remedy did not eliminate those bands, then another condition was added to the PCR 
program. This was accomplished by using the parameter dT (Temperature differential) 
available in the thermocycler used. The number of cycles in the first stage was increased, 
the annealing temperature was raised above the Tm of the primers, and the value for the 
dT parameter was set from -0.1 to -0.5. This parameter decreases the annealing 
temperature with each cycle by the value set for dT. For example, if the highest Tm of the 
primers is let‟s say 65 degrees Celsius, the initial annealing temperature would be set to 
66 degrees Celsius and the cycles to 15. If the value of dT is let‟s say -0.2, then with each 
cycle the annealing temperature will be lowered by 0.2 degrees. Thus, in the second cycle 
it would be 65.8, in the third 65.6, in the fourth 65.4 and so on. In the fifteenth cycle it 
would be 63.2 degrees Celsius. This technique is even more stringent and it enables the 
first stage to select only the template of interest. Again, when continuing with the second 
stage, enough product has been synthesized to compete effectively with other templates 
that facilitate miss-binding. 
In some samples the template of interest was so low that, even with the 
modifications described above, the amplified product was not enough to be detected. In 
these instances, a nested PCR was performed. In this protocol, the first PCR performed 
amplifies more than one template. Then the first PCR is used as a template for the 
subsequent PCR. In the second PCR appropriate primers are used that target a specific 
amplified template. 
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Another modification of the PCR protocol employed was when the two primers 
used in a PCR had a wide difference between their melting temperatures. For example, if 
the Tm of one primer is let‟s say 56 degrees Celsius and the Tm of the other primer is let‟s 
say 69 degrees Celsius, then the 13-degree difference could pose a problem. If the 
annealing temperature was set close to 69, the primer with the Tm of 59 may never bind. 
If the annealing temperature was set close to 56, then the primer with the Tm of 69 may 
produce many miss-bindings that would result in several byproducts. In this situation the 
first stage is performed in two separate tubes; one for each primer, and with a specific 
annealing temperature for each primer. Then the tubes were combined and the PCR 
continued with the second stage. 
 
In Vitro Transcription Templates 
Several DNA templates were constructed for in vitro transcription. The initial or 
early templates were PCR fragments. The later templates were linearized plasmids. The 
templates were given the names FH2, FH3, FH4, FH5, FH6, and FH7. For each template, 
for example FH2, there were several variations. These were indicated as FH2a, FH2b, 
FH2c, and so on. Each template was testing the splicing of exon betaII to exon betaI. 
Thus, each template included exonic sequences of exon betaII with its constitutive 5‟ 
splice site, exonic sequences of exon betaI with its 3‟ splice site, a fixed length of intronic 
sequence upstream of exon betaI that included the poly-pyrimidine tract and a branch 
point, and a varying length of the intronic sequence downstream of exon betaII. This last 
downstream intronic sequence included the additional 5‟ splice sites. Table 5 summarizes 
the construction of the templates. FH2 is the largest template and includes the most 
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additional 5‟ splice sites, and FH7 is the smallest template and does not include any 
additional 5‟ splice sites.  
Table 10. Summary of in vitro transcription PCR DNA templates 
DNA 
Template 
Varying 5’ Intronic 
sequence size 
Additional 5’ 
Splice sites  
included 
Furthest 5’ 
Splice site 
present 
Splice 
products 
expected 
FH2 1169 4 SSV 5 
FH3 684 3 SSIV 4 
FH4 351 2 SSIII 3 
FH5 121 1 SSII 2 
FH6 81 0 SSI 1 
FH7 2 0 SSI 1 
 
Variation 5‟ Extra 
Sequence 
Intron 5‟ 
of betaII 
exon 
Exon 
betaII 
Intron 3‟ of 
exon  betaI 
Exon 
betaI 
3‟UTR  
a 49 0 181 188 92 0 
 
All the above templates are the ligation of two PCR fragments. The first fragment 
represents exon betaII and its varying downstream intronic sequence, and the second 
fragment represents exon betaI with an upstream intronic sequence of fixed length. For 
the second fragment only one pair of primers was used. For the first fragment, the same 
forward primer was used for all constructs, but a different reverse primer for each 
construct. The PCR fragments were lifted from a pSPORT2 vector that contained part of 
the PKC  genomic sequence and the T7 promoter. The insert with the partial PKC  
genomic sequence was inserted at the PstI and NotI sites of the pSPORT2 MCS region.  
It has been stated earlier that exon betaII is 216 bases. The PKC  genomic insert 
mentioned above starts at the 36th base of exon betaII (in a 5‟ to 3‟ direction). Thus, the 
first 35 bases of exon betaII are not present. As a result, the insert contains 181 bases of 
exon betaII, the intron between exon betaII and exon betaI, exon betaI, and 498 bases 
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downstream of exon betaI. The complete T7 promoter sequence is 23 bases long as 
shown: 5‟ TAATACGACTCACTATAGGGAGA 3‟. The minimum sequence required for 
transcription is 19 bases long (shown underlined), and transcription starts at the base 
shown in bold in a 5‟ to 3‟ direction. The pSPORT2-betaII-betaI construct contains the 
first 21 bases of the T7 promoter, then 19 bases that are part of the vector‟s MCS region, 
and then the insert starting with the 181 bases of exon betaII. To lift the betaII exon, a 
forward primer was designed that binds at the T7 promoter. To accommodate future 
insertion of the fragments generated into the pTnT vector, the forward primer contains 
the KpnI site (see Table 6). Six reverse primers were designed; one for each fragment. To 
facilitate ligation of each betaII fragment to the betaI fragment, each reverse primer 
contains the BamHI site.  
The forward primer for the betaI fragment also contains the BamHI site, and it 
copies 188 intronic bases upstream of exon betaI. This intronic sequence contains the 
poly-pyrimidine tract and the branch point. The reverse primer for the betaI fragment 
binds on exon betaI and copies the first 77 bases of exon betaI. Thus, the betaI fragment 
is the same for all templates and it includes the first 77 bases of exon betaI and 188 bases 
of the intron upstream of exon betaI. To accommodate future insertion of the templates in 
a vector, the betaI fragment reverse primer contains the SacI site. Also for future 
considerations, right after the 77 base of exon betaI the primer contains the StuI site to 
facilitate blunt linearization of the vector construct. 
Six PCR reactions were carried out to generate the six different betaII fragments, 
and one PCR to generate the betaI fragment. The PCR reactions were cleaned up and then 
digested with BamHI. The digestion reactions were cleaned-up and the betaI fragment 
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was ligated to each betaII fragment in six ligation reactions. The ligations were used as 
PCR templates to synthesize the transcription DNA templates. Six PCR reactions were 
carried out using as forward primer the same one used for the betaII fragment, and using 
as reverse primer the same one used as reverse primer in the betaI fragment. The 
reactions were cleaned up and used for in vitro transcription reactions, and as PCR 
templates for amplification each time more transcription DNA templates were needed.  
Table 11. Primer list for betaII and betaI PCR fragments 
PCR Fragment Forward primer  Overhang 
All betaII‟s 5’-GCCGGTACCTAATACGACTCACTATAGGG-3’ KpnI 
 Reverse primer  
FH2.betaII 5’-AAGGGATCCTCGTTCGTTCGTTCTTCTCT-3’ BamHI 
FH3.betaII 5’-CCAGGATCCTCTAAGAACAGTGCCAAATG-3’ BamHI 
FH4.betaII 5’-AAGGGATCCGCCGGGAAGGTGGAAGAATG-3’ BamHI 
FH5.betaII 5’-ATTGGATCCCCTCGAAGATGGCTCCAAAC-3’ BamHI 
FH6.betaII 5’-ATTGGATCCCTGAAACATGGCCACTCTAG-3’ BamHI 
FH7.betaII 5’-AAAGGATCCCATGATAGCTGTTGAGCTTG-3’ BamHI 
PCR Fragment Forward primer  Overhang 
betaI 
5’-TCCGGATCCCGCCCCAAAGCCAGCATATA-3’ BamHI 
Reverse primer  
5’-AAGGAGCTCAGGCCTAGTTTGTCAGTGGGAGTCAGT-3’ SacI{StuI} 
 
The FHx PCR products were run on an agarose gel to verify the sizes. They were 
also digested with BamHI and run on an agarose gel to verify the ligated products. 
Finally, they were also sent for sequencing to verify the complete content of each 
template. The sequencing results verified the expected template constructs. 
The six templates were later modified and inserted into vector pTnT. Because 
exons betaII and betaI were partially copied in each of the transcription templates, there 
was a possibility that an ESE or even an ESS was present in the sequences not present in 
the templates. Thus, the modification included the entire length of exon betaII and exon 
betaI. The procedure was repeated as before where six PCR products were synthesized 
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for the betaII fragment, and one for the betaI fragment. The two fragments were ligated 
as before, and the ligated fragment was inserted into vector pTnT that contains a T7 
promoter and a poly(A) tract. The vector constructs were amplified, checked with 
digestion for proper size, and later sequenced. The vector constructs were linearized and 
purified before use for in vitro transcription. 
 
In Vitro Transcription 
Several kits were used for in vitro transcription (IVT) reactions, and several 
modifications were implemented. We used two types of kits from Ambion, two types 
from Epicentre, one type from Promega, and one type from Fermentas. We also carried 
out several IVT reactions where the components of a reaction were obtained separately 
from different companies. Because most of the reactions did not use a radiolabeled 
nucleotide, and because we carried several reactions at a time due to the many templates 
involved, with each round of reactions we used one tube specifically for optimization. 
This afforded us to compare results and make modifications. 
The first optimization was to increase the incubation temperature from 37 degrees 
Celsius to 42 and go as high as 55 depending on the template. The second optimization 
was to include in the reaction inorganic pyrophosphatase. None of the kits used included 
this reagent. During transcription, the RNA polymerase generates PPi (pyrophosphate) as 
it synthesizes the transcript using the nucleotides. The accumulation of PPi can slow 
down or inhibit the transcript synthesis. The pyrophosphatase catalyzes PPi to single 
phosphates. We found the addition of pyrophosphatase to be useful in reactions extended 
beyond 60 minutes. Some kits use Rnase inhibitors in the reaction while others use 
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Dithiothreitol (DTT). We used the Fermentas ribonuclease inhibitor (Ribolock) which 
contains 8mM DTT in the storage solution. Because DTT at high temperatures can cleave 
the di-sulfide bonds found in Rnases, and because it stabilizes polymerases, considering 
that the reactions are ran at higher temperatures, we included DTT in the reactions at a 
final concentration of 20mM. 
Some in vitro transcription reactions were followed by the capping enzyme 
reaction, or after half way through the in vitro transcription reaction the capping reaction 
was started and ran concurrently with the transcription reaction in the same tube until the 
end of the transcription reaction time. Some transcription reactions did not include 
capping. At the end of the transcription reaction, DNAse treatment was followed for 
about 30 to 60 min. We used Ambion, Zymo Research, Stratagene, and Fermentas DNase 
with its corresponding buffer. 
An aliquot of each reaction was run on a modified 1.4% gel. For example, for a 
36 ml gel volume, we used 34.9 ml‟s of 1X TBE, 375 l Ethidium Bromide solution 
(0.08 g/ l), 725 l of Ambion‟s 6% PAGE/Urea solution (cat# 8888), and 0.504 grams 
agarose. Before loading, the aliquot was mixed with Fermentas 2X loading buffer, heated 
at 75 degrees Celsius for 10 min, and then snap-cooled by placing the sample on ice for 3 
minutes. The gel was visualized on a UV trans-illuminator for accuracy and integrity of 
the transcript. If more than one band was observed, then the entire reaction would be run 
on the same gel, the band of interest would be excised and later gel-purified using a 
Zymo Research kit. If only one band was observed, and if the band matched the expected 
size, then the reaction was cleaned-up and concentrated using a Zymo Research spin 
column of 5 g, 25 g, or 35 g capacity. The spin columns were eluted either with water 
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or Ambion RSS (RNA Storage Solution). The elution products were stored at -20 degrees 
Celsius before used in splicing reactions. The same procedure was used if the reaction 
included a labeled nucleotide.  
 
Splicing Assays 
The splicing assays were carried out with nuclear extracts from Proteinone Inc. 
We used HeLa, S-100, and K-293 extracts. We used the supplied buffers and followed 
the manufacturer‟s suggested protocol. We incubated the reaction at room temperature 
between 30 to 60 min. Every splicing reaction was then cleaned and concentrated using a 
Zymo Research spin column as described previously. About 50% to 75% of the product 
was prepared for loading and ran on a gel as described previously. RT and PCR reactions 
were carried as described under the headings of RT and PCR. The spliced products were 
verified through digestion and sequencing of the PCR products. 
 
siRNA Knockdown  
L6 skeletal muscle cells were grown in 6-well plates.  Cells were ready for 
transfection at 60-75% confluency.  In one tube (per well), 5μL siPORT NeoFX 
Transfection Reagent (Applied Biosystems/Ambion, Austin, TX) was mixed with 95μL 
αMEM (no serum). This was incubated 10 minutes room temperature.  In another tube, 
RNA and αMEM (no serum) were combined up to 100μL.  Two tubes were mixed and 
incubated 10 minutes.  siPORT NeoFX – RNA solution was added to cells.  αMEM (no 
serum) was added to a final volume of 2.5mL.  After 6-8 hours, media was replaced with 
serum containing αMEM.  
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NT2 cells were grown in 6-well plates.  Cells were ready for transfection at 60-
75% confluency.  Mix preparations were the same as in L6 cells. Two siRNAs that target 
separate areas were used to knockdown expression of SC35.  SC35 siRNAs along with its 
scrambled control were purchased from Ambion® (IDs: 12628 and 12444) and 
transfected using Ambion‟s siRNA transfection kit. These are validated for specificity to 
eliminate off-target gene effects.  
 
Silver Staining  
6% polyacrylamide (using 40% Acrylamide/Bis  cat# 1610146 from Bio-Rad 
Laboratories, Hercules, CA) gel was prepared.  Samples were run on gel and put in 10% 
ethanol (Fisher) for 3 minutes.  The ethanol was replaced with 1% nitric acid (Fisher) for 
3 minutes.  Gel was then rinsed three times with water and soaked in 0.1% silver nitrate 
(Sigma) for 10 minutes.    After a quick wash with water, gel was developed using 6% 
sodium carbonate (Fisher) with 0.2% formaldehyde 37% solution (Fisher).  Reaction was 
terminated with addition of 10N glacial acetic acid (Fisher).  
 
Agarose Gels 
Different concentrations of agarose gels were prepared. Mostly 1.0% , 1.2% and 
1.4% agarose gels were prepared (Fisher Scientific, Agarose Molecular Biology Grade 
cat# BP1356). Most gels were made with ethidium bromide to detect nucleic acids. Some 
gels were made without ethidium bromide, but they were stained subsequently with 
ethidium bromide. 
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Western Blot Analysis 
Cell lysates were combined with 2X Laemmli Buffer (Bio-Rad Laboratories) with 
additional SDS up to 8%.  Lysates were subjected to 10% SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE).  Gel proteins were electrophoretically transferred to 
Hybond-C Extra nitrocellulose membranes (Amersham, Piscataway, NJ).   Membranes 
were blocked with Tris-buffered saline (Bio-Rad), 0.05% Tween 20 (Bio-Rad) containing 
5% nonfat dried milk, and then incubated with primary and secondary antibodies.  The 
only exception was when probing for PKCβII, where pig gelatin (Bio-Rad) was used for 
the blocking (3%), primary (1%) and secondary (1%).  Detection was performed using 
SuperSignal West Pico Chemiluminescent substrate (Pierce Biotechnology, Rockford, 
IL).  Antibodies used are as follows:  PKCγ C-19, PKCζ C-20, PKCδ C-17, PKCβI C-16, 
pPKCβII/δ Ser660,  pPKCδ Thr 410, Akt1/2/3 H-136, pAkt1/2/3 Thr308, GLUT4 sc1608 
(Santa Cruz Biotechnology Inc., Santa Cruz, CA), PPARγ 81B8, pIRβ Tyr 1150/1151, 
PKCα #2056, phospho mTOR Serine 2481, (Peroxisome proliferator-activated receptor γ 
coactivator 1α ) PGC1α 3G6, PU.1 9G7, pAkt Ser473 #4058, Adiponectin C45B10 (Cell 
Signaling,  Boston, MA), GLUT4 C-Terminus 07-1404 (Millipore, Billerica, MA), β-
actin A5441, anti-flag M2 (Sigma).  PKCβII (NH2–(GC) EGFSFVNSEFLKPEVKS-
COOH), SRp40 (NH2-(GC) EVTFADAHRPKLNE-COOH), and SRp55 NH2-(GC) 
GERVIVEHARGPRRDRD-COOH) were raised by BioSynthesis Inc. (Lewisville, TX) 
and purified using Nab Protein A Plus Spin Kit (Pierce #89948).  Film bands were 
quantified using UnScan software (Silk Scientific, Orem, UT). 
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Co-immunoprecipitation 
L6 myotubes, COS7 cell pellets, or mouse tissue samples were harvested with 
Cell Lysis Buffer (Cell Signaling #9803) with added protease inhibitors (SigmaFast 
Protease Inhibitor Tablet, Sigma).  500μg cell lysate was pre-cleared with 50μL Protein A 
Magnetic Beads #S1425S (New England Biolabs, NEB, Ipswich, MA) for 1 hour 4
o
C 
with rotation.  This step eliminated non-specific binding of protein to magnetic beads.  
Lysate was separated from beads using Magnetic Separation Rack (#S1506S, NEB).  
Anti-Clk/Sty polyclonal antibody (sc-210, Santa Cruz) or anti-Akt2 antibody (sc-7936, 
Santa Cruz) was incubated with pre-cleared lysate O/N 4
o
C with rotation.  Lysates were 
now incubated with 50μL Protein A Magnetic Beads for 1 hour 4oC.  Magnetic field was 
applied to separate beads from unbound lysate.  Beads were washed three times with cell 
lysis buffer.  75μL 2X Laemmli Buffer (Bio-Rad) with DTT was added to the beads.  
Samples were boiled for 10 minutes and loaded onto a 10% SDS PAGE gel.   
 
Real-time PCR 
Real-Time PCR reactions were performed using TaqMan Universal PCR 
MasterMix (Applied Biosystems (AB) Inc., Foster City, CA, #4304437) according to 
manufacturer′s protocol. Vic-labeled mouse β-actin was the endogenous control (AB, 
#4352341E).  PKCβII primers and probe were custom made from AB. 
Forward primer 5′ - GGAGATTCAGCCACCTTATAAACCA - 3′. 
Reverse primer 5′ - GGTGGATGGCGGGTGAAAA - 3′.  Fam-labeled probe 
(PKCβ2/PKCβ1 junction) 5′ - TTCGCCCACAAGCTT - 3′.  Real-Time PCR was 
analyzed on the ABI PRISM 7900HT Sequence Detection System (AB). 
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RESULTS 
Insulin-Regulated PKCßII Exon Splicing in Hepatocytes, 3T3-Adipocytes, and 
Hepatoma Cells [81]* 
Our previous work demonstrated that insulin regulated the inclusion of exon-
betaII, and also activated additional 5'-splice sites in PKCßII mRNA [82]. Here we 
wanted to repeat some of the experiments, and expand the study to other cell lines, and 
modify some of the treatments. As before, insulin regulated PKCßII exon inclusion in L6 
cells and activated an additional 5'-splice site in a time-dependent manner. Alternative 
splicing of the PKCß gene was further studied in other cell types to evaluate whether 
insulin regulated endogenous PKCßII expression in other insulin dependent target tissues. 
Insulin promoted exon inclusion of PKCßII mRNA using splice site I in primary rat 
hepatocytes and 3T3-L1 adipocytes (Fig. 22, B and C). Even though most data shown are 
for 30 min insulin treatment, we conducted experiments where we tested for 15 min, 45 
min, 60 min, and 90 min. The pattern observed is that the additional 5‟ splice sites require 
longer times to be activated. The PI3-kinase inhibitor LY294002 blocked insulin-
stimulated exon inclusion in 3T3-L1 adipocytes (Fig. 22C). In the human hepatoma 
HepG2 cells, insulin activated additional upstream PKCßII 5'-splice site (Fig. 22D) 
similar to L6 cells. However, it was difficult to reproduce endogenous exon inclusion in 
 vascular smooth muscle cells (data not shown). 
* The results presented here contributed to other projects/studies besides my dissertation project. For the 
results that have already been published, the heading includes the reference of the publication. 
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Development of an Insulin-Regulated Heterologous Minigene [81] 
To dissect the mechanism of regulation of PKCßII alternative splicing by insulin, 
a PKCßII heterologous minigene was constructed to identify insulin-responsive cis-
elements in vivo in eukaryotes (Fig. 23A). Because the splice variants detected in vivo in 
L6 and HepG2 cells appeared to use alternative 5'-splice sites, it was postulated that the 
Figure 22. Insulin-Regulated Endogenous Alternative Splicing of the C Terminus of 
PKCß pre-mRNA.  
A, Inclusion of PKCßII exon 17 generates PKCßII mRNA. A STOP codon within exon 
betaII hinders the translation of the PKCßI exon. Total RNA was isolated from either (B) 
primary rat hepatocytes, (C) 3T3-L1 adipocytes, or (D) Hepatoma HepG2 cells. RNA (2 
µg) was used in the RT-PCR analysis using primers for the last common, C4, domain 
(exon 16) and antisense primer to the PKCßI exon (indicated by arrows). The PCR 
product size was 187 bp for PKCßI and 404 bp (splice site I) or 539 bp (splice site II) for 
PKCßII. Primers for ß-actin were used for normalization. The experiments were repeated 
two to three times for each cell type and similar results were obtained. 
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elements involved in regulation of exon inclusion and splice site selection would reside 
within the PKCßII exon and its flanking 3'- and 5'-intronic sequences. 
 
Figure 23. Insulin-Regulated PKCßII Splicing Minigene.  
A, A heterologous splicing minigene was constructed by inserting the PKCßII genomic 
fragment (exon 17) into a multicloning site in between the SD and SA in pSL3. Putative 
cis-elements were identified by inspection of the sequence and are indicated relative to 
one another. PT, Pyrimidine tract; AURE, AU-rich Element; ISE, intronic splicing 
enhancer; CAG/GTG, splice site. B, Two sets of primers were used in the amplification 
of splice products. Primers SD-SA amplified three products: 263 bp when PKCßII exon 
was not included; 479 bp (I) when PKCßII exon was spliced using splice site I; 614 bp 
(II) when PKCßII exon was spliced using splice site II. Primers ßII-SA amplified two 
products: 352 bp (I) when PKCßII exon was spliced using splice site I; 487 bp (II) when 
PKCßII exon was spliced using splice site II. C, The pSPL3–32 minigene was transiently 
transfected into L6 cells. Cells either had no insulin treatment (I0) or were treated with 
insulin for 30 min (I30). Total RNA was extracted and RT-PCR was performed using 
primers corresponding to either SD-SA or ßII-SA. D, The PCR products were verified by 
Southern blot analysis using PKCßII-specific probe as described. Labeled probe 
hybridized to PCR products as predicted. 
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 Hence, the 216-bp PKCßII exon and 450-bp upstream and 948-bp downstream 
flanking intronic sequences were cloned into the pSPL3 vector between the splice site 
donor and the splice site acceptor exons.  
To determine whether the pSPL3–32 minigene could mimic RNA processing and 
splice site selection as observed for endogenous PKCßII mRNA, the pSPL3–32 minigene 
was transiently transfected into rat skeletal muscle (L6) cells. Insulin-responsive 
inclusion of the PKCßII exon and activation of another upstream splice site was 
demonstrated in L6 cells using two sets of primers. Primers to splice site donor (SD) and 
splice site acceptor (SA) amplified three products: 263 bp amplifying SD-SA showing 
constitutive minigene splicing; 479 bp (I) when PKCßII exon was included using splice 
site I; and 614 bp (II) when PKCßII exon was included using splice site II. Primers within 
the PKCßII exon and SA amplified two products: 352 bp (I) when PKCßII exon was 
included using splice site I; and 487 bp (II) when PKCßII exon was included using splice 
site II (Fig. 23B). When cells were not treated with insulin, only constitutive splicing of 
the minigene is observed using primers SD-SA whereas no product is detected using 
primers ßII-SA as the PKCßII exon is skipped (Fig. 23C). Both sets of primers detect 
products resulting from activation of splice sites I and II after insulin treatment. Hence, 
this minigene contained all the necessary sequences to promote insulin-regulated PKCßII 
exon inclusion and splice site selection.   
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Insulin-Regulated PKC II Minigene in Multiple Target Tissues [81] 
Hormonally responsive alternative splicing of endogenous PKCßII mRNA is 
readily detected in differentiated skeletal muscle cells such as L6 cells [35]. However, in 
rat vascular smooth muscle A10 cells, insulin-induced endogenous splicing of PKCßII 
isoform was not readily detected. This is presumably due to the complex transcriptional 
and posttranscriptional regulation of PKCßII mRNA [83].  
 
 
To further test the model in other insulin-responsive cells, the pSPL3–32 
minigene was transiently transfected into the rat vascular smooth muscle A10 cells, 
Figure 24. The pSPL3–32 Minigene was Regulated by Insulin in Various Cell Types.  
Cells either had no insulin treatment (I0) or were treated with insulin for 15 min (I15), 30 
min (I30), or 60 min (I60). RT-PCR was performed using primers for ßII-SA to detect 
activation of splice sites I and II by insulin. ß-actin levels were equivocal between the 
treatments. Each experiment was repeated two to four times with similar results to 
establish activation of splice sites I and II. 
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human hepatoma cell line, HepG2 cells, 3T3-pre-adipocytes, and murine embryonic 
fibroblasts. Insulin regulated PKCßII exon inclusion and splice site activation of the 
pSPL3–32 minigene in each cell line (Fig. 24). Additionally, splice site II was activated 
in all cell types by insulin in a time-dependent manner similar to that detected in L6 cells. 
Interestingly, different cells show distinct responses to insulin treatment. L6 
skeletal muscle cells show a preference to utilizing splice site II after 15 min of insulin 
stimulation whereas in A10 vascular smooth muscle cells, insulin stimulation for 15 min 
promoted the use of splice site I. Both cell types utilize splice sites I and II with longer 
insulin treatment. HepG2 hepatomas predominantly use splice site II whereas 3T3-L1 
preadipocytes utilize splice site I with longer (30–60 min) insulin treatments. Also, 3T3-
L1 preadipocytes and the embryonic fibroblasts show constitutive PKCßII exon inclusion 
using splice site I without insulin stimulation. Hence five distinct cell types (i.e. skeletal 
muscle, vascular smooth muscle cells, hepatoma cells, preadipocytes, and embryonic 
fibroblasts) demonstrate PKCßII exon splice site activation regulated by insulin within a 
short time of the stimulation, although the use of splice sites I and II are cell and time 
dependent.    
 
Insulin-Activated PKCßII 5'-Splice Sites [81] 
 To determine whether the 3'-intron was involved in insulin-regulated 5'-splice site 
selection, the 3'-flanking intron and a portion of the PKCßII exon including the 3'-splice 
site were deleted from the pSPL3–32 minigene. A new 3'-splice site that the exon can 
utilize was introduced in the cloning process as described in Materials and Methods. This 
truncated minigene, pSPL3–17, containing 108 bp of the exon and the intronic sequences 
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flanking the 5'-splice site (Fig. 25A) was transfected into L6 and A10 cells. Insulin still 
regulated the 5'-splice site selection of the PKCßII exon (Fig. 25B) in the pSPL3–17 
minigene in a time-dependent manner in both the cell types. This suggests that the 
elements around the 3'-splice site and its flanking intron were not required for activation 
of the 5'-splice site in vivo by insulin.    
 
Figure 25. 3' Intronic Sequences Are Not Involved in Insulin-Regulated 5' Splice 
Site Selection.  
A, The pSPL3–17 minigene contains 108 bp of the ßII exon and approximately 1200 bp 
of 5'-intronic sequence. SSI, Splice site I (ATG/GTG); SSII, splice site II (CAG/GTG). 
B, pSPL3–17 minigene was transiently transfected into L6 skeletal muscle and A10 
vascular smooth muscle cells. Cells either had no insulin treatment (I0) or were treated 
with insulin for 15 min (I15), 30 min (I30), or 60 min (I60). RT-PCR was performed 
using primers for SD-SA. Insulin activated splice sites I and II in both cell types. The 
experiment was repeated five times with similar results in both cell types. The graph 
shows percent maximal ßII-exon inclusion using either splice site I or II, assuming 
utilization of splice sites I and II as 100% after 60 min of insulin treatment. 
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Insulin Signals via PI3-Kinase to Regulate PKCßII Minigene [81] 
 Our previous work [84] and studies in 3T3 L1 adipocytes (Fig. 22A) indicated 
that a PI3-kinase-dependent pathway was involved in the in vivo regulation of alternative 
splicing of PKCßII mRNA by insulin. Because pSPL3–17 contained all the cis-elements 
required for insulin-stimulated activation of 5'-splice sites, this minigene was transiently 
transfected into L6 cells. To determine whether the splicing of the minigene was also 
regulated via a PI3-kinase pathway, PI3-kinase inhibitors, LY294002 (100 nM) or 
Wortmannin (100 nM), were added 30 min before addition of insulin for 30 min. 
Moreover, pSPL3–17 was cotransfected with p85, the dominant negative mutant of the 
regulatory subunit of PI3-kinase [85, 86], which lacks the binding site for the p110 
catalytic subunit, thereby inhibiting the association of PI3-kinase with insulin receptor 
substrate-1. Results show inhibition of PKCßII splice site activation, hence demonstrating 
that splice site selection of the PKCßII minigene was also regulated via the PI3-kinase 
pathway (Fig. 26, A and B).   
 
Akt2 Is a Downstream Kinase Regulating PKCßII Exon Splice Site Selection [81] 
 The role of Akt kinase has been implicated in insulin action because it is activated 
by PI3-kinase [87]. Also, SR proteins contain the consensus sequence RXRXXS 
recognized by Akt kinase. They have been shown to be potential substrates in vitro [88] 
for Akt kinase. Further, data from our laboratory demonstrate Akt2 kinase 
phosphorylated SRp40 in vivo. To identify the intermediary kinases involved in the 
phosphorylation cascade, the minigene pSPL3–17 was cotransfected with constitutively 
active Akt2 kinase (CA-Akt2) into the L6 skeletal cells. CA-Akt2 kinase mimicked the 
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action of insulin (Fig. 26C) by promoting exon inclusion and activating the additional 5'-
splice site in the minigene.  
 
  
Figure 26. 5' Splice Site Selection in pSPL3-17 Minigene Is Regulated by PI3-Kinase 
Pathway.  
Insulin (100 nM) was added for 30 min (I30) or cells had no insulin treatment (I0). A, 
The PI3-kinase inhibitor, LY294002, was added for 30 min before total RNA isolation; 
or (B) The PI3-kinase inhibitor, wortmannin, was added 30 min before total RNA 
isolation. The dominant negative subunit of PI3-kinase, p85 DN, was cotransfected with 
pSPL3–17. C, Constitutively active Akt2 kinase or (D) Clk/Sty was cotransfected with 
pSPL3–17. Total RNA was isolated and RT-PCR was performed using primers for ßII-
SA in panels A and D. ß-Actin was used as an internal control. RT-PCR was performed 
using primers for SD-SA in panels B and C. The graph shows percent maximal ßII-exon 
inclusion using either splice site I or II, assuming utilization of splice sites I and II as 
100% after 30 min of insulin treatment. The experiments were repeated at least four times 
each. 
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Clk/Sty Cotransfection Regulated PKCßII Exon Splice Site Selection [81] 
 The Clk/Sty protein kinase interacts with RNA binding proteins and, in particular, 
phosphorylates the SR family of splicing factors [52]. Mammalian Clk/Sty was shown to 
phosphorylate SR splicing factors in a physiologically relevant manner. It was suggested 
that the Clk kinase family could act as a link between signal transduction and regulated 
splicing [89],[90]. Hence, the minigene pSPL3–17 was cotransfected with Clk/Sty in L6 
cells. Clk/Sty also activated 5'-splice sites (Fig. 26D), suggesting that several kinases 
could play a role with insulin activating multiple signaling pathways involved in splice 
site selection.     
 
Binding of SRp40 Is Essential for Insulin-Regulated Splice Site Activation [81] 
 It was established that the phosphorylation of SRp40 was a key step in the 
regulation of splice site selection and exon inclusion by insulin[84]28). However, binding 
of SRp40 to the pre-mRNA may be exclusive of its phosphorylation and function in 
PKCßII splicing. To further elucidate the role of SRp40 in splice site selection, its RNA-
binding site, TGGGAGCTTGGCTTAGA, in the downstream intron flanking the PKCßII 
exon {which has a 2-bp mismatch with the sequence predicted by SELEX [91]} was 
replaced with AGCGAATCATTGAATCC in the pSPL3–32 minigene. This sequence 
replacement ablated the insulin-stimulated exon inclusion and splice site activation in the 
minigene (Fig. 27A). This emphasizes the requirement of SRp40 binding to its site on the 
pre-mRNA in addition to its phosphorylation by an upstream kinase in insulin-regulated 
PKCßII 5'-splice site selection. 
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Figure 27. SRp40 Binding and Phosphorylation Affect PKCßII 5' Splice Site Selection 
A, The SRp40 binding site in the 5'-intronic sequence was replaced with 
AGCCGAATCATTGAATCC in the pSPL3–32 minigene. Both the pSPL3–32 and mutated 
pSPL3–32* minigenes were transiently transfected into L6 cells. Insulin was added for 30 min 
(I30) or 60 min (I60), or cells were not treated with insulin (I0). RT-PCR was performed using 
primers for SD-SA. The experiment was repeated five times with similar results. The graphs 
shows percent maximal ßII-exon inclusion using either splice site I or II, assuming utilization of 
splice sites I and II as 100% after 60 min of insulin treatment in the pSPL3–32 minigene. The 
experiments were repeated at least three times with similar results. B, The pSPL3–32 minigene 
was cotransfected into L6 cells along with increasing amounts (0.8–1.6 µg) of SRp40. Insulin 
(100 nM) was added 30 min before total RNA isolation. RT-PCR was performed using primers 
to SD-SA. ß-Actin was used as an internal control. The experiment was repeated four times with 
similar results. C, The pSPL3–32 minigene was cotransfected into L6 cells along with either 
SRp40 or constitutively active Akt2 kinase (CA-Akt2). Insulin (100 nM) was added 30 min 
before total RNA isolation. ß-Actin was used as an internal control. RT-PCR was performed 
using primers to ßII-SA. The experiment was repeated thrice to ensure reproducible results. 
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Overexpression of SR factors has also been shown to enhance exon inclusion 
[92]. Although we hypothesize that phosphorylation of SRp40 regulates its RNA binding 
activity, overexpression should mimic, to an extent, insulin effects. Increasing amounts of 
SRp40 (0.8–1.6 µg/35-mm plate) were cotransfected with pSPL3–32 to observe its 
influence on splice site selection. Results indicate that although cotransfection of 0.8 µg 
SRp40 activated splice sites I and II (compared with no insulin treatment), addition of 
insulin leading to phosphorylation of SRp40 enhanced splice site activation to 100% (Fig. 
27B). Cotransfection with 1.6 µg SRp40 (per 35-mm plate) activated splice sites I and II 
(Fig. 27B) although amounts higher than 2.4 µg of SRp40 per 35-mm plate suppressed 
splicing (data not shown).  
Further, the constitutively active form of Akt2 kinase, CA-Akt2, was 
cotransfected along with pSPL3–32 and SRp40 (0.8 µg/35-mm plate) in L6 cells. It 
mimicked insulin-induced splice site activation (Fig. 27C). This provides a link to the 
downstream kinase cascade leading to the splice site selection in PKCßII mRNA.   
 
Consecutive Deletion of the 5'-Intronic Sequences in PKCßII Minigene Reveals 
Multiple Regulatory Effects [81] 
The contribution of the downstream intronic sequence for activating splice sites I 
and II was important but unknown. Hence, consecutive deletions were performed on the 
minigene pSPL3–17 to truncate the 5'-intron and elucidate the importance of other 
putative elements on the 5'-splice site selection (Fig. 28A). GA-rich intronic splicing 
enhancers, present at the 5'-end of introns, have been implicated in promoting exon 
inclusion [93]. To determine whether these sequences played a role in PKCßII exon 
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inclusion and splice site selection, the minigene pSPL3–18 was truncated after the AU-
rich element, thereby eliminating the GA-rich splicing enhancers and then transfected 
into A10 cells. The pSPL3–18 minigene still demonstrated regulated PKCßII splice site 
selection (Fig. 28B) with activation of splice sites I and II, suggesting no involvement of 
these putative distal intronic splicing enhancers in insulin action. 
Figure 28. Consecutive Deletions of PKCßII Minigene Reveal Multiple Regulatory Effects  
A, Schematic shows the consecutive deletions of putative cis-elements in the 5'-intronic 
sequence of ßII exon. B, The truncated minigene pSPL3–18 was transiently transfected 
into A10 cells. Insulin was added for 30 min (I30) or 60 min (I60) or cells were not 
treated with insulin (I0). Total RNA was isolated and RT-PCR was performed using 
primers to ßII-SA. C, The truncated minigenes pSPL3–19, pSPL3–20, and pSPL3–22 
were transiently transfected into A10 cells. Insulin was added for 30 min (I30) or 60 min 
(I60), or cells were not treated with insulin (I0). Total RNA was isolated and RT-PCR 
was performed using primers to ßII-SA. ß-Actin was used as an internal control. The 
experiments were repeated at least two times to ensure reproducible effects of insulin. 
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Further deletion of an additional 177 nucleotides, eliminating the AU-rich 
element sequence but maintaining the SRp40 binding site in pSPL3–19 minigene, also 
preserved insulin-regulated activation of splice sites (Fig. 28B). Interestingly, however, 
splice site II was activated only after 60 min of insulin treatment. It could be 
hypothesized that the AU-rich element was involved in secondary structure formation 
facilitating splice site selection. Also, the splicing factor hnRNP A1 binding site is 
downstream of the SRp40 site (see Fig. 28A). This may suggest that elimination of the 
AU-rich element may have enabled hnRNPA1 to bind to an intronic splicing silencer, 
thereby decreasing the utilization of splice site II. Further studies are indicated to clarify 
the role of hnRNP A1.  
Minigene pSPL3–20 truncated at the SRp40 site, destroying a portion of it, 
showed splice site I activation within 30 min; however, splice site II was not used even at 
60 min (Fig. 28B). This indicates that SRp40 is a key factor in early insulin regulation of 
splice site selection of PKCßII exon and is essential for splice site II activation. 
The removal of the SRp40 binding site and the proximal sequences in minigene 
pSPL3–22 to a minimum of 39 nucleotides of the 5'-intronic sequences resulted in only 
20% utilization of splice site I even at 60 min after insulin treatment. This emphasizes the 
importance of cis-elements flanking the 5'-splice site in PKCßII exon inclusion and 5'-
splice site selection by insulin (Fig. 28B).   
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Transfection of cells with constitutively active Akt2 kinase mimics insulin-induced 
splicing of PKCβII [94] 
Insulin-stimulated inclusion of the exon specifying the C-terminal V5 region of 
PKC II [32, 82] and insulin-regulated splicing of the II exon involved phosphorylation 
of SRp40 by a PI 3-kinase-dependent signaling pathway [84]. It has been shown that the 
physiological responses of insulin such as glucose uptake and Glut4 translocation are 
preferentially mediated by Akt2 kinase [95]. We hypothesized that insulin activation of 
Akt would also result in the increased phosphorylation of SRp40 because SR proteins are 
potential in vitro substrates for Akt [49], and SRp40 overexpression increased glucose 
uptake [84]. To demonstrate this relationship, skeletal muscle (L6) cells were either 
treated with insulin for 30 min or left untreated (control), or cells were transiently 
transfected with constitutively active (CA) Akt2 cDNA construct [96]. Simultaneously, 
separate wells were transiently transfected with SRp40. The endogenous splicing of 
PKC II in cells with CA-Akt2 was compared with insulin-treated cells and to cells 
transfected with SRp40 cDNA where inclusion of the II exon was detected without 
insulin treatment as reported earlier [84]. In cells transiently transfected with 
constitutively active Akt2, PKC II exon inclusion was detected without insulin treatment 
(Fig. 29), suggesting that Akt2 kinase acted downstream of PI 3-kinase. 
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Akt2 Kinase Phosphorylated SRp40 in Vivo [94] 
We previously found increased phosphorylation of SRp40 by a PI 3-kinase-
dependent pathway following insulin treatment [84], although the specificity of the 
Figure 29. Constitutively active Akt2 kinase mimics insulin-induced endogenous 
PKCβII splicing  
A, the figure depicts alternative splicing of PKCβII mRNA regulated by insulin. Upon 
insulin treatment, SRp40 is phosphorylated which then mediates PKCβII exon inclusion 
to produce mature PKCβII mRNA. B, L6 cells were transfected with CA-Akt2 or SRp40 
and treated with insulin for 30 min. Total RNA was isolated, and RTPCR was performed 
using sense primers for C4 and antisense primer for βIV5. 5% of products were resolved 
on 6% PAGE gels and detected by silver staining. The experiments were repeated thrice 
to ensure reproducibility. Splicing efficiency was quantified by densitometric scanning of 
the silver-stained gels from three experiments and represented on the graph. An arbitrary 
value of 100% splicing efficiency is attached to βI exon in the control (I0) sample and 
100% βII splicing efficiency in the insulin-treated (I30) sample.,. 
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kinases involved and the phosphorylation sites were not identified. We asked whether a 
downstream effecter such as Akt kinase was phosphorylating serine residue(s) in the SR 
domain of the SR protein.  
 
Figure 30. Akt2 kinase phosphorylates SRp40 in vivo  
L6 cells were transfected with pcDNA3 alone or myc-Akt2/pcDNA3. Following serum 
starvation in phosphate-free Dulbecco‟s modified Eagle‟s medium for 6 h, the cells were 
labeled for 6 h in medium containing [
32
P]orthophosphate (0.5 mCi), treated with insulin 
for 30 min, lysed, and immunoprecipitated with anti-SRp40 antibody. Top panel, 
immunoprecipitations were separated by SDS-PAGE and examined by phosphorus 
imaging. The graph depicts densitometric analysis of the blot and indicates fold increase 
of phosphorylated SRp40 under the above conditions. Bottom panel, the blot was 
immunoprobed with antibodies to SRp40 and Akt2 kinase. The experiments were 
repeated three times with similar results. IB, immunoblot. 
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Recent studies from other laboratories demonstrated that Akt could phosphorylate 
SR proteins in vitro [49]. However, the in vivo evidence linking a hormone-signaling 
pathway to the phosphorylation of a specific SR protein resulting in regulation of a 
splicing event was lacking. To demonstrate that Akt2 kinase phosphorylates SRp40, L6 
myotubes that had been transfected with CA myc-Akt2 or treated with insulin were 
labeled with [
32
P]orthophosphate prior to immunoprecipitation with SRp40 antibody. 
Following SDS-PAGE separation of immunoprecipitates, the autoradiogram revealed that 
SRp40 in the basal state was phosphorylated. CA HA-Akt2 transfection increased its 
phosphorylation 2.5-fold compared with the empty vector control. Insulin treatment of 
cells transfected with the empty vector resulted in a 3-fold increase in SRp40 
phosphorylation (Fig. 30). 
 
SRp40 Is an Akt2 Substrate [94] 
Akt2 regulates PKC II exon inclusion as shown above in Fig. 29. Also, 
phosphorylation of SRp40 via insulin and its downstream kinases is essential for PKC II 
exon inclusion [84]. Further, protein sequence analysis revealed a consensus Akt2 
phosphorylation sequence (RXRXXS) at Ser residue 86. Hence, to examine whether 
Akt2 phosphorylated SRp40 in vitro, an Akt kinase assay was performed. L6 cells were 
transfected with either myc-SRp40 or HA-Akt2 CA. Following immunoprecipitation with 
Myc antibody and HA antibody, respectively, the assay was performed in the kinase 
reaction buffer for 30 min in the presence of [ -
32
P]ATP. The samples were separated on 
SDS-PAGE and analyzed by phosphorus imaging (Bio-Rad). The results indicated that 
 104 
Akt2 phosphorylated SRp40 (Fig. 31a). Further, when Ser
86
 was mutated to alanine 
(SRp40*), the mutation abolished Akt phosphorylation of SRp40. The constructs were 
validated in separate experiments (Fig. 31b) using anti-Myc and anti-SRp40 antibodies.  
 
 
Figure 31. SRp40 Is an Akt2 Substrate  
a, in vitro Akt2 kinase assay. Constitutively active Akt2 kinase immunoprecipitates were 
incubated with 10 mCi of [ -
32
P]ATP (ICN Biomedicals) and myc-SRp40 (or mutated 
myc-SRp40*) immunoprecipitates for 30 min in 25 ml of kinase buffer (20 mM HEPES, 
10 mM MgCl2, 10 mM MnCl2, 1 mM dithiothreitol, 5 mM ATP) at 25 °C. The reactions 
were terminated using Laemmli SDS sample buffer. The proteins were separated on 
12.5% SDS-PAGE, and phosphorylation was visualized by phosphorus imaging (Bio-
Rad). The experiments were repeated five times with similar results. 
b, the myc-SRp40 construct was validated in separate experiments. The construct was 
transfected into L6 cells, and the lysate was immunoprecipitated with using antimyc 
antibody. The SRp40 antibody was then used for detection. In a separate experiment 
performed simultaneously, the lysate was immunoprecipitated with SRp40 antibody, and 
anti-myc was used for detection. Lane 1, mock transfection; lane 2, insulin at 0 min; lane 
3, insulin at 30 min. IP, immunoprecipitation; IB, immunoblot. 
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Mutation of Akt2 Phosphorylation Site in SRp40 Attenuated PKC II Exon 
Inclusion [94] 
We surmised that phosphorylation at Ser
86
 was a key regulatory factor in splice 
site selection. A heterologous minigene pSPL3–32 [81] was developed to study insulin 
regulation of in vivo splice site selection of PKC II exon. In this system, SD splices on to 
SA constitutively, but inclusion of PKC II exon and activation of its splice sites occurs 
only upon insulin treatment. The mutated SRp40, SRp40*, was co-transfected in L6 cells 
with the splicing minigene pSPL3- II and treated with insulin for 30 min. RT-PCR was 
performed using primers for SD and SA such that inclusion of PKC II exon as well as 
activation of the splice sites could be observed. Cells transfected with mutated SRp40 
showed decreased PKC II 5‟ splice site activation and exon inclusion in the presence of 
insulin (Fig. 32a). The endogenous SRp40 may have been responsible for some residual 
splicing. This confirmed a role for Akt2 phosphorylation of Ser
86
 in SRp40 as a key 
regulatory mechanism in splice site selection.  
 
Fibroblasts from Akt2(-/-) Mice Splice the PKC II Exon Inefficiently [94] 
To evaluate the role of Akt2 kinase in exon inclusion, pSPL3- II minigene was 
transiently transfected into fibroblasts from Akt2(-/-) mice cells or (+/+) cells. Insulin 
treatment of cells for 30 min resulted in activation of splice sites I and II in wild type 
(+/+) cells, whereas the Akt2-deficient (-/-) cells did not show PKC II exon inclusion 
(Fig. 32b). This provided direct genetic evidence that Akt2 mediated PKC II splice site 
selection.  
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Figure 32. Akt2 Phosphorylation Site in SRp40 regulates PKC II exon inclusion  
a, mutation of Akt2 phosphorylation site on SRp40 attenuates PKC II exon inclusion. The 
PKC II exon is cloned between the splice donor and splice acceptor of pSPL3 to generate the 
pSPL3- II splicing minigene (11). L6 cells were co-transfected with the heterologous splicing 
minigene pSPL3- II alone or along with the mutated SRp40* and treated with insulin (100 nM) 
for 30 min. Total RNA was isolated and RT-PCR performed using sense primers for SD (5‟-
TCTCAGTCACCTGGACAACC-3‟) and antisense primer for SA (5‟-
CCACACCAGCCACCACCTTCT-3‟). 5% of products were resolved on 6% PAGE gels and 
detected by silver staining. PKC II exon inclusion and splice sites I and II activation occurs upon 
insulin treatment in L6 cells transfected with pSPL3- II (control), whereas those co-transfected 
with pSPL3- II and the mutated SRp40 (SRp40*) showed decreased exon inclusion. Constitutive 
splicing of SD to SA was observed in all of the samples. The results represent two separate 
experiments performed with similar results. b, fibroblasts from Akt2(-/-) mice show defective 
PKC II minigene splicing. Immortalized mouse fibroblasts derived from wild type (+/+) or Akt2-
deficient (-/-) mice were transfected with the PKC II splicing minigene. Total RNA was isolated, 
and RT-PCR was performed using sense primers for SD and antisense primer for SA. 5% of 
products were resolved on 6% PAGE gels and detected by silver staining. Constitutive splicing of 
SD to SA occurs in both cell types. PKC II exon inclusion and splice site activation occurs upon 
insulin treatment in Akt2(+/+) cells. SSI, splice site I; SSII, splice site II. The results are 
representative of two experiments with similar results. 
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Akt2 Kinase Association with SRp40 Is Regulated by Insulin [94] 
Although recent reports have indicated nuclear targeting of Akt kinase [97], our 
studies did not examine shuttling of Akt2 kinase or SRp40. We examined SRp40 
immunoprecipitates for the presence of Akt2 kinase. SRp40 was immunoprecipitated 
from L6 whole cell lysates using SRp40-specific antibody. Western analysis was then 
performed on SRp40 immunoprecipitates using Akt2 antibodies. Endogenous Akt2 was 
present in the SRp40 immunoprecipitates but not in the control nonspecific IgG 
immunoprecipitates (Fig. 33a).  
 
Figure 33. Co-immunoprecipitation of Akt2 and SRp40 
a, L6 whole cell lysates were immunoprecipitated with SRp40 antibody as described and 
separated by SDS-PAGE, and endogenous Akt2 was detected with anti-Akt2 antibody. 
Control using nonspecific IgG and protein G-agarose beads (IgG) showed no interaction. 
L6 lysates prior to SRp40 immunoprecipitation is shown in the bottom panel. b and c, in 
a separate experiment, L6 lysates were immunoprecipitated using Akt2 antibody, 
separated by SDS-PAGE, and detected by Western blotting using SRp40 antibody (b) or 
ASF/SF2 antibody (c). Control using nonspecific IgG and protein G-agarose beads (IgG) 
showed no interaction. L6 lysates prior to Akt2 immunoprecipitation is shown in the 
bottom panel. The experiments were repeated thrice with similar results. IP, 
immunoprecipitation; IB, immunoblot. 
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To confirm specific interaction of SRp40 with Akt2 kinase, we performed reverse 
immunoprecipitation of Akt2 followed by Western analysis using SRp40-specific 
antibodies. SRp40 was detected in the Akt2 immunoprecipitates but was absent from the 
control nonspecific IgG immunoprecipitates (Fig. 33b). Both experiments demonstrated 
that the association was further enhanced upon insulin treatment for 30 min. This 
association confirms their enzyme-substrate interaction following insulin treatment. 
Because all SR proteins have an RS domain and hence are potential substrates of 
Akt2 kinase, we performed Western blot analysis using ASF/SF2 antibody on the Akt2 
immunoprecipitates (Fig. 33c). As expected, Akt2 associates with ASF/SF2, but this 
association is not enhanced by insulin treatment. This leads us to suggest that even 
though Akt2 kinase has the potential to phosphorylate the SR proteins, insulin regulates 
the Akt2-mediated phosphorylation only of specific SR proteins such as SRp40.   
   
Fibroblasts from Akt2 (-/-) Mice Do Not Phosphorylate-SRp40 in Vivo [94] 
 In humans, mutation in AKT2 is linked to severe insulin resistance and type 2 
diabetes mellitus [98]. Further, because the loss of Akt2 in mice is linked to the 
development of type 2 diabetes and a reduction in insulin-dependent glucose uptake [99, 
100], we hypothesized that cells from these animals would be defective in insulin-
dependent phosphorylation of SRp40 and alternative splicing of PKC II when compared 
with wild type cells. Immortalized fibroblasts from wild type (+/+) or Akt2-deficient (-/-) 
mice were treated with insulin for 15 or 30 min or treated with vehicle (0 min), and cell 
lysates were separated on SDS-PAGE. It was then analyzed with mAb104 antibody, 
which detects the phosphoepitope of SR proteins, anti-SRp40 antibody, or anti-PKC II 
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antibody. As seen in Fig. 34, insulin treatment increased the phosphorylation of SRp40 in 
wild type (+/+) cells, whereas the Akt2-deficient (-/-) cells did not show increased 
phosphorylation with insulin stimulation. The levels of SRp40 remained unaltered in both 
cell types. In Akt2(-/-) cells, PKC II levels were less than one-half of the levels noted in 
(+/+) cells. In Akt(+/+) cells, the PKC II levels represent the synthesis of new enzyme at 
30 min as reported earlier for other cell types [82, 101]. This provided genetic evidence 
that Akt2 deficiency resulted in a lack of increased phosphorylation of SRp40 following 
insulin treatment and resulted in reduced PKC II protein levels. 
Figure 34. Mouse fibroblasts from Akt2(-/-) cells do not phosphorylate SRp40 in 
vivo upon insulin treatment 
Mouse embryonic fibroblasts derived from wild type (+/+) or Akt2-deficient (-/-) mice 
were treated with insulin for 0 (control), 15, or 30 min as indicated. a, cell lysates were 
separated on 12.5% SDS-PAGE and analyzed with mAb104 antibody, which detects 
phospho-epitopes of SR proteins. Akt2-deficient (-/-) samples do not show increase in 
phosphorylation of SRp40 upon insulin treatment. b, the levels of SRp40 in the above 
samples remain unchanged in both the wild type (+/+) or Akt2(-/-) cells upon insulin 
treatment. c, PKC II increased upon insulin treatment in wild type Akt2(+/+) cells, 
whereas Akt2-deficient (-/-) cells show decreased PKC II expression that remains 
unchanged upon insulin treatment. The experiments were repeated thrice to ensure 
reproducibility. Ab, antibody. 
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Muscle Tissues from Akt2(-/-) Mice Expressed Less PKC II mRNA [94] 
 Gastrocnemius muscle tissues from 16-week-old Akt2(+/+) and (-/-) mice [49] 
were examined for levels of PKC I and PKC II mRNA by real time quantitative PCR. 
Results indicated a 54% decrease in the expression of PKC II in Akt2(-/-) samples (Fig. 
35), whereas PKC I mRNA levels remained unchanged in both (+/+) and (-/-) tissues, 
indicating a defect in exon inclusion. This is consistent with the 2-fold difference in 
proteins noted in fibroblasts. (Curves for the statistical analysis of the quantitative real 
time PCR using the (2
- Ct
) method are not shown). 
 
 
 
 
 
 
   
 
 
 
 
Figure 35. Real time quantitative PCR shows decreased PKC II mRNA levels in 
Akt2(-/-) cells. 
Gastrocnemius muscle tissues (n=4) from Akt2(+/+) and (-/-) mice were examined for 
levels of PKC I and PKC II mRNA by real time quantitative PCR. All of the 
measurements were made in triplicate. Results indicated a 54% decrease in the 
expression of PKC II in Akt2(-/-) samples. 
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HeLa cell and HEK-293 cell nuclear extracts splice exon II to I in vitro 
 Hormonally responsive splicing of PKC- II by insulin in its target cells provides 
an efficient means of switching the expression of beta isoforms. Alternative pre-mRNA 
splicing events are controlled by cis-acting elements within the transcript. SR proteins 
interact with trans-acting enhancers/silencers and regulate splice site utilization. Our in 
vivo experiments identified SRp40 as the mediator of splice site selection via its 
phosphorylation by PI3-kinase regulated pathways [84]. The minimum boundaries of 
RNA required for insulin responsive splicing were defined in a series of heterologous 
minigenes. Next, corresponding DNA templates for in vitro splicing were constructed 
using the minimum intronic sequences that supported in vivo splicing. The templates 
were used to synthesize transcripts that were labeled with 
32
P and the labeled transcripts 
were used in splicing assays with HeLa and HEK-293 cell nuclear extracts. All templates 
represent the same pattern which is Exon-Intron-Exon. The sizes of the exons remain 
constant in all the templates while the size of the intron varies. The upstream exon is 
always 201 bases long and represents exon-betaII. The downstream exon is always 94 
bases long and represents exon-betaI. Thus, if the intron is fully excised it makes a 
spliced product of 295 bases. Here we show the data from template FH6 that generates a 
transcript of 573 bases with an intronic length of 278 bases. The 278 bases intron is a 
composite chimeric intron of the actual intron (~5,200 bases long) between exons betaII 
and betaI. All the composite chimeric introns contain the same length (188 bases) of the 
intronic sequence upstream of exon-betaI. What varies in each template is the intronic 
sequence downstream of exon-betaII. Since the FH6 composite chimeric intron is 278 
bases, and since the exon-betaI upstream intronic sequence is 188 bases, the varying 
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intronic sequence downstream of exon-betaII is 90 bases. The data in figure 36 show that 
exon-betaII splices to exon-betaI as expected. It appears that the ligation step of the two 
exons is not very efficient and it results in single exon products. Exon-betaI appears 
shifted indicating that the particle holding exon-betaI for the ligation step may be 
covalently attached to it. The data imply that both nuclear preparations supported 
spliceosome assembly as shown by native non-denaturing electrophoresis. 
 
Figure 36. In vitro splicing of exon-betaII to exon-betaI 
The FH6 template represents a fused construct of exon betaII plus 90 bases of its 
downstream intronic sequence and exon-betaI plus 188 bases of its upstream intronic 
sequence. Besides the expected spliced product of 295 bases, the splicing reaction 
generates single exons due to incompletion of the ligation step. The excised lariat runs a 
bit lower than its size because of its cyclic structure. The results indicate that HeLa and 
HEK-293 cell nuclear extracts have all the splicing factors needed to splice exon-betaII 
to exon-betaI. M: Molecular weight marker. 
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In Vitro Splicing of exon II to I utilizes SSI and SSII 
 In vivo, we observed the utilization of additional 5‟splice sites downstream of 
exon-betaII when the cells were treated with insulin. We were wondering if the additional 
5‟ splice sites would produce any spliced products in vitro.  
 
 
Here we show the data from template FH4 that generates a transcript of 843 bases 
with an intronic length of 548 bases. The FH4 composite chimeric intron contains a 
Figure 37. In Vitro Splicing of exon II to I can utilize SSI and SSII 
The FH4 template represents a fused construct of exon betaII plus 360 bases of its 
downstream intronic sequence and exon-betaI plus 188 bases of its upstream intronic 
sequence. The intronic sequence downstream of exon betaII includes two additional 5‟ 
splice sites. The results indicate that HeLa and HEK-293 cell nuclear extracts have all the 
splicing factors needed to utilize SSI and SSII as been observed in vivo under insulin 
regulation. 
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varying intronic sequence downstream of exon-betaII of 360 bases. The FH4 template 
includes the additional 5‟ splice sites SSII and SSIII. The data in figure 37 show that both 
SSI and SSII are utilized in vitro just as it has been observed in vivo under the regulation 
of insulin. The data imply that the nuclear extracts contain the necessary splicing factors 
to utilize both splice sites as it was observed in vivo. 
The splicing reactions were always cleaned-up with a spin column to purify the 
RNA products from all other components. Then, most of the purified product was run on 
a non-denaturing acrylamide gel. The remaining of the product was sometimes used in 
RT-PCR. Our results (not shown) indicate that not only the additional 5‟ splice site SSII 
is utilized in in vitro splicing, but also all the other additional 5‟ splice sites up to SSV in 
template FH2. Template FH2 is the longest template and it generates a transcript of 1661 
bases that includes a composite chimeric intron of 1366 bases. As a result, the varying 
intronic sequence downstream of exon-betaII is 1169 bases.  
The products of in vitro transcription experiments and splicing assays were used 
in RT-PCR. In addition to running the PCR products on agarose gels to visualize the 
expected bands, we selected the best gels to excise the bands observed for gel 
purification. The gel purified PCR fragments were used in digestion reactions to verify 
the content of the PCR fragments. In most gel purified products we measured the DNA 
concentration. We selected the best purified products and sent them for sequencing. The 
sequencing results matched and verified the expected sequences. 
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A role for Clk/Sty in splicing of PKCβ mRNA [41] 
PKCβI and PKCβII are the products of alternative splicing of PKCβ pre-mRNA. 
The last common exon of the C4 domain (exon 16) splices to the βIV5 exon (exon 18) to 
produce PKCβI mRNA which is constitutively expressed. Insulin regulates the inclusion 
of PKCβII exon (exon 17) between the C4 and βIV5 domains thereby producing mature 
PKCβII mRNA. The βI exon then becomes 3‟ UTR on PKCβII mRNA due to a STOP 
codon within the –βII exon. Insulin exerts its effects via Akt2 phosphorylation of SRp40, 
a nuclear splicing factor [94].  
 
Figure 38. Role of Clk/Sty and Akt2 in PKCβII exon inclusion 
Schematic shows PKCβ domains and C-terminal alternative exons. Arrows indicate the 
primer positions on PKCβ pre-mRNA. The primer set allows for simultaneous detection 
of endogenous PKCβI mRNA and –βII mRNA (in which βII exon is included between 
C4 and βI exon). After serum starvation for 6 h, differentiated L6 myotubes were treated 
with TG003 (10 µM) for 60 min prior to insulin addition (10 nM, 30 min).  DMSO 
served as the solvent control. Total RNA was extracted and 2 µg analyzed for PKCβI and 
PKCβII by RT-PCR using primers corresponding to the C4 and βI/V5 exon as shown on 
the diagram.  β-actin was amplified as an internal control.  Clk/Sty inhibitor blocked 
insulin-stimulated PKCβII exon inclusion. 
A
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The notion that Clk/Sty might be involved in the insulin response was suggested 
from the observation that the splicing of PKCβII pre-mRNA requires phosphorylation of 
SR proteins [82], and Clk/Sty influences the activity of SR proteins [89, 102, 103].  Our 
previous studies using a PKCßII splicing minigene demonstrated that ßII exon inclusion 
is regulated by insulin and minigene exon inclusion was mimicked by Clk/Sty 
overexpression [81, 82, 84, 104]. Here, the selective Clk/Sty inhibitor, TG003, was used 
to block its activity in L6 myotubes to establish a role for the kinase in insulin action. 
TG003, a benzothiazole kinase inhibitor that targets Clk/Sty, is capable of suppressing 
dissociation of nuclear speckles, altering splicing patterns, and rescues embryonic defects 
induced by excessive Clk activity [44]. DMSO, the solvent control, did not affect PKC 
βII splicing.  TG009, the control compound [44], also did not affect splicing (data not 
shown). TG003, blocked insulin stimulatory effects on βII exon inclusion (Figure 38). 
This suggested that Clk/Sty was involved in the splicing signal cascade.   
Cells overexpressing Clk/Sty increased exon 17 (-ßII exon) inclusion (Figure 39) 
and PKCßII protein expression was also elevated in a manner similar to that of insulin. 
When cells overexpressing Clk/Sty were treated with LY294002, an inhibitor known to 
block Akt2 activation and Akt2-mediated exon inclusion [102], -ßII exon inclusion was 
blocked, suggesting that Akt2 was acting upstream of Clk/Sty.  
Splicing was also assessed with a heterologous minigene containing the PKCβII 
exon and its flanking intronic sequences. To confirm the specificity of the Clk/Sty 
inhibitor, Clk/Sty and Akt2 siRNA were used to lower intracellular kinase levels in 
combination and alone in the presence of insulin. Insulin-induced inclusion of the 
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PKCβII exon was blocked >90% in the presence of both Clk/Sty and Akt2 siRNA and 
>75% in the presence of either kinase siRNA alone (Figure 40).   
 
The partial activation of an alternative 5‟ splice site was still noted with Clk/Sty 
and Akt2 siRNA, suggesting roles for both kinases.  Activation of both 5‟ splice sites is 
also regulated by insulin [81]. Only one protein is translated as there is a stop codon 
upstream of the first splice site. The longer mRNA is predicted to be more stable since it 
would not be subject to degradation [84]. The inhibition of Clk/Sty and Akt2 blocked 
alternative exon inclusion and not merely splicing, since SD-SA splicing (vector splice 
sites) was not affected. The possibility of Akt2 regulating Clk/Sty was examined since 
LY294002 blocked Clk-induced ßII exon inclusion. 
 
Figure 39. Cells overexpressing Clk/Sty increased exon 17 (-ßII exon) inclusion 
Clk/Sty-induced PKCβII exon inclusion was blocked by the PI3K inhibitor LY294002.  
L6 myotubes were transfected with Clk/Sty cDNA expressing construct for 36 h and 
treated with insulin (10 nM, 30 min) in the presence or absence of LY294002 (10 µM, 30 
min).  Endogenous PKCβI and PKCβII mRNA levels were amplified by RT-PCR as 
described in Figure 38. Cell lysates from duplicate plates were analyzed for protein levels 
of PKCβII by Western blot analysis following SDS-PAGE. The graph is representative of 
multiple RT-PCR analysis. Percent splicing efficiency is calculated as a ratio of 
PKCβII/βI mRNA with control PKCβI mRNA assigned a value of 100%. 
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Phosphorylation of Clk/Sty by Akt [41] 
Both serine and tyrosine phosphorylation of Clk/Sty are required for its full 
activation [89, 102, 103]. However, the kinases regulating its activity have not been 
identified. The possible phosphorylation and activation of Clk/Sty by PI3K/Akt2 and Src 
tyrosine kinases was examined in COS7 cells.  COS7 cells are easily transfected and 
insulin signaling pathways have been demonstrated for them [105].  COS7 cells were co-
transfected with Akt2 and Clk/Sty prior to treatment with LY294002 or PP1 (an inhibitor 
of Src kinases), and then stimulated with insulin. Clk/Sty immunoprecipitates were 
Figure 40. Clk/Sty and Akt2 siRNA block splicing of heterologous minigene 
L6 myotubes were co-transfected with pSPL3-17 minigene, Clk/Sty and/or Akt2 siRNA 
(Silencer™ siRNA 161218 and 200808, 15 nM for 48 h) with lipofectamine.  After 6 h 
serum starvation, cells were treated with insulin (10 nM, 30 min).  Total RNA was 
extracted and PKCβII exon inclusion was analyzed using primers to the splice site donor 
and acceptor as shown.  SSI: Utilization of PKCβII exon 5′ splice site I. SSII: Utilization 
of PKCβII exon 5′ splice site II. SD-SA: constitutive splicing of pSPL3 splicing vector 
which also serves as an internal control. 
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analyzed by immunoblot using an antibody that specifically detects phosphorylation of 
serines in the Akt substrate motif and with another antibody which detects 
phosphorylated tyrosine residues.   
 
 
Insulin stimulated both Akt motif serine and tyrosine phosphorylation of Clk/Sty 
(Figure 41, panels a and b), and the insulin-stimulated phosphorylation was suppressed 
by the PI3K inhibitor, LY294002, and by the Src kinase inhibitor, PP1, respectively. 
Insulin is required to activate transfected Akt2 as in the absence of insulin, there is no 
Figure 41. Transiently expressed Clk/Sty was phosphorylated by Akt2 
COS7 cells were transiently transfected with Clk/Sty, Akt2 or pcDNA3 control vector 
constructs for 36 h with lipofectamine. After serum starvation for 6 h, cells were 
stimulated by insulin (10 nM, 30 min) and whole cell lysates were immunoprecipitated 
with anti-Clk/Sty (IP: Clk1). The phosphorylation of tyrosine residues and Akt-substrate 
serine residues on Clk/Sty was analyzed by Western blot using anti-phospho-tyrosine or 
anti-phospho-Akt substrate antibodies (top panels a and b).  Whole cell lysates run on 
gels were probed for Clk1, Ha-Akt2 and Actin (lower panels c, d, and e). 
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phosphorylation of Clk (Figure 44, panels a, b). It is also noted that there may be cross-
talk between Akt and Src kinases since the Src inhibitor PP1 blocked phosphorylation on 
Akt motifs and LY294002 blocked phospho-tyrosine phosphorylation.  Insulin is known 
to activate Src in skeletal muscle [106]. Hence, Clk/Sty was a substrate for Akt in vivo 
and insulin coordinated both serine and tyrosine phosphorylation of Clk/Sty.  
 
Since the Clk antibody in Figure 41 immunoprecipitated both endogenous Clk/Sty 
as well as overexpressed Clk, we then examined whether endogenous Clk/Sty was 
phosphorylated on its Akt substrate motifs in L6 myotubes. Increased phosphorylation of 
endogenous Clk/Sty immunoprecipitates was detected by the Akt substrate antibody and 
phosphorylation was blocked by LY294002 (Figure 42). Clk/Sty was a substrate for 
insulin-activated Akt signaling in both transfected COS7 cells and in cultured L6 
myotubes.  
Figure 42. Endogenous Clk/Sty was phosphorylated by Akt2 during insulin 
signaling 
L6 myotubes were serum-starved, insulin stimulated, and lysed (WCL); Clk/Sty was 
immunoprecipitated and analyzed for phosphorylation of Akt-substrate serine residues as 
in figure 41 (lower panels).  Phosphorylation of Akt induced by insulin was confirmed 
with phospho-Akt-473 antibody (top panel). 
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5’ Splice Site I to 5’ Splice Site II switch in another PKC isoform (PKC ) 
We have seen that in the PKC  gene, insulin regulates the inclusion of exon 
betaII, and it also regulates the switch from the 5‟ splice site I (SSI) of exon betaII to the 
5‟ splice site II (SSII). Here we demonstrate that the switch from the 5‟ SSI to the 5‟ SSII 
of a specific exon occurs also on another isoform (PKC ), of the PKC family and that the 
effector is not insulin but retinoic acid. Furthermore, the splicing factor involved in the 
alternative splicing was SC35 (SRp30b). 
 
 
We indicated earlier that the PKC  gene contains 18 exons. In humans, the 
standard size of exon-10 is 97-bases, and when included in the mature transcript, PKC I 
is expressed. Exon-10 has an additional 5‟-splice site (SSII) that extends its size by 93 
Figure 43. Alternative splicing of human PKC  gene 
Schematic of PKCδ domains and relation to the region undergoing alternative splicing. 
Alternative 5' splice site selection in exon 10 of human PKCδ pre-mRNA results in the 
generation of PKCδI mRNA and PKCδVIII mRNA which differ by 93 bp in the V3 hinge 
region. All-trans retinoic acid (RA) promotes expression of PKCδVIII mRNA. The exon 
and intron lengths are indicated in the figure. SSI: 5' splice site I; SSII: 5' splice site II. 
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bases for a total of 190-bases. When this extended size is included in the mature 
transcript, PKC VIII is expressed. Thus, the human PKCδ gene has at least two 
alternatively spliced variants: PKCδI and PKCδVIII (Figure 43). When the PKCδVIII is 
generated via alternative splicing of the PKCδ pre-mRNA, the 93 additional nucleotides 
result in 31 additional amino acids such that their inclusion disrupt the caspase-3 
recognition sequence in the hinge region of PKCδVIII protein.  
 
Retinoic Acid regulates the expression of PKC VIII in neuronal cells 
Our previous study demonstrated that PKCδVIII functions as a pro-survival 
protein whereas PKCδI promotes apoptosis. Further, we demonstrated that RA (24h) 
significantly increased the expression of PKCδVIII in NT2 cells [54].  
Figure 44. Retinoic Acid regulates the expression of PKC VIII 
(a) Schematic of the primers specific for PKCδI and PKCδVIII used in real time RT-PCR 
such that they span the exon-exon boundaries. (b) Primary human neuronal cells from 
hippocampus were treated with or without RA (10 μM) for 24 h. Total RNA was 
extracted and real time RTPCR analysis using SYBR green was performed in triplicates 
and repeated 3 times in separate experiments. The absolute mRNA expression of PKCδI 
and PKCδVIII transcripts are shown. PKCδVIII expression increases significantly 
following 24 hours of RA treatment; ***, p<0.0001 (by two-tailed Student‟s t-test). 
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Here, we sought to extend our findings in primary neuronal cells derived from the 
adult hippocampus to demonstrate the expression pattern of PKCδVIII and its response to 
RA. Total RNA was extracted from these primary neuronal cells treated with or without 
RA (24h). We performed quantitative, two-step real-time RT-PCR using Syber (SYBR) 
Green technology [107-109]. SYBR green method allows each transcript to be measured 
independently by using primer pairs that will amplify only that transcript. The primers 
were specific to the exon junctions of PKCδI mRNA and PKCδVIII mRNA as shown in 
Figure 44a. Each transcript was normalized to the endogenous control, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) to obtain absolute quantification. Here we 
demonstrated that PKCδVIII increased with RA treatment while PKCδI levels remained 
constant in the primary neuronal cells (Figure 44b).  
 
Expression of PKC VIII in various tissues also regulated by RA 
Next, to establish the tissue-specific expression pattern of PKCδVIII, human fetal 
tissue-specific cDNAs (from Origene) were used in the RT-PCR reaction using 
PKC VIII specific primers to determine its expression pattern. Our earlier studies in 
adult cells had shown higher expression of PKCδVIII in neuronal cells. Here, our data 
indicated that the expression of PKCδVIII was highest in fetal brain (Figure 45) 
compared to other tissues tested (fetal testis, kidney, heart and spleen). These 
experiments demonstrate that PKCδVIII expression is predominant in human adult and 
fetal brain.  
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Concurrent increases in SC35 and PKCδVIII levels in RA mediated PKCδ 
alternative splicing  
Alternative splicing is regulated by recruiting trans-factors such as nuclear serine-
arginine rich (SR) proteins that bind to exonic or intronic splicing enhancers (ESE, ISE) 
on the pre-mRNA. Hence, the elucidation of trans-factors involved in RA-mediated 
PKCδ alternative splicing is of critical importance. NT2 cells were treated with or 
without RA (24 hours) and whole cell lysates were analyzed by western blot analysis 
using mAb104 antibody that simultaneously detects the phosphoepitopes on all SR 
proteins. Our results indicated that upon RA treatment, an SR protein at ~30kDa 
increased in expression (Figure 46). The family of SR splicing proteins includes 
SF2/ASF and SC35 whose molecular weight is about ~30 kDA (SF2/ASF is also known 
as SFRS1 or SRp30a, and SC35 is also known as SFRS2 or SRp30b). Both of these 
Figure 45. Expression of PKC VIII in human fetal tissues 
Human fetal tissue-specific cDNAs were used in PCR analysis using PKCδVIII-specific 
primers as shown in schematic. (i) Spleen (ii) kidney (iii) heart (iv) testis (v) brain. 5% of 
products were separated on PAGE and detected by silver nitrate staining. Graph indicates 
PKCδVIII densitometric units normalized to GAPDH and is representative of mean ± 
SEM in 3 separate experiments. 
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proteins have been shown to function as splicing enhancers [110]. Hence, antibodies 
specific to these individual SR proteins were used next. We observed an increase in SC35 
concurrent with increased PKCδVIII levels in response to RA while SF2/ASF expression 
remained relatively constant (Figure 46).  
 
 
SC35 mimics RA-mediated PKCδVIII alternative splicing 
To validate that an increase in PKCδVIII expression is due to increased SC35 
expression levels, SC35 plasmid (from Origene) was transiently transfected into NT2 
cells. SF2/ASF plasmid was used as a control and transfected in a separate well. Total 
RNA was extracted and RT-PCR performed using human PKCδ primers which amplify 
both PKCδI and PKCδVIII products simultaneously (Figure 47a). An increase in 
endogenous PKCδVIII mRNA levels in cells over-expressing SC35 was observed (Figure 
47b) while SF2/ASF transfected cells remained constant. GAPDH levels remained 
constant in all samples. In separate experiments, 2 μg of SC35 or SF2/ASF was 
Figure 46. Detection of SR proteins involved in RA-mediated PKCδVIII expression 
NT2 cells were treated with all-trans retinoic acid (RA, 10 μM) for 0-24 hours and western 
blot analysis was performed on whole cell lysates using (a) mAb104 antibody which 
detects all SR proteins and (b) specific antibodies as indicated in figure. Molecular weights 
are indicated (kDa). Gels are representative of three separate experiments and results 
indicate that SC35 may be involved in increased expression of PKCδVIII by RA. 
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transfected in NT2 cells and western blot analysis was performed using antibodies as 
indicated in Figure 47c. PKCδVIII expression specifically increased with SC35 but not 
with over-expression of SF2/ASF. 
 
  
Figure 47. SC35 and not SF2/ASF promotes PKCδVIII expression 
(a) Schematic of primer positions used in PCR amplification. These primers detect 
PKCδI and PKCδVIII simultaneously. NT2 cells were transfected with SC35 or SF2/ASF 
or treated with RA (10 μM) for 24 hours. (b) Total RNA was extracted and RT-PCR was 
performed using human PKCδ primers as shown above. 5% of the products were 
separated by PAGE and silver stained for visualization. Graph represents percent exon 
inclusion calculated as PKCδVIII/(δVIII + δI) X 100 in control and RA (24h) samples 
and is representative of mean ± SEM in three experiments. (c) Whole cell lysates were 
extracted from NT2 cells treated with or without RA (10 μM, 24h). Western blot analysis 
was performed using specific antibodies as indicated in the figure. The experiments were 
repeated 3 times with similar results. 
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To further determine the role of SC35, increasing amounts of SC35 (0 to 2 μg) 
were transfected into NT2 cells to determine whether PKCδVIII expression levels 
increased in direct proportion with increasing amounts of SC35. Whole cell lysates were 
collected and western blot analysis was carried out using antibodies for PKCδVIII, SC35 
and GAPDH (internal control). As seen in Figure 48, PKCδVIII protein levels increase 
with increasing doses of SC35 comparable to the increase in PKCδVIII protein seen with 
RA treatment. 
 
Figure 48. SC35 promotes PKCδVIII expression in a dose-dependent manner 
Increasing amounts of SC35 (0 to 2 μg) were transfected into NT2 cells and treated with 
or without RA (10μM, 24h).  Western blot analysis was performed on whole cell lysates 
using antibodies as indicated within the figure. Graph represents four experiments 
performed separately and represents PKCδVIII densitometric units normalized to 
GAPDH as mean ± SEM... 
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SC35 knockdown directly affects the expression of PKCδVIII  
To determine the effect of SC35 knockdown on the expression of PKCδVIII, 
siRNA specific for SC35 were transfected in increasing amounts (0 to 150 nM) into NT2 
cells. Two sets of SC35 siRNA (Ambion‟s siRNA ID:12628 and 12444) along with its 
scrambled control, were used to validate specificity and eliminate off-target knockdowns. 
Results indicated similar data with either SC35 siRNAs.  
 
 
Whole cell lysates were collected and western blot analysis was carried out using 
antibodies for PKCδVIII, SC35 and GAPDH (internal control). As seen in Figure 49, 
PKCδVIII protein levels decreased with increasing dose of SC35 siRNA. Graph is 
representative of four individual experiments performed with either SC35 siRNA. The 
Figure 49. Knockdown of SC35 inhibits PKCδVIII expression 
Increasing amounts of SC35 siRNA (0 to 150 nM) were transfected into NT2 cells.  
Scrambled siRNA was used as a control. Post-transfection, cells were treated with or 
without RA (10μM, 24h). Whole cell lysates were collected and western blot analysis 
was performed using antibodies as indicated. Graph represents four experiments 
performed separately and expressed as mean ±SEM of densitometric units. 
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above data confirms the involvement of nuclear SR splicing factor SC35 in RA mediated 
alternative splicing of PKCδ. 
 
Antisense oligonucleotides indicate a role of SC35 cis-element in PKCδ alternative 
splicing  
Previous studies identified consensus sequences [87] for several cis-elements 
present either in the exonic or intronic sequences of pre-mRNA. These consensus 
sequences serve as a guideline to dissect and analyze putative cis-elements in alternative 
splicing of pre-mRNA. We combined a web-based resource “ESE finder” [111] and also 
manually checked for published consensus sequences of cis-elements on PKCδ pre-
mRNA to predict putative enhancer and silencer elements (Figure 50a) that could recruit 
trans-factors in RA regulated alternative splicing of PKCδ. To focus on identifying the 
cis-elements involved in RA mediated increase in PKCδVIII mRNA levels, antisense 
oligonucleotides (ASO) (synthesized by Isis Pharmaceuticals, San Diego, CA) which are 
2'-methoxyethyl-modified, RNAse-H resistant were used. These ASOs inhibit binding of 
transfactors to their cis-elements without disrupting the splicing event or degrading the 
mRNA [112, 113]. We transfected a series of 20mer ASOs which were designed 
according to predicted sites as depicted in figure 50a such that they sequentially spanned 
the unspliced PKCδ pre-mRNA. Total RNA was isolated from ASO-transfected and RA 
treated cells and RT-PCR was performed. Only the ASO 81 transfection showed a 
significant change in PKCδVIII splicing while the other ASOs did not affect the 
expression of PKCδVIII (data not shown). Results (Figure 50b) shown here represent 
three experiments performed individually using the scrambled ASO as control, ASO 81 
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(which had an effect on PKCδVIII splicing) and ASO 80 which was in close proximity to 
ASO 81.  
Figure 50. Analysis of putative cis-elements and antisense oligonucleotides (ASO) 
(a) Schematic of ASOs relative to putative cis-elements in the PKCδ exon 10 and its 
flanking 3' and 5' intronic 11 sequence. ASO ctrl: scrambled control ASO. SC35: SR 
protein SFRS2; BP: branch point; PT: polypyrimidine tract; Tra2β: splicing factor; 
SF2/ASF: SR protein SFRS1; SRp55: SR protein SFRS6; PTB: Pyrimidine tract binding 
protein; SSI: 5' splice site I; SSII: 5' splice site II. (b) ASOs were transfected into NT2 
cells and after overnight incubation cells were treated with or without RA (10 μM, 24h). 
Gel represents experiments conducted with scrambled ASO, ASO 81 (corresponding to 
SC35 binding site) and ASO 80 which is in close proximity as indicated in the lanes. 
Total RNA was extracted and RT-PCR performed using PKCδVIII specific primers 
(schematic shown in figure 44a). 5% products were separated on PAGE and detected by 
silver nitrate staining. Graph indicates PKCδVIII densitometric units normalized to 
GAPDH and is representative of mean ± SEM in 3 separate experiments. 
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These results demonstrated that ASO 81 inhibited RA-induced PKCδVIII 
alternative splicing. ASO 81 corresponded to the SC35 binding site as identified by ESE 
finder and further determined by its consensus sequence –ggccaaag. This indicated the 
position of SC35 cis-element on PKCδ pre-mRNA. 
 
Construction of a heterologous pSPL3-PKCδ splicing minigene which is responsive 
to RA 
Splicing minigenes are advantageous to identify cis-elements on the pre-mRNA 
involved in regulated alternative splicing. Further, minigenes aid to correlate the binding 
of specific SR proteins to individual splicing events. Hence, to dissect the mechanism of 
RA-mediated regulation of endogenous PKCδ alternative splicing and analyze factors 
influencing 5' splice site selection, a PKCδ heterologous minigene was developed. Since 
the human PKCδ splice variants used alternative 5′ splice sites as determined previously 
[54], exon 10 of PKCδ pre-mRNA along with its flanking 3′ and 5′ intronic sequences 
was cloned in the multiple cloning site (MCS) between the splice donor (SD) and splice 
acceptor (SA) exons of pSPL3, a vector developed to study splicing events [114] as 
described in the methods section (schematic shown in Figure 51a). 5′ splice site II (which 
encodes for PKCδVIII mRNA) is 93 bp downstream of PKCδ exon 10 and hence we 
cloned 200 bp of the 5′ intronic sequence. The minigene also contains the retinoic acid 
response element (RARE) in its promoter region. The resulting minigene pSPL3-PKCδ 
was confirmed using restriction digestion and sequencing. Minigene pSPL3-PKCδ was 
transfected into NT2 cells, cells were treated with RA (24h) and RT-PCR performed on 
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total RNA using SD-SA primers. The empty vector pSPL3 with the same modifications 
used for cloning the minigene, was transfected simultaneously in a separate well. The 
predicted products using SD-SA primers are shown (Figure 51b). RA increased 
utilization of 5′ splice site II of PKCδ exon 10 in pSPL3-PKCδ minigene thereby 
mimicking RA mediated increase in endogenous PKCδVIII expression.  
 
 
 
Figure 51. Minigene analysis elucidates 5' splice site usage on PKCδ exon 10 
(a) Schematic represents PKCδ pre-mRNA exon 10 and flanking introns cloned into 
pSPL3 splicing vector between the splice donor (SD) and splice acceptor (SA) exons. 
The resulting minigene is referred to as pSPL3_PKCδ minigene. Arrows indicate 
position of primers used in RT-PCR analysis. (b) After overnight transfection of pSPL3-
PKCδ minigene and pSPL3 empty vector as control, NT2 cells were treated with or 
without 10μM RA for 24 h. Total RNA was extracted and RT-PCR performed using 
primers as described above. 5% of the products were separated by PAGE and silver 
stained for visualization. Expected products are SD-SA: constitutive splicing; SSI: 
Usage of 5' splice site I; SSII: Usage of 5′ splice site II. Graph represents percent exon 
inclusion calculated as SS II/(SS II + SSI) X 100 in control and RA (24h) samples and is 
representative of three experiments performed separately. 
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SC35 promoted the utilization of 5′ splice site II in the heterologous pSPL3_PKCδ 
splicing minigene  
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Next, we sought to determine if SC35 could increase the utilization of 5' splice 
site II on pSPL3_PKCδ minigene such that it mimics the increase of RA-mediated 
endogenous expression of PKCδVIII. SC35 expression vector (2μg) was co-transfected 
along with the pSPL3-PKCδ minigene into NT2 cells. RA was added to a separate well 
transfected with pSPL3-PKCδ minigene. RT-PCR was performed on total RNA using 
PKCδ-exon 10 (sense) and SA (antisense) primers as shown (Figure 52). SC35 promoted 
the selection of 5′ splice site II on PKCδ exon 10 in pSPL3-PKCδ splicing minigene 
thereby mimicking RA-mediated increased expression of PKCδVIII. 
Figure 52. Co-transfection of SC35 with the pSPL3_PKCδ minigene promotes 
utilization of 5' splice site II. 
SC35 (2μg) was co-transfected along with the pSPL3-PKCδ splicing minigene. In 
separate wells, 10 μM RA was added for 24h. Total RNA was extracted and RT-PCR 
performed 
using SD and SA primers as described in figure 7. 5% of the products were separated by 
PAGE and silver stained for visualization. SD-SA: constitutive splicing; SSI: Usage of 5' 
splice site I; SSII: Usage of 5' splice site II. Graph represents percent exon inclusion 
calculated as SS II/(SS II + SSI) X 100 and is representative of three experiments 
performed separately. 
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Deletion analysis of the pSPL3-PKCδ minigene  
 
 
Figure 53. Deletion analysis of minigene demonstrates role of SC35 cis-element on 
RA-mediated utilization of 5' splice site II on PKCδ exon 10 
(a) Schematic represents PKCδ pre-mRNA exon 10 and deletions of the 5' intronic 
sequences which were cloned into pSPL3 vector. (b) Schematic of arrows indicating the 
position of primers on the minigenes. (c) The truncated minigenes were transfected into 
NT2 cells. After overnight transfection, NT2 cells were treated with or without 10μM 
RA for 24 h. Total RNA was extracted and RT-PCR performed using primers for PKCδ 
exon 10 sense and SA antisense as depicted in figure. 5% of the products were separated 
by PAGE and silver stained for visualization. SSI: Usage of 5' splice site I; SSII: Usage 
of 5' splice site II. Graphs represent percent exon inclusion calculated as SS II/(SS II + 
SSI) X 100 and is representative of three experiments performed separately. 
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To determine if any additional cis-elements influencing RA-mediated PKCδ 
alternative splicing were present, 5′ intronic sequence of PKCδ exon-10 was 
consecutively deleted and recloned into the pSPL3 vector as described in methods. The 3′ 
splice site and the minimum defining sequences (the branch point and pyrimidine tract) 
were maintained in all constructs (Figure 53a). The resulting minigenes were transfected 
into NT2 cells, treated with RA and 5′ splice site selection was evaluated. The 
experiments (Figure 53b, c) demonstrated that RA was unable to promote 5‟ splice site II 
selection upon deletion of the intronic sequences containing the SC35 cis-element. This 
demonstrated that additional sequences present in the 5‟ intronic region were not 
influencing RA-mediated utilization of 5‟ splice site II on PKCδ pre-mRNA. This further 
demonstrates the involvement of SC35 in RA-mediated PKCδ alternative splicing. 
 
Mutation of SC35 binding site on the heterologous pSPL3-PKCδ minigene 
disrupted utilization of 5’ splice site II  
To establish that the binding of SC35 to its cis-element on PKCδ pre-mRNA was 
essential for PKCδVIII alternative splicing, mutagenesis of the SC35 cis element was 
carried out. The SC35 site identified by its consensus sequence and ASO binding (figures 
54a,b) was mutated within the pSPL3-PKCδ minigene (described in methods) and the 
mutated pSPL3-PKCδ** minigene was transfected into NT2 cells. The original pSPL3-
PKCδ minigene was transfected in separate wells as the control. RA was added for 24h 
and RT-PCR was performed on total RNA using PKCδ-exon 10 (sense) and SA 
(antisense) primers. RA did not promote the selection of 5′ splice site II on PKCδ exon 10 
in the pSPL3-PKCδ** mutated minigene (Figure 54 a, b). This verified the interaction of 
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SC35 in PKCδ pre-mRNA 5′ splice site II activation and confirmed that RA mediates its 
effects on PKCδ alternative splicing via the nuclear splicing factor SC35. 
 
Figure 54. Mutation of SC35 binding site blocks RA effect on PKCδVIII splicing 
(a) Schematic indicating the position of the SC35 cis-element (**) on the pSPL3_PKCδ 
splicing minigene. Arrows indicate the position of primers used in PCR analysis. (b) 
SC35 binding site was mutated and the resulting minigene pSPL3_PKCδ** was 
transfected into NT2 cells along with the pSPL3_PKCδ splicing minigene in separate 
wells. After overnight transfection, NT2 cells were treated with or without 10μM RA 
for 24 h. Total RNA was extracted and RT-PCR performed using primers for PKCδ 
exon 10 sense and SA antisense as shown in figure 9. 5% of the products were separated 
by PAGE and silver stained for visualization. SSI: Usage of 5' splice site I; SSII: Usage 
of 5' splice site II. Graph represents percent exon inclusion calculated as SS II/(SS II + 
SSI) X 100 and is representative of three experiments performed separately. 
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DISCUSSION 
In this study we focused on two PKC genes, namely PKC  and PKC , and we 
showed that the splicing of PKC  is regulated by insulin and mediated by SRp40, while 
the splicing of PKC  is regulated by retinoic acid and mediated by SRp30b. While SR 
proteins play a key role in alternative splicing, the SR proteins are also linked to 
pathways regulated by hormonal or metabolic stimuli. Studies have shown that 
alternative splicing is sometimes tissue-specific or developmentally specific [115]. Since 
alternative splicing can be regulated by a signal transduction pathway, some splice 
variants can become excellent targets for gene therapy [116]. The alternative splicing of 
the PKC  gene is unique in that exon- II in its downstream intronic sequence contains 
four additional 5‟ splice sites. We identified one cis-element that interacts with SRp40, 
but we hypothesize that there are more cis-elements that may interact with one or more 
SR proteins (including SRp40). By using heterologous minigenes, we were able to show 
that insulin regulates the inclusion of exon- II and the utilization of additional 5‟ splice 
sites in five distinct cell types: skeletal muscle, vascular smooth muscle cells, hepatoma 
cells, pre-adipocytes and fibroblasts. 
In addition to verifying the insulin regulation of the PKC  gene, the deletion 
series of the heterologous minigenes pSPL3-18, 19, 20 and 22 pinpointed the locus of the 
cis-element involved in the alternative splicing of SSI and SSII of PKC II.  Using 
additional methods, we showed that insulin regulates those splice sites through mediation 
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with SRp40. Through in vitro transcription and splicing assays we identified up to four 
additional 5‟ splice sites downstream of exon- II. We have left the task of elucidating the 
binding mechanisms and/or any cis-elements involved for the additional 5‟ splice sites 
SSIII, SSIV and SSV for the future. 
Our studies also showed that the insulin-regulated splice site selection is 
facilitated via the PI3-kinase phosphorylation pathway route of the insulin signal 
transduction pathway. In our model, Akt2 and Clk/Sty become phosphorylated via the 
PI3-kinase pathway which in turn phosphorylates SR proteins that mediate splice site 
utilization. The phosphorylation of SR proteins by Akt2 and Clk/Sty highlights the 
importance of phosphorylation cascades in alternative splicing. 
Unlike the classical models of developmental and tissue-specific alternative 
splicing, the insulin regulation of the PKC II alternative splicing introduces a novel 
approach for regulated splicing. In this scenario, in cell lines/tissues expressing the 
insulin receptor, a hormone whose levels change dramatically in response to glucose is 
shown to regulate exon inclusion. For endogenous alternative splicing, our lab had shown 
that insulin addition to skeletal muscle cells results in the rapid post-transcriptional 
processing of the PKC  pre-mRNA transcript resulting in the inclusion of an exon that 
encodes PKC II mRNA [32]. The expression of PKC II in skeletal muscle cells has also 
shown to result in increased glucose transport activity [35, 82].  
In attempting to elucidate the signaling pathway associated with alternative 
splicing of PKC II, we employed first the overexpression of SRp40. Previous studies had 
shown that SRp40 was associated with 5‟ splice site selection, and it was determined that 
the phosphorylation state of the protein rather than its cellular levels was the crucial 
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factor in its function [84]. Since PI3-kinase modulated the phosphorylation state of 
SRp40, we hypothesized that Akt could act as an SR kinase. We further conjectured that 
insulin modulation of the Akt phosphorylation activity was responsible for regulating 
exon inclusion (perhaps in part if not fully). Transfection of cells with a tagged Akt2 
adenovirus construct allowed for the identification of phosphorylated SRp40 in cells 
endogenously labeled with [
32
P]orthophosphate. This protein is highly phosphorylated in 
its endogenous state, and the overexpression of Akt2 resulted in a 2.5-fold increase in the 
incorporation of 
32
P into the immunoprecipitated protein. Insulin, an activator of Akt2 
and other potential SR kinases, increased its phosphorylation by 3-fold. Insulin may also 
increase the phosphorylation of SRp40 via kinases such as PKC in addition to Akt. PKC 
is another potential SR kinase that is modulated during insulin signaling by a PI 3-kinase-
dependent mechanism. Further, SR kinases such as Clk/Sty may also phosphorylate 
SRp40 [52, 117] independent of Akt2 kinase. The phosphorylation of SR proteins most 
likely facilitates their recruitment to nuclear speckles where they are likely to interact 
with other spliceosomal proteins [118].  
Although it has not been directly tested, the current view is that all Akt/PKB 
isoforms are thought to have similar substrate specificity. Akt2 expression is the highest 
in insulin-responsive tissues, including liver, brown fat, and skeletal muscle, suggesting 
its importance in insulin signaling. The involvement of insulin-activated Akt isozymes in 
mRNA splicing is predicted because SR proteins contain multiple Akt phosphorylation 
consensus sequences, RXRXX(S/T) [119] within their C-terminal RS domain. SR 
proteins are optimal substrates for Akt in vitro when solid phase phosphorylation 
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screening identified several spliceosomal proteins [49]. Some of these proteins have more 
than 20 possible Akt phosphorylation motifs in their protein sequences.  
The present study demonstrated that Akt2 phosphorylated a specific site within 
SRp40. Mutation of this site further attenuated PKC II exon inclusion and splice site 
activation. The precise role of SRp40 has not been defined in insulin-regulated splice site 
selection, but antisense oligonucleotides that block the interaction of the SR protein with 
the RNA-binding domain demonstrated its requirement for insulin action in L6 myotubes 
because the antisense also blocked insulin effects on glucose uptake [84], and 
overexpression of the protein, also shown here, mimicked insulin effects on splicing of 
PKC II mRNA. In fibroblasts derived from Akt2(-/-) mice, phosphorylation of SRp40, 
splicing of PKC II and insulin-induced increases were not detected.  
Muscle tissue from Akt2(-/-) mice also expressed lower levels of PKC II mRNA, 
whereas PKC I levels remained unchanged. These tissues are also insulin-resistant [120]. 
Hence the phosphorylation state of SR proteins may be important in the development of 
type 2 diabetes. It is interesting that muscle tissues from diabetic patients was shown to 
express lower levels of splicing factors, many of which are alternatively spliced [121]. In 
this study we have been able to link Akt2 activation by a hormone, such as insulin, to a 
specific SR protein that regulates the splicing of an mRNA variant with functional 
consequences in the action of the hormone. Our study provides a means of relating Akt to 
nuclear functions that sustain insulin-signaling pathways post-transcriptionally. 
It had been previously shown that Clk/Sty is a dual specificity kinase that mostly 
phosphorylates the serine residues of SR protein splicing factors [50, 51, 89, 102, 103, 
122]. The degree to which Clk/Sty phosphorylates the RS domain of SR proteins alters 
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their activity and sub-cellular localization [89, 102, 103]. Therefore, we sought to 
elucidate the mechanism by which Clk/Sty itself is regulated. Examination of Clk/Sty 
protein disclosed prominent phosphorylations on both serine/threonine and tyrosine 
residues [50], leading us to question whether it is regulated by any other serine/threonine 
kinase in addition to autophosphorylation. In this study, we determined that Clk/Sty was 
regulated by a PI3K/Akt2 kinase pathway in vivo based on a number of criteria. 
Our results showed that Akt2 and Clk/Sty kinases were significant for insulin-
mediated PKCβII splicing and expression. Our earlier work indicated that over-
expression of Clk/Sty mimicked insulin signaling by promoting PKCβII exon inclusion 
[81]. In the present study we found that insulin-regulated PKCβII mRNA alternative 
splicing was inhibited by Clk/Sty- and Akt2 siRNA as well as by TG003, a specific 
Clk/Sty inhibitor, which further indicated that Clk/Sty was involved in insulin signaling.  
Because Clk1 stimulated-splicing was blocked by LY294002, this suggested that an 
upstream kinase was probably involved in the process. 
Additional work by the Cooper lab related to this study identified SRp75, SRp55 
and SRp30b/SC35 as Clk/Sty substrates using various criteria including siRNA in 
addition to a specific Clk inhibitor to differentiate Clk phosphorylation from Akt 
phosphorylation in immunoprecipitated SR proteins. That study also revealed that 
insulin-induced Clk/Sty-mediated regulation of SR proteins was distinct from serum-
induced Clk/Sty regulation. In our study, to ascertain if Akt2 and Clk/Sty regulation of 
phosphorylation and resulting activation of SR splicing factors was a universal 
phenomenon, we showed that SR proteins are also substrates for Akt2-regulated Clk/Sty 
activation. It was also shown that the PI3K/Akt2→Clk/Sty connection was also involved 
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in the regulation of SRp75 phosphorylation induced by serum, and there was also a 
requirement for PI3K/Akt2 in Clk/Sty phosphorylation of SRp30b/SC35 where 
SRp30b/SC35 appeared to be a less-preferred substrate for Clk/Sty during insulin 
activation but a more robust substrate with serum conditions. The combined studies 
indicated that insulin regulation of splicing was best demonstrated following serum 
starvation and that the results suggest that this serum-initiated PI3K/Akt2→Clk/Sty 
pathway was distinct from the one utilized by insulin.  
In our model we surmised that Akt2 phosphorylated Clk/Sty, activating Clk/Sty-
mediated SR protein phosphorylation and PKCβII exon inclusion in response to insulin 
stimulation. Furthermore, our observations that SR protein phosphorylation depends on 
PI3K are supported by a recent finding that SRp55, SRp40 and SC35 phosphorylation 
was decreased by wortmannin, another inhibitor of PI3K, in anti-IgM receptor-induced 
splicing of BPV-1 pre-mRNAs in an ASF/SF2-depleted B cell line DT40 [123]. At this 
juncture we further hypothesized that the PI3K/Akt2 pathway may regulate different 
kinases involved in SR protein phosphorylation and splicing complexes such as PKC or 
SRPK, since insulin-initiated pathway is distinctive from the one utilized by serum in 
regulating SR proteins.  
Other studies have shown that Akt modulates gene expression via regulation of 
gene transcription by phosphorylating CREB and forkhead transcription factors [124, 
125]. In contrast, the role(s) and the control of signaling by Akt in splicing regulation had 
not been clearly characterized. Multiple Akt-substrate consensus motifs exist in the C-
terminal Arg/Ser domains of all the SR proteins [49, 94, 126]. Our combined studies 
revealed that Akt phosphorylates these consensus sequences in multiple SR proteins 
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(SRp75, SRp55 and SRp30b). A recent report has provided both in vivo and in vitro 
evidence for Akt-mediated modification of SR proteins SF2/ASF and 9G8 by direct 
phosphorylation [126]. Akt associates with and phosphorylates YB-1, an RNA-binding 
protein involved in regulation of mRNA transcription, splicing and translation [127]. 
 
 
Thus far we have provided biochemical and genetic evidence showing that Akt2 
also phosphorylates Clk/Sty, and have identified a new role played by Akt2: regulation of 
alternative splicing and gene expression via simultaneously modulating Clk/Sty kinases 
and specific SR splicing factors. Identification of such a dual regulation demonstrated a 
new category of controlling pre-mRNA splicing and gene expression initiated by 
extracellular signaling.  
 
Our combined studies suggest that multiple stimuli regulate SR proteins through 
the PI3K/Akt2 signaling pathway. As summarized in Figure 55 the signaling linkage 
Figure 55. Signaling linkage between PI3K, Akt2, Clk/Sty, SR proteins and PKCβ 
pre-mRNA alternative splicing [41] 
Proposed dual role of Akt2 and Clk/Sty in mediating insulin-induced pre-mRNA splicing 
and gene expression via networked phosphorylation of SR proteins. 
Insulin
IR/IRS
p85/p110 Akt2
Clk/Sty
Phospho-SR proteins
PKC β pre-mRNA 
alternative splicing
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implies that PI3K/Akt2 is pivotal in mediating pre-mRNA splicing and gene expression 
through inducing a sophisticated phosphorylation network that acts on Clk/Sty and SR 
proteins.  Whether other SR protein kinases such as SRPK2 [42, 128] function similarly 
under Akt2 regulation is under investigation. The hierarchy of SR protein 
phosphorylation sites is also questioned. Clk and Akt are both nuclear kinases and 
whether Clk primes SR proteins for Akt phosphorylation is currently unknown.  Previous 
work demonstrated that PKCβII is necessary for full insulin action as measured by 
alterations in glucose uptake in multiple systems [32, 35, 95, 129, 130].  The PKCβ splice 
variants differ in their binding to F-actin and implicate PKCβII in the process of insulin-
stimulated actin rearrangements [131].  Since tissues from Akt2-null mice with early 
stages of type 2 diabetes had impaired Clk/Sty activation, reduced SR protein 
phosphorylation, and reduced PKCβII, these new experiments identifying a 
PI3K/Akt2/Clk/Sty/SR protein/PKCβII linkage, place Clk/Sty, a candidate gene for 
predisposition for Type 2 diabetes, in the signaling pathways of insulin action. 
It was indicated earlier that the Patel lab had recently identified a new splice 
variant of human PKCδ, PKCδVIII (GenBank Accession No. DQ516383). It was shown 
that this human splice variant is generated by utilization of an alternative downstream 5' 
splice site of PKCδ pre-mRNA exon 10 [54]. Thus far it was established that exon- I 
(exon-17) of PKC  and exon-10 of PKCδ have competing 5‟ splice sites that are utilized 
under certain conditions. We showed that in PKC  the regulation is under insulin and 
mediated through SRp40, while in PKC  the regulation is through RA and it‟s mediated 
through SRp30b (SC35). 
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Vitamin A, an important micro-nutrient and its active metabolite all-trans retinoic 
acid (RA) influence a broad range of physiological and pathological processes both in 
embryonic central nervous system (CNS) as well as in the mature brain. It is well 
established that RA directly affects transcription of genes. Here we demonstrated that RA 
also regulates alternative splicing of genes. An important mechanism of regulating gene 
expression is alternative splicing which expands the coding capacity of a single gene to 
produce different proteins with distinct functions [132]. It is now established that close to 
76% of human genes undergo alternative splicing and encode for at least two isoforms. 
Divergence observed in gene expression due to alternative splicing may be tissue-specific 
[133, 134], developmentally regulated [135, 136] or hormonally regulated [84, 137]. 
During constitutive exon splicing, a dynamic process involving the spliceosome 
assembly joins the 5  and 3  splice sites that define the exon-intron boundary by the 
interplay of small nuclear riboproteins (snRNPs) and other associated proteins with the 
pre-mRNA sequences [138]. Alternative splicing can occur through various mechanisms 
such as exon skipping, exon inclusion, alternative 3  splice site usage, alternative 5  splice 
site usage, or alternative polyadenylation site usage. The spliceosome catalyzes the pre-
mRNA splicing reaction within a large multicomponent ribonucleoprotein complex. This 
complex comprises of small nuclear RNAs (snRNAs) and associated proteins (such as SR 
proteins). The information present in the canonical splicing signals that define exon-
intron boundaries is not sufficient for correct assembly of the spliceosome for pre-mRNA 
splicing. Additional signals exist in the pre-mRNA as auxiliary cis-elements that recruit 
trans-acting factors to promote splicing. The regulation of alternative splicing is often the 
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result of dynamic antagonism between trans-acting factors binding to these cis-elements 
[111]. Defective alternative splicing causes a large number of diseases [116, 139, 140]. 
Exonic or intronic splicing enhancers (ESE, ISE) often bind the serine-arginine 
rich nuclear factors - SR proteins - to promote the choice of splice sites in the pre-mRNA. 
SR proteins belong to the class of proteins associated with small nuclear RNAs called the 
snRNPs. Members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family and 
polypyrimidine tract binding protein (PTB) bind to exon/intron splicing silencers (ESS, 
ISS) to function as splicing repressors. Further, specific cellular stimuli can favor the 
binding of certain trans-factors over others, thereby changing the splicing pattern. Hence, 
the elucidation of the trans-factors involved in alternative splicing is of critical 
importance. SC35, also known as SFRS2 or SRp30b, is a member of the nuclear serine-
arginine rich (SR) splicing proteins family and functions as a splicing enhancer [141]. 
SC35 has an N-terminal RNA recognition motif (RRM) domain and a C-terminal 
arginine/serine rich (RS) domain. The RRM domain interacts and binds to the target pre-
mRNA while the RS domain is highly phosphorylated and suggested to be the protein 
interaction region. SC35 along with other splicing factors, kinases and phosphatases 
reside in the splicing factor compartments within the nucleoplasm. SC35 has been shown 
to be involved in pathways that regulate genomic stability and cell proliferation during 
mammalian organogenesis [142]. It plays a role in T cell development and alternative 
splicing of CD45 [143]. SC35 is involved in aberrant splicing of tau exon 10 in 
Alzheimer‟s disease [144] as well as in splicing of neuronal acetylcholinesterase mRNA 
[145]. Our data demonstrated that SC35 enhanced the splicing of a pro-survival protein, 
PKCδVIII in neurons. It is possible that the phosphorylation state of SC35 may further 
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influence splicing of PKCδ pre-mRNA though inhibitors of several signaling pathways 
did not affect RA-mediated PKCδ splicing (data not shown). Phosphorylation of SR 
proteins may result in their differential distribution to alternate sites. Splicing factors are 
phosphorylated on their RS domain and the phosphorylation state (hypo- or hyper-) may 
also affect splice site selection.  
RA treatment alters expression of genes associated with early stages of neuronal 
differentiation [146]. Neurogenesis in the adult brain came to limelight in the early 
1990s. The birth of new neurons, outgrowth of neurites and formation of synapses are 
documented in the adult CNS. RA regulates neural development as well as its plasticity 
and promotes neurogenesis and increases survival [147]. Alternative pre-mRNA splicing 
in neurons is now considered to be a central phenomenon in development, evolution and 
survival of neurons [148]. Previously we demonstrated that RA regulates alternative 
splicing of pro- and anti-apoptotic PKCδ splice variants [149]. RA also changes the 
splicing pattern of the co-activator CaAA as well as of the delta isoform of CaM kinase in 
P19 embryonal carcinoma stem cells during RA-induced differentiation [150, 151]. 
However, the mechanism of RA-induced alternative splicing of genes has not yet been 
elucidated. We demonstrate here that the splicing factor, SC35 plays a crucial role in 
mediating RA effects on alternative splicing of PKCδVIII. Understanding how RA 
signals and regulates gene expression thereby increasing the expression of the pro-
survival protein PKCδVIII is a step closer to realizing the therapeutic potential of RA in 
neurodegenerative diseases. To our knowledge, this is the first report elucidating the 
mechanisms of alternative splicing regulated by RA. 
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We have shown that the splicing of PKC  is regulated by insulin while the 
splicing of PKC  is regulated by RA. Even though the regulation may involve the same 
or different signaling pathway, the final splice variants are mediated by SR proteins; 
SRp40 in PKC  and SRp30b in PKC . Both genes display alternative splicing that 
involves competing 5‟ splice sites. The construction of heterologous minigenes and the 
deletion series of these minigenes is a unique tool that enabled us to demonstrate and/or 
verify the alternative splicing patterns involved and enabled us to elucidate and/or verify 
the cis-elements interacting with the mediating SR proteins.  The in vitro studies 
corroborated the minigene studies and provided further evidence in the alternative 
splicing patterns involved.  
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